<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis - Virgili, G - 2018 | Cochrane Library</title> <meta property="og:title" content="Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis - Virgili, G - 2018 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub6/references" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD007419.pub6" /> <meta name="citation_title" content="Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis" /> <meta name="citation_author" content="Gianni Virgili" /> <meta name="citation_author_institution" content="University of Florence" /> <meta name="citation_author_email" content="gianni.virgili@unifi.it" /> <meta name="citation_author" content="Mariacristina Parravano" /> <meta name="citation_author_institution" content="Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia‐IRCCS" /> <meta name="citation_author" content="Jennifer R Evans" /> <meta name="citation_author_institution" content="London School of Hygiene &amp; Tropical Medicine" /> <meta name="citation_author" content="Iris Gordon" /> <meta name="citation_author_institution" content="London School of Hygiene &amp; Tropical Medicine" /> <meta name="citation_author" content="Ersilia Lucenteforte" /> <meta name="citation_author_institution" content="University of Florence" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="10" /> <meta name="citation_doi" content="10.1002/14651858.CD007419.pub6" /> <meta name="citation_date" content="2018" /> <meta name="citation_online_date" content="2018/10/16" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub6/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub6/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub6/pdf/CDSR/CD007419/CD007419.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Angiogenesis Inhibitors [adverse effects, *therapeutic use]; Aptamers, Nucleotide [adverse effects, therapeutic use]; Bevacizumab [adverse effects, therapeutic use]; Diabetic Retinopathy [*complications]; Laser Coagulation [methods]; Macular Edema [*drug therapy, etiology, surgery]; Network Meta‐Analysis; Quality of Life; Randomized Controlled Trials as Topic; Ranibizumab [adverse effects, therapeutic use]; Receptors, Vascular Endothelial Growth Factor [therapeutic use]; Recombinant Fusion Proteins [adverse effects, therapeutic use]; Triamcinolone [adverse effects, therapeutic use]; Vascular Endothelial Growth Factor A [*antagonists &amp; inhibitors]; Visual Acuity [*drug effects, physiology]" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:["P#DRAAEAC","EAL00000056729","DRAA3TITLES","TSINGH009S","EAL0001468","EAL00000045347"],individualId:null,brandedCustomer:"EAL0001468",roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1513680834000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718256000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EfT7x5RD";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007419\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007419\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","de","ru","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007419.pub6",title:"Anti\\u2010vascular endothelial growth factor for diabetic macular oedema: a network meta\\u2010analysis",firstPublishedDate:"Oct 16, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581422282000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007419.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007419.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<p class="auxiliary-menu-item access">Access provided by: <strong>Tsinghua University</strong></p>
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD007419.pub6/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD007419.pub6/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007419.pub6%2Freferences" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
<div class="access-provider-mobile">
<p class="access">Access provided by: <strong>Tsinghua University</strong></p>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
<li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD007419.PUB6" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD007419.pub6/#" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <a id="read-comments-on-review" class="js-old-version-modal-trigger" data-new-version="" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/read-comments"> Read comments on this Review(2) </a> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007419.pub6/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007419.pub6/full"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-sec1-0006"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/appendices#CD007419-sec1-0012"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/table_n/CD007419StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/table_n/CD007419StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD007419.PUB6"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis</h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD007419-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD007419-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">Ahmadieh 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0001"> <div class="citation-journal">Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. <span class="citation-title">Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo‐controlled, randomized clinical trial</span>. <span class="citation"> Graefe's Archive for Clinical and Experimental Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">246</span>(4):483‐9. <a class="crsref citation-link central-link" data-crsref="2950120" href="" ref="info:x-wiley/crsRef/2950120" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17917738" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+with+or+without+triamcinolone+for+refractory+diabetic+macular+edema;+a+placebo%E2%80%90controlled,+randomized+clinical+trial+&author=H+Ahmadieh&author=A+Ramezani&author=N+Shoeibi&author=B+Bijanzadeh&author=A+Tabatabaei&author=M+Azarmina&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">Azad 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0002"> <div class="citation-other">Azad R, Sain S, Sharma YR, Mahajan D. <span class="citation-title">Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study</span>. Oman Journal of Ophthalmology<span class="pubYear">2012</span>; Vol. 5, issue 3:166‐70. <a class="crsref citation-link central-link" data-crsref="2950122" href="" ref="info:x-wiley/crsRef/2950122" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+intravitreal+bevacizumab,+intravitreal+triamcinolone+acetonide,+and+macular+grid+augmentation+in+refractory+diffuse+diabetic+macular+edema:+A+prospective,+randomized+study+&author=R+Azad&author=S+Sain&author=YR+Sharma&author=D+Mahajan&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">BOLT 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0003"> <div class="citation-journal">Michaelides M, Kaines A, Hamilton RD, Fraser‐Bell S, Rajendram R, Quhill F, et al. <span class="citation-title">A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12‐month data: report 2</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">117</span>(6):1078‐86. <a class="crsref citation-link central-link" data-crsref="2950124" href="" ref="info:x-wiley/crsRef/2950124" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20416952" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+prospective+randomized+trial+of+intravitreal+bevacizumab+or+laser+therapy+in+the+management+of+diabetic+macular+edema+(BOLT+study)+12%E2%80%90month+data:+report+2+&author=M+Michaelides&author=A+Kaines&author=RD+Hamilton&author=S+Fraser%E2%80%90Bell&author=R+Rajendram&author=F+Quhill&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0004"> <div class="citation-journal">Rajendram R, Fraser‐Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. <span class="citation-title">A 2‐year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24‐month data: report 3</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">130</span>(8):972‐9. <a class="crsref citation-link central-link" data-crsref="2950125" href="" ref="info:x-wiley/crsRef/2950125" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22491395" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+2%E2%80%90year+prospective+randomized+controlled+trial+of+intravitreal+bevacizumab+or+laser+therapy+(BOLT)+in+the+management+of+diabetic+macular+edema:+24%E2%80%90month+data:+report+3+&author=R+Rajendram&author=S+Fraser%E2%80%90Bell&author=A+Kaines&author=M+Michaelides&author=RD+Hamilton&author=SD+Esposti&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0005"> <div class="citation-journal">Sivaprasad S, Crosby‐Nwaobi R, Esposti S, Peto T, Rajendram R, Michaelides M, et al. <span class="citation-title">Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4)</span>. <span class="citation"> PloS ONE </span><span class="pubYear">2013</span>;<span class="volume">8</span>(8):e72755. <a class="crsref citation-link central-link" data-crsref="2950126" href="" ref="info:x-wiley/crsRef/2950126" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24013651" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Structural+and+functional+measures+of+efficacy+in+response+to+bevacizumab+monotherapy+in+diabetic+macular+oedema:+exploratory+analyses+of+the+BOLT+Study+(Report+4)+&author=S+Sivaprasad&author=R+Crosby%E2%80%90Nwaobi&author=S+Esposti&author=T+Peto&author=R+Rajendram&author=M+Michaelides&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">DA VINCI 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0006"> <div class="citation-journal">Do DV, Nguyen QD, Boyer D, Schmidt‐Erfurth U, Brown DM, Vitti R, et al. <span class="citation-title">One‐year outcomes of the DA VINCI Study of VEGF Trap‐Eye in eyes with diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">119</span>(8):1658‐65. <a class="crsref citation-link central-link" data-crsref="2950128" href="" ref="info:x-wiley/crsRef/2950128" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22537617" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=One%E2%80%90year+outcomes+of+the+DA+VINCI+Study+of+VEGF+Trap%E2%80%90Eye+in+eyes+with+diabetic+macular+edema+&author=DV+Do&author=QD+Nguyen&author=D+Boyer&author=U+Schmidt%E2%80%90Erfurth&author=DM+Brown&author=R+Vitti&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0007"> <div class="citation-journal">Do DV, Schmidt‐Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, et al. <span class="citation-title">The DAVINCI Study: phase 2 primary results of VEGF Trap‐Eye in patients with diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2011</span>;<span class="volume">118</span>(9):1819‐26. <a class="crsref citation-link central-link" data-crsref="2950129" href="" ref="info:x-wiley/crsRef/2950129" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21546089" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+DAVINCI+Study:+phase+2+primary+results+of+VEGF+Trap%E2%80%90Eye+in+patients+with+diabetic+macular+edema+&author=DV+Do&author=U+Schmidt%E2%80%90Erfurth&author=VH+Gonzalez&author=CM+Gordon&author=M+Tolentino&author=AJ+Berliner&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">DRCRnet 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0008"> <div class="citation-journal">Anonymous. <span class="citation-title">Erratum: Patient‐reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339‐1347) DOI: 10.1001/jamaophthalmol.2013.4592)</span>. <span class="citation"> JAMA Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">131</span>(12):1652. <a class="crsref citation-link central-link" data-crsref="2950131" href="" ref="info:x-wiley/crsRef/2950131" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Erratum:+Patient%E2%80%90reported+visual+function+outcomes+improve+after+ranibizumab+treatment+in+patients+with+vision+impairment+due+to+diabetic+macular+edema:+Randomized+clinical+trial+(JAMA+Ophthalmology+(2013)+131:10+(1339%E2%80%901347)+DOI:+10.1001/jamaophthalmol.2013.4592)+&author=+Anonymous&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0009"> <div class="citation-journal">Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, et al. <span class="citation-title">Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">130</span>(9):1153‐61. <a class="crsref citation-link central-link" data-crsref="2950132" href="" ref="info:x-wiley/crsRef/2950132" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22965591" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Factors+associated+with+changes+in+visual+acuity+and+central+subfield+thickness+at+1+year+after+treatment+for+diabetic+macular+edema+with+ranibizumab+&author=SB+Bressler&author=H+Qin&author=RW+Beck&author=KV+Chalam&author=JE+Kim&author=M+Melia&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0010"> <div class="citation-journal">Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, et al. <span class="citation-title">Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial</span>. <span class="citation"> JAMA Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">131</span>(8):1033‐40. <a class="crsref citation-link central-link" data-crsref="2950133" href="" ref="info:x-wiley/crsRef/2950133" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23807371" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exploratory+analysis+of+the+effect+of+intravitreal+ranibizumab+or+triamcinolone+on+worsening+of+diabetic+retinopathy+in+a+randomized+clinical+trial+&author=SB+Bressler&author=H+Qin&author=M+Melia&author=NM+Bressler&author=RW+Beck&author=CK+Chan&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0011"> <div class="citation-journal">Dewan V, Lambert D, Edler J, Kymes S, Apte RS. <span class="citation-title">Cost‐effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">119</span>(8):1679‐84. <a class="crsref citation-link central-link" data-crsref="2950134" href="" ref="info:x-wiley/crsRef/2950134" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22503301" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cost%E2%80%90effectiveness+analysis+of+ranibizumab+plus+prompt+or+deferred+laser+or+triamcinolone+plus+prompt+laser+for+diabetic+macular+edema+&author=V+Dewan&author=D+Lambert&author=J+Edler&author=S+Kymes&author=RS+Apte&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0012"> <div class="citation-journal">Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. <span class="citation-title">Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">117</span>(6):1064–77. <a class="crsref citation-link central-link" data-crsref="2950135" href="" ref="info:x-wiley/crsRef/2950135" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Randomized+trial+evaluating+ranibizumab+plus+prompt+or+deferred+laser+or+triamcinolone+plus+prompt+laser+for+diabetic+macular+edema+&author=MJ+Elman&author=LP+Aiello&author=RW+Beck&author=NM+Bressler&author=SB+Bressler&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0013"> <div class="citation-journal">Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, et al. <span class="citation-title">Expanded 2‐year follow‐up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2011</span>;<span class="volume">118</span>(4):609‐14. <a class="crsref citation-link central-link" data-crsref="2950136" href="" ref="info:x-wiley/crsRef/2950136" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21459214" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Expanded+2%E2%80%90year+follow%E2%80%90up+of+ranibizumab+plus+prompt+or+deferred+laser+or+triamcinolone+plus+prompt+laser+for+diabetic+macular+edema+&author=MJ+Elman&author=NM+Bressler&author=H+Qin&author=RW+Beck&author=FL+Ferris&author=SM+Friedman&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0014"> <div class="citation-journal">Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL, et al. <span class="citation-title">Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three‐year randomized trial results</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">119</span>(11):2312‐8. <a class="crsref citation-link central-link" data-crsref="2950137" href="" ref="info:x-wiley/crsRef/2950137" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22999634" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+ranibizumab+for+diabetic+macular+edema+with+prompt+versus+deferred+laser+treatment:+three%E2%80%90year+randomized+trial+results+&author=MJ+Elman&author=H+Qin&author=LP+Aiello&author=RW+Beck&author=NM+Bressler&author=FL+Ferris&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">DRCRnet 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0015"> <div class="citation-journal">Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. <span class="citation-title">Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2015</span>;<span class="volume">372</span>(13):1193‐203. <a class="crsref citation-link central-link" data-crsref="5770008" href="" ref="info:x-wiley/crsRef/5770008" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25692915" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Aflibercept,+bevacizumab,+or+ranibizumab+for+diabetic+macular+edema&author=JA+Wells&author=AR+Glassman&author=AR+Ayala&author=LM+Jampol&author=LP+Aiello&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0016"> <div class="citation-journal">Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, et al. <span class="citation-title">Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two‐year results from a comparative effectiveness randomized clinical trial</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2016</span>;<span class="volume">123</span>(6):1351‐9. <a class="crsref citation-link central-link" data-crsref="5770009" href="" ref="info:x-wiley/crsRef/5770009" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26935357" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Aflibercept,+bevacizumab,+or+ranibizumab+for+diabetic+macular+edema:+two%E2%80%90year+results+from+a+comparative+effectiveness+randomized+clinical+trial+&author=JA+Wells&author=AR+Glassman&author=AR+Ayala&author=LM+Jampol&author=NM+Bressler&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">Ekinci 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0017"> <div class="citation-journal">Ekinci M, Ceylan E, Cakici O, Tanyildiz B, Olcaysu O, Cagatay HH. <span class="citation-title">Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections</span>. <span class="citation"> Expert Review of Ophthalmology </span><span class="pubYear">2014</span>;<span class="volume">9</span>(2):139‐43. <a class="crsref citation-link central-link" data-crsref="2950139" href="" ref="info:x-wiley/crsRef/2950139" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+of+macular+edema+in+diabetic+retinopathy:+Comparison+of+the+efficacy+of+intravitreal+bevacizumab+and+ranibizumab+injections+&author=M+Ekinci&author=E+Ceylan&author=O+Cakici&author=B+Tanyildiz&author=O+Olcaysu&author=HH+Cagatay&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">Ishibashi 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0018"> <div class="citation-journal">Ishibashi T, Yuzawa M, Yoshimura N, Ohji M, Ishida S, Isogawa N, et al. <span class="citation-title">Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema</span>. <span class="citation"> Nippon Ganka Gakkai Zasshi </span><span class="pubYear">2014</span>;<span class="volume">118</span>(9):773‐82. <a class="crsref citation-link central-link" data-crsref="5770010" href="" ref="info:x-wiley/crsRef/5770010" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25318186" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Japan+phase+3+study+of+pegaptanib+sodium+in+patients+with+diabetic+macular+edema&author=T+Ishibashi&author=M+Yuzawa&author=N+Yoshimura&author=M+Ohji&author=S+Ishida&author=N+Isogawa&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0019"> <div class="citation-other">NCT01100307. <span class="citation-title">A phase 3 study to compare the efficacy and safety of 0.3 mg pegaptanib sodium to sham Injections In subjects with diabetic macular edema</span> [A phase 3, randomized, controlled, double‐masked, multi‐center, comparative, in parallel roups (for 24 weeks), to compare the efficacy and safety of 0.3 mg pegaptanib sodium, with sham injections, and open study (for 30 weeks) to confirm the safety of 0.3 mg pegaptanib sodium in subjects with diabetic macular edema (DME)]. clinicaltrials.gov/show/NCT01100307 (first received 7 April 2010). <a class="crsref citation-link central-link" data-crsref="2950220" href="" ref="info:x-wiley/crsRef/2950220" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">Korobelnik 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0020"> <div class="citation-journal">Korobelnik JF, Do DV, Schmidt‐Erfurth U, Boyer DS, Holz FG, Heier JS, et al. <span class="citation-title">Intravitreal aflibercept for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2014</span>;<span class="volume">121</span>(11):2247‐54. <a class="crsref citation-link central-link" data-crsref="2950141" href="" ref="info:x-wiley/crsRef/2950141" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25012934" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+aflibercept+for+diabetic+macular+edema&author=JF+Korobelnik&author=DV+Do&author=U+Schmidt%E2%80%90Erfurth&author=DS+Boyer&author=FG+Holz&author=JS+Heier&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">Lopez‐Galvez 2014 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0021"> <div class="citation-journal">Lopez‐Galvez MI, Arias L, Roura M. <span class="citation-title">Efficacy and safety profile of ranibizumab versus laser photocoagulation in patients with diabetic macular edema. Re‐Des Study</span>. <span class="citation"> Ophthalmologica </span><span class="pubYear">2014</span>;<span class="volume">232</span>:115. <a class="crsref citation-link central-link" data-crsref="5770012" href="" ref="info:x-wiley/crsRef/5770012" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+profile+of+ranibizumab+versus+laser+photocoagulation+in+patients+with+diabetic+macular+edema.+Re%E2%80%90Des+Study+&author=MI+Lopez%E2%80%90Galvez&author=L+Arias&author=M+Roura&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">LUCIDATE 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0022"> <div class="citation-other">Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, Xing W, et al. <span class="citation-title">A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study)</span>. American Journal of Ophthalmology<span class="pubYear">2014</span>; Vol. 157, issue 5:960‐70. <a class="crsref citation-link central-link" data-crsref="2950143" href="" ref="info:x-wiley/crsRef/2950143" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+randomized+trial+to+assess+functional+and+structural+effects+of+ranibizumab+versus+laser+in+diabetic+macular+edema+(the+LUCIDATE+study)+&author=O+Comyn&author=S+Sivaprasad&author=T+Peto&author=MM+Neveu&author=GE+Holder&author=W+Xing&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">Macugen 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0023"> <div class="citation-journal">Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. <span class="citation-title">A phase II randomized double‐masked trial of pegaptanib, an anti‐vascular endothelial growth factor aptamer, for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2005</span>;<span class="volume">112</span>(10):1747‐57. <a class="crsref citation-link central-link" data-crsref="2950145" href="" ref="info:x-wiley/crsRef/2950145" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16154196" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+phase+II+randomized+double%E2%80%90masked+trial+of+pegaptanib,+an+anti%E2%80%90vascular+endothelial+growth+factor+aptamer,+for+diabetic+macular+edema+&author=ET+Cunningham&author=AP+Adamis&author=M+Altaweel&author=LP+Aiello&author=NM+Bressler&author=DJ+D'Amico&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">Macugen 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0024"> <div class="citation-journal">Loftus JV, Sultan MB, Pleil AM, Macugen 1013 Study Group. <span class="citation-title">Changes in vision and health‐related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham</span>. <span class="citation"> Investigative Ophthalmology and Visual Science </span><span class="pubYear">2011</span>;<span class="volume">52</span>(10):7498‐505. <a class="crsref citation-link central-link" data-crsref="2950147" href="" ref="info:x-wiley/crsRef/2950147" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21896838" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Changes+in+vision+and+health%E2%80%90related+quality+of+life+in+patients+with+diabetic+macular+edema+treated+with+pegaptanib+sodium+or+sham+&author=JV+Loftus&author=MB+Sultan&author=AM+Pleil&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0025"> <div class="citation-journal">Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS, Macugen 1013 Study Group. <span class="citation-title">A phase 2/3, multicenter, randomized, double‐masked, 2‐year trial of pegaptanib sodium for the treatment of diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2011</span>;<span class="volume">118</span>(6):1107‐18. <a class="crsref citation-link central-link" data-crsref="2950148" href="" ref="info:x-wiley/crsRef/2950148" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21529957" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+phase+2/3,+multicenter,+randomized,+double%E2%80%90masked,+2%E2%80%90year+trial+of+pegaptanib+sodium+for+the+treatment+of+diabetic+macular+edema+&author=MB+Sultan&author=D+Zhou&author=J+Loftus&author=T+Dombi&author=KS+Ice&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">Nepomuceno 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0026"> <div class="citation-journal">Nepomuceno AB, Takaki E, Paes de Almeida FP, Peroni R, Cardillo JA, Siqueira RC, et al. <span class="citation-title">A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema</span>. <span class="citation"> American Journal of Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">156</span>(3):502‐10. <a class="crsref citation-link central-link" data-crsref="2950153" href="" ref="info:x-wiley/crsRef/2950153" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23795985" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+prospective+randomized+trial+of+intravitreal+bevacizumab+versus+ranibizumab+for+the+management+of+diabetic+macular+edema+&author=AB+Nepomuceno&author=E+Takaki&author=FP+PaesdeAlmeida&author=R+Peroni&author=JA+Cardillo&author=RC+Siqueira&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">READ2 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0027"> <div class="citation-journal">Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, et al. <span class="citation-title">Ranibizumab for edema of the macula in diabetes study: 3‐year outcomes and the need for prolonged frequent treatment</span>. <span class="citation"> JAMA Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">131</span>(2):139‐45. <a class="crsref citation-link central-link" data-crsref="2950155" href="" ref="info:x-wiley/crsRef/2950155" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23544200" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ranibizumab+for+edema+of+the+macula+in+diabetes+study:+3%E2%80%90year+outcomes+and+the+need+for+prolonged+frequent+treatment+&author=DV+Do&author=QD+Nguyen&author=AA+Khwaja&author=R+Channa&author=YJ+Sepah&author=R+Sophie&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0028"> <div class="citation-journal">Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. <span class="citation-title">Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ‐2) study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">116</span>(11):2175‐81. <a class="crsref citation-link central-link" data-crsref="2950156" href="" ref="info:x-wiley/crsRef/2950156" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19700194" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Primary+end+point+(six+months)+results+of+the+ranibizumab+for+edema+of+the+mAcula+in+diabetes+(READ%E2%80%902)+study+&author=QD+Nguyen&author=SM+Shah&author=JS+Heier&author=DV+Do&author=J+Lim&author=D+Boyer&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0029"> <div class="citation-journal">Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. <span class="citation-title">Two‐year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ‐2) study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">117</span>(11):2146‐51. <a class="crsref citation-link central-link" data-crsref="2950157" href="" ref="info:x-wiley/crsRef/2950157" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20855114" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Two%E2%80%90year+outcomes+of+the+ranibizumab+for+edema+of+the+mAcula+in+diabetes+(READ%E2%80%902)+study+&author=QD+Nguyen&author=SM+Shah&author=AA+Khwaja&author=R+Channa&author=E+Hatef&author=DV+Do&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">RELATION 2012 {unpublished data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0030"> <div class="citation-other">CRFB002DD13. <span class="citation-title">A 12‐month, two‐armed, randomized, double‐masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period</span>. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). <a class="crsref citation-link central-link" data-crsref="2950150" href="" ref="info:x-wiley/crsRef/2950150" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0031"> <div class="citation-other">NCT01131585. <span class="citation-title">A 12‐month, two‐armed, randomized, double‐masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period</span>. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). <a class="crsref citation-link central-link" data-crsref="2950151" href="" ref="info:x-wiley/crsRef/2950151" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">RESOLVE 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0032"> <div class="citation-other">CRFB002D2201. <span class="citation-title">A randomized, double‐masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non‐treatment control for the treatment of diabetic macular edema with center involvement</span>. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). <a class="crsref citation-link central-link" data-crsref="2950159" href="" ref="info:x-wiley/crsRef/2950159" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0033"> <div class="citation-journal">Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. <span class="citation-title">Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12‐month, randomized, controlled, double‐masked, multicenter phase II study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2010</span>;<span class="volume">33</span>(11):2399‐405. <a class="crsref citation-link central-link" data-crsref="2950160" href="" ref="info:x-wiley/crsRef/2950160" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20980427" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+efficacy+of+ranibizumab+in+diabetic+macular+edema+(RESOLVE+Study):+a+12%E2%80%90month,+randomized,+controlled,+double%E2%80%90masked,+multicenter+phase+II+study+&author=P+Massin&author=F+Bandello&author=JG+Garweg&author=LL+Hansen&author=SP+Harding&author=M+Larsen&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">RESPOND 2013 {unpublished data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0034"> <div class="citation-other">Berger A, Sheidow T, Li R, Rehel B, Takacsy F, Courseau AS. <span class="citation-title">A Canadian 12‐month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis (&quot;RESPOND&quot;)</span>. 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17‐19; Montreal. <span class="pubYear">2013</span>. <a class="crsref citation-link central-link" data-crsref="2950162" href="" ref="info:x-wiley/crsRef/2950162" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+Canadian+12%E2%80%90month,+phase+IIIb+study+of+ranibizumab+combination+or+monotherapy+in+visual+impairment+due+to+diabetic+macular+edema:+Preliminary+analysis+(" RESPOND")+&author=A+Berger&author=T+Sheidow&author=R+Li&author=B+Rehel&author=F+Takacsy&author=AS+Courseau&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0035"> <div class="citation-other">CRFB002DCA05. <span class="citation-title">A Canadian 12‐month, prospective, randomized, open‐label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema</span>. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). <a class="crsref citation-link central-link" data-crsref="2950163" href="" ref="info:x-wiley/crsRef/2950163" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">RESTORE 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0036"> <div class="citation-journal">Anonymous. <span class="citation-title">Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312‐8)</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2014</span>;<span class="volume">121</span>(3):805. <a class="crsref citation-link central-link" data-crsref="2950165" href="" ref="info:x-wiley/crsRef/2950165" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Erratum:+Intravitreal+ranibizumab+for+diabetic+macular+edema+with+prompt+versus+deferred+laser+treatment:+Three+year+randomized+trial+results+(Ophthalmology+2012;119:2312%E2%80%908)+&author=+Anonymous&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0037"> <div class="citation-other">Lang GE, Berta A, Eldem BM, Simader C, Sharp D, Holz FG, et al. <span class="citation-title">Two‐year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study</span>. Ophthalmology<span class="pubYear">2013</span>; Vol. 120, issue 10:2004‐12. <a class="crsref citation-link central-link" data-crsref="2950166" href="" ref="info:x-wiley/crsRef/2950166" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Two%E2%80%90year+safety+and+efficacy+of+ranibizumab+0.5+mg+in+diabetic+macular+edema:+interim+analysis+of+the+RESTORE+extension+study+&author=GE+Lang&author=A+Berta&author=BM+Eldem&author=C+Simader&author=D+Sharp&author=FG+Holz&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0038"> <div class="citation-other">Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K, et al. <span class="citation-title">Cost‐effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial</span>. British Journal of Opthalmology<span class="pubYear">2012</span>; Vol. 96, issue 5:688‐93. <a class="crsref citation-link central-link" data-crsref="2950167" href="" ref="info:x-wiley/crsRef/2950167" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cost%E2%80%90effectiveness+of+ranibizumab+in+treatment+of+diabetic+macular+oedema+(DME)+causing+visual+impairment:+evidence+from+the+RESTORE+trial+&author=P+Mitchell&author=L+Annemans&author=M+Gallagher&author=R+Hasan&author=S+Thomas&author=K+Gairy&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0039"> <div class="citation-journal">Mitchell P, Bandello F, Schmidt‐Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. <span class="citation-title">The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2011</span>;<span class="volume">118</span>(4):615–62. <a class="crsref citation-link central-link" data-crsref="2950168" href="" ref="info:x-wiley/crsRef/2950168" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+RESTORE+study:+ranibizumab+monotherapy+or+combined+with+laser+versus+laser+monotherapy+for+diabetic+macular+edema+&author=P+Mitchell&author=F+Bandello&author=U+Schmidt%E2%80%90Erfurth&author=GE+Lang&author=P+Massin&author=RO+Schlingemann&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0040"> <div class="citation-journal">Mitchell P, Bressler N, Tolley K, Gallagher M, Petrillo J, Ferreira A, et al. <span class="citation-title">Patient‐reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial</span>. <span class="citation"> JAMA Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">131</span>(10):1339‐47. <a class="crsref citation-link central-link" data-crsref="2950169" href="" ref="info:x-wiley/crsRef/2950169" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23974915" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Patient%E2%80%90reported+visual+function+outcomes+improve+after+ranibizumab+treatment+in+patients+with+vision+impairment+due+to+diabetic+macular+edema:+randomized+clinical+trial+&author=P+Mitchell&author=N+Bressler&author=K+Tolley&author=M+Gallagher&author=J+Petrillo&author=A+Ferreira&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0041"> <div class="citation-journal">Schmidt‐Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, et al. <span class="citation-title">Three‐year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2014</span>;<span class="volume">121</span>(5):1045‐53. <a class="crsref citation-link central-link" data-crsref="2950170" href="" ref="info:x-wiley/crsRef/2950170" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24491642" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Three%E2%80%90year+outcomes+of+individualized+ranibizumab+treatment+in+patients+with+diabetic+macular+edema:+the+RESTORE+extension+study+&author=U+Schmidt%E2%80%90Erfurth&author=GE+Lang&author=FG+Holz&author=RO+Schlingemann&author=P+Lanzetta&author=P+Massin&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">REVEAL 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0042"> <div class="citation-journal">Ishibashi T, Li X, Koh A, Lai TY, Lee FL, Lee WK, et al. <span class="citation-title">The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in asian patients with diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2015</span>;<span class="volume">122</span>(7):1402‐15. <a class="crsref citation-link central-link" data-crsref="5770014" href="" ref="info:x-wiley/crsRef/5770014" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25983216" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+REVEAL+Study:+ranibizumab+monotherapy+or+combined+with+laser+versus+laser+monotherapy+in+asian+patients+with+diabetic+macular+edema+&author=T+Ishibashi&author=X+Li&author=A+Koh&author=TY+Lai&author=FL+Lee&author=WK+Lee&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">RISE‐RIDE {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0043"> <div class="citation-journal">Bressler NM, Varma R, Suñer IJ, Dolan CM, Ward J, Ehrlich JS, et al. <span class="citation-title">Vision‐related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2014</span>;<span class="volume">121</span>(12):2461‐72. <a class="crsref citation-link central-link" data-crsref="5770015" href="" ref="info:x-wiley/crsRef/5770015" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25148789" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Vision%E2%80%90related+function+after+ranibizumab+treatment+for+diabetic+macular+edema:+results+from+RIDE+and+RISE+&author=NM+Bressler&author=R+Varma&author=IJ+Su%C3%B1er&author=CM+Dolan&author=J+Ward&author=JS+Ehrlich&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0044"> <div class="citation-journal">Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. <span class="citation-title">Long‐term outcomes of ranibizumab therapy for diabetic macular edema: the 36‐month results from two phase III trials: RISE and RIDE</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">120</span>(10):2013‐22. <a class="crsref citation-link central-link" data-crsref="2950172" href="" ref="info:x-wiley/crsRef/2950172" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23706949" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+outcomes+of+ranibizumab+therapy+for+diabetic+macular+edema:+the+36%E2%80%90month+results+from+two+phase+III+trials:+RISE+and+RIDE+&author=DM+Brown&author=QD+Nguyen&author=DM+Marcus&author=DS+Boyer&author=S+Patel&author=L+Feiner&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0045"> <div class="citation-journal">Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. <span class="citation-title">Long‐term effects of ranibizumab on diabetic retinopathy severity and progression</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">130</span>(9):1145‐52. <a class="crsref citation-link central-link" data-crsref="2950173" href="" ref="info:x-wiley/crsRef/2950173" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22965590" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+effects+of+ranibizumab+on+diabetic+retinopathy+severity+and+progression&author=MS+Ip&author=A+Domalpally&author=JJ+Hopkins&author=P+Wong&author=JS+Ehrlich&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0046"> <div class="citation-other">Mieler WF, Kim JE, Yau L, Ehrlich JS. <span class="citation-title">Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab</span>. 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21‐25; Chicago. <span class="pubYear">2013</span>. <a class="crsref citation-link central-link" data-crsref="2950174" href="" ref="info:x-wiley/crsRef/2950174" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Earlier+treatment+is+important+in+diabetic+macular+edema:+Outcomes+from+phase+III+trials+of+intravitreal+ranibizumab+&author=WF+Mieler&author=JE+Kim&author=L+Yau&author=JS+Ehrlich&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0047"> <div class="citation-journal">Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. <span class="citation-title">Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">119</span>(4):789‐801. <a class="crsref citation-link central-link" data-crsref="2950175" href="" ref="info:x-wiley/crsRef/2950175" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22330964" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ranibizumab+for+diabetic+macular+edema:+results+from+2+phase+III+randomized+trials:+RISE+and+RIDE+&author=QD+Nguyen&author=DM+Brown&author=DM+Marcus&author=DS+Boyer&author=S+Patel&author=L+Feiner&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">Soheilian 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0048"> <div class="citation-journal">Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA. <span class="citation-title">Two‐year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema</span>. <span class="citation"> Retina </span><span class="pubYear">2012</span>;<span class="volume">32</span>(2):314‐21. <a class="crsref citation-link central-link" data-crsref="2950177" href="" ref="info:x-wiley/crsRef/2950177" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22234244" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Two%E2%80%90year+results+of+a+randomized+trial+of+intravitreal+bevacizumab+alone+or+combined+with+triamcinolone+versus+laser+in+diabetic+macular+edema+&author=M+Soheilian&author=KH+Garfami&author=A+Ramezani&author=M+Yaseri&author=GA+Peyman&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0049"> <div class="citation-journal">Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. <span class="citation-title">Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema</span>. <span class="citation"> Retina </span><span class="pubYear">2007</span>;<span class="volume">27</span>(9):1187‐95. <a class="crsref citation-link central-link" data-crsref="2950178" href="" ref="info:x-wiley/crsRef/2950178" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18046223" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+(avastin)+injection+alone+or+combined+with+triamcinolone+versus+macular+photocoagulation+as+primary+treatment+of+diabetic+macular+edema+&author=M+Soheilian&author=A+Ramezani&author=B+Bijanzadeh&author=M+Yaseri&author=H+Ahmadieh&author=MH+Dehghan&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD007419-bib-0050"> <div class="citation-journal">Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. <span class="citation-title">Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">116</span>(6):1142‐50. <a class="crsref citation-link central-link" data-crsref="2950179" href="" ref="info:x-wiley/crsRef/2950179" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19376585" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Randomized+trial+of+intravitreal+bevacizumab+alone+or+combined+with+triamcinolone+versus+macular+photocoagulation+in+diabetic+macular+edema+&author=M+Soheilian&author=A+Ramezani&author=A+Obudi&author=B+Bijanzadeh&author=M+Salehipour&author=M+Yaseri&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">Turkoglu 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0051"> <div class="citation-journal">Turkoglu EB, Celık E, Aksoy N, Bursalı O, Ucak T, Alagoz G. <span class="citation-title">Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?</span>. <span class="citation"> Journal of Diabetes and its Complications </span><span class="pubYear">2015</span>;<span class="volume">29</span>(4):540‐3. <a class="crsref citation-link central-link" data-crsref="5770017" href="" ref="info:x-wiley/crsRef/5770017" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25817172" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Changes+in+vision+related+quality+of+life+in+patients+with+diabetic+macular+edema:+ranibizumab+or+laser+treatment?+&author=EB+Turkoglu&author=E+Cel%C4%B1k&author=N+Aksoy&author=O+Bursal%C4%B1&author=T+Ucak&author=G+Alagoz&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD007419-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Wiley 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0052"> <div class="citation-journal">Wiley HE, Thompson DJ, Bailey C, Chew EY, Cukras CA, Jaffe GJ, et al. <span class="citation-title">A crossover design for comparative efficacy: a 36‐week randomized trial of bevacizumab and ranibizumab for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2016</span>;<span class="volume">123</span>(4):841‐9. <a class="crsref citation-link central-link" data-crsref="5770019" href="" ref="info:x-wiley/crsRef/5770019" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26875003" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+crossover+design+for+comparative+efficacy:+a+36%E2%80%90week+randomized+trial+of+bevacizumab+and+ranibizumab+for+diabetic+macular+edema+&author=HE+Wiley&author=DJ+Thompson&author=C+Bailey&author=EY+Chew&author=CA+Cukras&author=GJ+Jaffe&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD007419-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD007419-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">Ahmadieh 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0053"> <div class="citation-journal">Ahmadieh H, Nourinia R, Hafezi‐Moghadam A. <span class="citation-title">Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema</span>. <span class="citation"> JAMA Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">131</span>(7):923‐4. <a class="crsref citation-link central-link" data-crsref="2950181" href="" ref="info:x-wiley/crsRef/2950181" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23640178" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+fasudil+combined+with+bevacizumab+for+persistent+diabetic+macular+edema&author=H+Ahmadieh&author=R+Nourinia&author=A+Hafezi%E2%80%90Moghadam&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">CRFB002DFR08 (LUDIC) {unpublished data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0054"> <div class="citation-other">CRFB002DFR08. <span class="citation-title">Open‐label, multicenter, study of the efficacy and safety of Lucentis® (ranibizumab 0.5 mg) in diabetic patients presenting a visual impairment due to diabetic macular edema in current medical practice (LUDIC)</span>. Novartis clinical trial results database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=9803 (accessed 28 May 2014). <a class="crsref citation-link central-link" data-crsref="2950183" href="" ref="info:x-wiley/crsRef/2950183" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">CRFB002DGB14 (RELIGHT) {unpublished data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0055"> <div class="citation-other">CRFB002DGB14. <span class="citation-title">RELIGHT ‐ Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18‐month, prospective, open‐label, multicentre, single‐arm Phase IIIb study, with 12‐month primary endpoint, assessing the efficacy and safety of Ranibizumab in patients with visual impairment</span>. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/products.jsp?divisionId=2&amp;diseaseAreaID=12 (accessed 28 May 2014). <a class="crsref citation-link central-link" data-crsref="2950185" href="" ref="info:x-wiley/crsRef/2950185" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">CRFB002DNO02 (PTIMAL) {unpublished data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0056"> <div class="citation-other">CRFB002DNO02. <span class="citation-title">An open‐label, prospective, multicenter, uncontrolled, Proof of concept study assessing the efficacy of Lucentis (ranibizumab) administered by an individualized “treat and extend” dosing regimen in patients with visual impairment due to dIabetic macular edema</span>. Novartis clinical trial results database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=10423 (accessed 28 May 2014). <a class="crsref citation-link central-link" data-crsref="2950187" href="" ref="info:x-wiley/crsRef/2950187" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">DRCRnet 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0057"> <div class="citation-journal">Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. <span class="citation-title">A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2007</span>;<span class="volume">114</span>(10):1860‐7. <a class="crsref citation-link central-link" data-crsref="2950189" href="" ref="info:x-wiley/crsRef/2950189" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17698196" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+phase+II+randomized+clinical+trial+of+intravitreal+bevacizumab+for+diabetic+macular+edema+&author=IU+Scott&author=AR+Edwards&author=RW+Beck&author=NM+Bressler&author=CK+Chan&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">DRCRnet 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0058"> <div class="citation-journal">Diabetic Retinopathy Clinical Research Network, Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, et al. <span class="citation-title">Randomized trial evaluating short‐term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation</span>. <span class="citation"> Retina </span><span class="pubYear">2011</span>;<span class="volume">31</span>(6):1009‐27. <a class="crsref citation-link central-link" data-crsref="2950191" href="" ref="info:x-wiley/crsRef/2950191" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21394052" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Randomized+trial+evaluating+short%E2%80%90term+effects+of+intravitreal+ranibizumab+or+triamcinolone+acetonide+on+macular+edema+after+focal/grid+laser+for+diabetic+macular+edema+in+eyes+also+receiving+panretinal+photocoagulation+&author=J+Googe&author=AJ+Brucker&author=NM+Bressler&author=H+Qin&author=LP+Aiello&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">DRCRnet 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0059"> <div class="citation-other">Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, et al. <span class="citation-title">Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three‐year randomized trial results</span>. Ophthalmology<span class="pubYear">2012</span>; Vol. 119, issue 11:2312‐8. <a class="crsref citation-link central-link" data-crsref="2950193" href="" ref="info:x-wiley/crsRef/2950193" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+ranibizumab+for+diabetic+macular+edema+with+prompt+versus+deferred+laser+treatment:+three%E2%80%90year+randomized+trial+results+&author=MJ+Elman&author=H+Qin&author=LP+Aiello&author=RW+Beck&author=NM+Bressler&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">Faghihi 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0060"> <div class="citation-journal">Faghihi H, Roohipoor R, Mohammadi SF, Hojat‐Jalali K, Mirshahi A, Lashay A, et al. <span class="citation-title">Intravitreal bevacizumab versus combined bevacizumab‐triamcinolone versus macular laser photocoagulation in diabetic macular edema</span>. <span class="citation"> European Journal of Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">18</span>(6):941‐8. <a class="crsref citation-link central-link" data-crsref="2950195" href="" ref="info:x-wiley/crsRef/2950195" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18988166" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+versus+combined+bevacizumab%E2%80%90triamcinolone+versus+macular+laser+photocoagulation+in+diabetic+macular+edema+&author=H+Faghihi&author=R+Roohipoor&author=SF+Mohammadi&author=K+Hojat%E2%80%90Jalali&author=A+Mirshahi&author=A+Lashay&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">NCT02985619 (BEVATAAC) {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0061"> <div class="citation-other">NCT02985619. <span class="citation-title">Bevacizumabe or triamcinolone for persistent diabetic macular edema (BEVATAAC)</span> [Randomized trial evaluating bevacizumabe or triamcinolone for persistent diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT02985619 (first received 1 December 2016). <a class="crsref citation-link central-link" data-crsref="5770021" href="" ref="info:x-wiley/crsRef/5770021" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">Paccola 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0062"> <div class="citation-journal">Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. <span class="citation-title">Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">92</span>(1):76‐80. <a class="crsref citation-link central-link" data-crsref="2950199" href="" ref="info:x-wiley/crsRef/2950199" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17965109" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+triamcinolone+versus+bevacizumab+for+treatment+of+refractory+diabetic+macular+oedema+(IBEME+study)+&author=L+Paccola&author=RA+Costa&author=MS+Folgosa&author=JC+Barbosa&author=IU+Scott&author=R+Jorge&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">Solaiman 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0063"> <div class="citation-journal">Solaiman KA, Diab MM, Abo‐Elenin M. <span class="citation-title">Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema</span>. <span class="citation"> Retina </span><span class="pubYear">2010</span>;<span class="volume">30</span>(10):1638‐45. <a class="crsref citation-link central-link" data-crsref="2950201" href="" ref="info:x-wiley/crsRef/2950201" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20838357" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+and/or+macular+photocoagulation+as+a+primary+treatment+for+diffuse+diabetic+macular+edema+&author=KA+Solaiman&author=MM+Diab&author=M+Abo%E2%80%90Elenin&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD007419-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">Zehetner 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0064"> <div class="citation-journal">Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. <span class="citation-title">Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age‐related macular degeneration, and in patients with diabetic macular oedema</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">97</span>(4):454‐9. <a class="crsref citation-link central-link" data-crsref="2950203" href="" ref="info:x-wiley/crsRef/2950203" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23385630" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Plasma+levels+of+vascular+endothelial+growth+factor+before+and+after+intravitreal+injection+of+bevacizumab,+ranibizumab+and+pegaptanib+in+patients+with+age%E2%80%90related+macular+degeneration,+and+in+patients+with+diabetic+macular+oedema+&author=C+Zehetner&author=R+Kirchmair&author=S+Huber&author=MT+Kralinger&author=GF+Kieselbach&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD007419-bbs1-0003"> <h3 class="title">References to studies awaiting assessment</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD007419-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD007419-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">Chen 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0065"> <div class="citation-journal">Chen ZX, Fu JS, Song W, Wang CX, Zhang YL. <span class="citation-title">Effect analysis of ranibizumab with laser photocoagulation therapy for diabetic macular edema</span>. <span class="citation"> International Eye Science </span><span class="pubYear">2016</span>;<span class="volume">16</span>(4):706‐8. <a class="crsref citation-link central-link" data-crsref="5770023" href="" ref="info:x-wiley/crsRef/5770023" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+analysis+of+ranibizumab+with+laser+photocoagulation+therapy+for+diabetic+macular+edema+&author=ZX+Chen&author=JS+Fu&author=W+Song&author=CX+Wang&author=YL+Zhang&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD007419-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">Fouda 2017 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0066"> <div class="citation-journal">Fouda SM, Bahgat AM. <span class="citation-title">Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema</span>. <span class="citation"> Clinical Ophthalmology </span><span class="pubYear">2017</span>;<span class="volume">23</span>:567‐71. <a class="crsref citation-link central-link" data-crsref="5770025" href="" ref="info:x-wiley/crsRef/5770025" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+aflibercept+versus+intravitreal+ranibizumab+for+the+treatment+of+diabetic+macular+edema+&author=SM+Fouda&author=AM+Bahgat&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD007419-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">Huang 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0067"> <div class="citation-journal">Huang JD, Song ZY. <span class="citation-title">Clinical study of grid pattern laser photocoagulation with ranibizumab for diabetic macular edema</span>. <span class="citation"> International Eye Science </span><span class="pubYear">2016</span>;<span class="volume">16</span>(3):493‐5. <a class="crsref citation-link central-link" data-crsref="5770027" href="" ref="info:x-wiley/crsRef/5770027" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+study+of+grid+pattern+laser+photocoagulation+with+ranibizumab+for+diabetic+macular+edema+&author=JD+Huang&author=ZY+Song&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD007419-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">Jovanovic 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0068"> <div class="citation-journal">Jovanović S, Čanadanović V, Sabo A, Grgić Z, Mitrović M, Rakić D. <span class="citation-title">Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema</span>. <span class="citation"> Vojnosanitetski Pregled </span><span class="pubYear">2015</span>;<span class="volume">72</span>(10):876‐82. <a class="crsref citation-link central-link" data-crsref="5770029" href="" ref="info:x-wiley/crsRef/5770029" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26665553" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+injection+alone+or+combined+with+macular+photocoagulation+compared+to+macular+photocoagulation+as+primary+treatment+of+diabetic+macular+edema+&author=S+Jovanovi%C4%87&author=V+%C4%8Canadanovi%C4%87&author=A+Sabo&author=Z+Grgi%C4%87&author=M+Mitrovi%C4%87&author=D+Raki%C4%87&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD007419-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">NCT00387582 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0069"> <div class="citation-other">NCT00387582. <span class="citation-title">Efficacy study of lucentis in the treatment of diabetic macular edema ‐ a phase II, single center, randomized study to evaluate the efficacy of ranibizumab versus focal laser treatment in subjects with diabetic macular edema</span> [Lucentis in the treatment of macular edema ‐ a phase II, single center, randomized study to evaluate the efficacy of ranibizumab versus focal laser treatment in subjects with diabetic macular edema]. clinicaltrials.gov/show/NCT00387582 (first received 11 October 2006). <a class="crsref citation-link central-link" data-crsref="2950212" href="" ref="info:x-wiley/crsRef/2950212" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD007419-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">NCT00997191 (IBeTA) {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0070"> <div class="citation-other">NCT00997191. <span class="citation-title">Intravitreal bevacizumab and intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema (IBeTA)</span>. clinicaltrials.gov/show/NCT00997191 (first received 15 October 2009). <a class="crsref citation-link central-link" data-crsref="2950218" href="" ref="info:x-wiley/crsRef/2950218" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD007419-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">NCT01445899 (MATISSE) {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0071"> <div class="citation-other">NCT01445899. <span class="citation-title">PF‐04523655 dose escalation study, and evaluation of PF‐04523655 with/without ranibizumab in diabetic macular edema (DME) (MATISSE)</span> [An open‐label dose escalation study of PF‐04523655 (Stratum I) combined with a prospective, randomized, double‐masked, multi‐center, controlled study (Stratum II) evaluating the efficacy and safety of PF‐04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema (MATISSE STUDY)]. clinicaltrials.gov/ct2/show/study/NCT01445899 (first received 30 September 2011). <a class="crsref citation-link central-link" data-crsref="2950226" href="" ref="info:x-wiley/crsRef/2950226" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD007419-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">NCT01565148 (IDEAL) {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0072"> <div class="citation-other">NCT01565148. <span class="citation-title">A randomized, multi‐center, phase II study of the safety, tolerability, and bioactivity of repeated intravitreal injections of iCo‐007 as monotherapy or in combination with ranibizumab or laser photocoagulation in the treatment of diabetic macular edema (the iDEAL Study) (iDEAL)</span> [A randomized, multi‐center, phase II study of the safety, tolerability, and bioactivity of repeated intravitreal injections of iCo‐007 as monotherapy or in combination with ranibizumab or laser photocoagulation in the treatment of diabetic macular edema with involvement of the foveAL center (the iDEAL Study)]. clinicaltrials.gov/ct2/show/study/NCT01565148 (first received 15 March 2012). <a class="crsref citation-link central-link" data-crsref="2950234" href="" ref="info:x-wiley/crsRef/2950234" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD007419-bbs1-0004"> <h3 class="title">References to ongoing studies</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD007419-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0005">additional references</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD007419-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">ChiCTR‐TRC‐12002417 {unpublished data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0073"> <div class="citation-other">ChiCTR‐TRC‐12002417. <span class="citation-title">A randomized controlled trial to compare the efficacy and safety of 1) macular laser vs. 2) repeated intravitreal bevacizumab vs. 3) combined repeated intravitreal bevacizumab with macular laser for diabetic macular edema</span>. www.chictr.org.cn/hvshowproject.aspx?id=3319 (accessed 17 September 2014). <a class="crsref citation-link central-link" data-crsref="2950210" href="" ref="info:x-wiley/crsRef/2950210" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD007419-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">NCT01635790 (BRDME) {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0074"> <div class="citation-other">NCT01635790. <span class="citation-title">Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular edema (BRDME) (BRDME)</span>. clinicaltrials.gov/ct2/show/NCT01635790 (first received 28 June 2012). <a class="crsref citation-link central-link" data-crsref="5770030" href="" ref="info:x-wiley/crsRef/5770030" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD007419-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">NCT02194634 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0075"> <div class="citation-other">NCT02194634. <span class="citation-title">Safety and efficacy study of conbercept in diabetic macular edema (DME) (Sailing)</span>. clinicaltrials.gov/ct2/show/NCT02194634 (first received 14 July 2014). <a class="crsref citation-link central-link" data-crsref="5770032" href="" ref="info:x-wiley/crsRef/5770032" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD007419-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">NCT02259088 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0076"> <div class="citation-other">NCT02259088. <span class="citation-title">A 12‐month, randomized, efficacy and safety study of 0.5 mg ranibizumab vs laser in Chinese DME patients</span> [A 12‐month, randomized, double‐masked, multicenter, laser‐controlled phase III study assessing the efficacy and safety of 0.5 mg ranibizumab dosed PRN in subjects with visual impairment due to diabetic macular edema in Chinese patients]. clinicaltrials.gov/ct2/show/NCT02259088 (first received 3 October 2014). <a class="crsref citation-link central-link" data-crsref="5770034" href="" ref="info:x-wiley/crsRef/5770034" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD007419-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">NCT02348918 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0077"> <div class="citation-other">NCT02348918. <span class="citation-title">A phase 2 randomized, controlled, double‐masked, multicenter clinical trial designed to evaluate the safety and exploratory efficacy of Luminate® (ALG‐1001) as compared to Avastin® and focal laser photocoagulation in the treatment of diabetic macular edema</span>. clinicaltrials.gov/ct2/show/NCT02348918 (first received 12 January 2015). <a class="crsref citation-link central-link" data-crsref="5770036" href="" ref="info:x-wiley/crsRef/5770036" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD007419-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">NCT02645734 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0078"> <div class="citation-other">NCT02645734. <span class="citation-title">The effect of bevacizumab and ziv‐aflibercept in diabetic macular edema</span> [The comparison between the therapeutic effect of intravitreal bevacizumab and ziv‐aflibercept in diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT02645734 (first received 2 January 2016). <a class="crsref citation-link central-link" data-crsref="5770038" href="" ref="info:x-wiley/crsRef/5770038" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD007419-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">NCT02699450 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0079"> <div class="citation-other">NCT02699450. <span class="citation-title">A phase 2 study of RO6867461 in participants with center‐involving diabetic macular edema (CI‐DME) (BOULEVARD)</span>. clinicaltrials.gov/ct2/show/NCT02699450 (first received 1 March 2016). <a class="crsref citation-link central-link" data-crsref="5770040" href="" ref="info:x-wiley/crsRef/5770040" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD007419-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">NCT02712008 {published data only} </h4> </div> <div class="bibliography-section" id="CD007419-bib-0080"> <div class="citation-other">NCT02712008. <span class="citation-title">Anti‐vasculaR endothelial growth factor plUs anti‐angiopoietin 2 in fixed comBination therapY: evaluation for the treatment of diabetic macular edema</span> [A randomized, double‐masked, active‐controlled, phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910‐3 in patients with diabetic macular edema]. clinicaltrials.gov/ct2/show/NCT02712008 (first received 14 March 2016). <a class="crsref citation-link central-link" data-crsref="5770042" href="" ref="info:x-wiley/crsRef/5770042" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD007419-bbs1-0005"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD007419-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0006">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">Aiello 2005</h4> </div> <div class="bibliography-section" id="CD007419-bib-0081"> <div class="citation-journal">Aiello LP. <span class="citation-title">Angiogenic pathways in diabetic retinopathy</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2005</span>;<span class="volume">353</span>(8):839‐41. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16120866" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Angiogenic+pathways+in+diabetic+retinopathy&author=LP+Aiello&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">Antcliff 1999</h4> </div> <div class="bibliography-section" id="CD007419-bib-0082"> <div class="citation-journal">Antcliff RJ, Marshall J. <span class="citation-title">The pathogenesis of edema in diabetic maculopathy</span>. <span class="citation"> Seminars in Ophthalmology </span><span class="pubYear">1999</span>;<span class="volume">14</span>(4):223‐32. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10758223" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+pathogenesis+of+edema+in+diabetic+maculopathy&author=RJ+Antcliff&author=J+Marshall&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">Arevalo 2013</h4> </div> <div class="bibliography-section" id="CD007419-bib-0083"> <div class="citation-journal">Arevalo JF, Lasave AF, Wu L, Diaz‐Llopis M, Gallego‐Pinazo R, Alezzandrini AA, et al. <span class="citation-title">Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan‐american Collaborative Retina Study Group at 24 months</span>. <span class="citation"> Retina </span><span class="pubYear">2013</span>;<span class="volume">33</span>(2):403‐13. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23222389" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+plus+grid+laser+photocoagulation+or+intravitreal+bevacizumab+or+grid+laser+photocoagulation+for+diffuse+diabetic+macular+edema:+results+of+the+Pan%E2%80%90american+Collaborative+Retina+Study+Group+at+24+months+&author=JF+Arevalo&author=AF+Lasave&author=L+Wu&author=M+Diaz%E2%80%90Llopis&author=R+Gallego%E2%80%90Pinazo&author=AA+Alezzandrini&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0056"> <div class="reference-title-banner"> <h4 class="title">ATC 1994</h4> </div> <div class="bibliography-section" id="CD007419-bib-0084"> <div class="citation-journal">Anonymous. <span class="citation-title">Collaborative overview of randomised trials of antiplatelet therapy‐I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration</span>. <span class="citation"> BMJ </span><span class="pubYear">1994</span>;<span class="volume">308</span>(6921):81‐106. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8298418" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Collaborative+overview+of+randomised+trials+of+antiplatelet+therapy%E2%80%90I:+Prevention+of+death,+myocardial+infarction,+and+stroke+by+prolonged+antiplatelet+therapy+in+various+categories+of+patients.+Antiplatelet+Trialists'+Collaboration+&author=+Anonymous&publication_year=1994&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0057"> <div class="reference-title-banner"> <h4 class="title">Banfi 2013</h4> </div> <div class="bibliography-section" id="CD007419-bib-0085"> <div class="citation-journal">Banfi R, Attanasio F, Palazzi N, Colombini S, Falai T, Cecchi M, et al. <span class="citation-title">Bevacizumab versus ranibizumab: why are we not playing the joker?</span>. <span class="citation"> International Journal of Clinical Pharmacy </span><span class="pubYear">2013</span>;<span class="volume">35</span>(4):507‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23625322" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Bevacizumab+versus+ranibizumab:+why+are+we+not+playing+the+joker?&author=R+Banfi&author=F+Attanasio&author=N+Palazzi&author=S+Colombini&author=T+Falai&author=M+Cecchi&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0058"> <div class="reference-title-banner"> <h4 class="title">Borm 2009</h4> </div> <div class="bibliography-section" id="CD007419-bib-0086"> <div class="citation-journal">Borm GF, Lemmers O, Fransen J, Donders R. <span class="citation-title">The evidence provided by a single trial is less reliable than its statistical analysis suggests</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2009</span>;<span class="volume">62</span>(7):711‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19171462" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+evidence+provided+by+a+single+trial+is+less+reliable+than+its+statistical+analysis+suggests+&author=GF+Borm&author=O+Lemmers&author=J+Fransen&author=R+Donders&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0059"> <div class="reference-title-banner"> <h4 class="title">Brown 2004</h4> </div> <div class="bibliography-section" id="CD007419-bib-0087"> <div class="citation-journal">Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. <span class="citation-title">Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2004</span>;<span class="volume">122</span>(3):330‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15006844" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Detection+of+diabetic+foveal+edema:+contact+lens+biomicroscopy+compared+with+optical+coherence+tomography+&author=JC+Brown&author=SD+Solomon&author=SB+Bressler&author=AP+Schachat&author=C+DiBernardo&author=NM+Bressler&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0060"> <div class="reference-title-banner"> <h4 class="title">Browning 2008</h4> </div> <div class="bibliography-section" id="CD007419-bib-0088"> <div class="citation-journal">Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU, Diabetic Retinopathy Clinical Research Network. <span class="citation-title">Diabetic macular edema: what is focal and what is diffuse?</span>. <span class="citation"> American Journal of Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">146</span>(5):649‐55. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18774122" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+macular+edema:+what+is+focal+and+what+is+diffuse?&author=DJ+Browning&author=MM+Altaweel&author=NM+Bressler&author=SB+Bressler&author=IU+Scott&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0061"> <div class="reference-title-banner"> <h4 class="title">Campochiaro 2010</h4> </div> <div class="bibliography-section" id="CD007419-bib-0089"> <div class="citation-journal">Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. <span class="citation-title">Ranibizumab for macular edema following branch retinal vein occlusion: six‐month primary end point results of a phase III study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">117</span>(6):1102‐12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20398941" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ranibizumab+for+macular+edema+following+branch+retinal+vein+occlusion:+six%E2%80%90month+primary+end+point+results+of+a+phase+III+study+&author=PA+Campochiaro&author=JS+Heier&author=L+Feiner&author=S+Gray&author=N+Saroj&author=AC+Rundle&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0062"> <div class="reference-title-banner"> <h4 class="title">CATT 2011</h4> </div> <div class="bibliography-section" id="CD007419-bib-0090"> <div class="citation-journal">CATT Research Group. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. <span class="citation-title">Ranibizumab and bevacizumab for neovascular age‐related macular degeneration</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2011</span>;<span class="volume">364</span>(20):1897‐908. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21526923" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ranibizumab+and+bevacizumab+for+neovascular+age%E2%80%90related+macular+degeneration&author=MG+Maguire&author=GS+Ying&author=JE+Grunwald&author=SL+Fine&author=GJ+Jaffe&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0063"> <div class="reference-title-banner"> <h4 class="title">Chaimani 2013</h4> </div> <div class="bibliography-section" id="CD007419-bib-0091"> <div class="citation-journal">Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. <span class="citation-title">Graphical tools for network meta‐analysis in STATA</span>. <span class="citation"> PLoS One </span><span class="pubYear">2013</span>;<span class="volume">8</span>(10):e76654. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24098547" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Graphical+tools+for+network+meta%E2%80%90analysis+in+STATA&author=A+Chaimani&author=JP+Higgins&author=D+Mavridis&author=P+Spyridonos&author=G+Salanti&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0064"> <div class="reference-title-banner"> <h4 class="title">Chong 2016</h4> </div> <div class="bibliography-section" id="CD007419-bib-0092"> <div class="citation-journal">Chong V. <span class="citation-title">Ranibizumab for the treatment of wet AMD: a summary of real‐world studies</span>. <span class="citation"> Eye </span><span class="pubYear">2016</span>;<span class="volume">30</span>(11):270‐86. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26634711" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ranibizumab+for+the+treatment+of+wet+AMD:+a+summary+of+real%E2%80%90world+studies&author=V+Chong&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0065"> <div class="reference-title-banner"> <h4 class="title">Ciulla 2003</h4> </div> <div class="bibliography-section" id="CD007419-bib-0093"> <div class="citation-journal">Ciulla TA, Amador AG, Zinman B. <span class="citation-title">Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2003</span>;<span class="volume">26</span>(9):2653‐64. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12941734" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+retinopathy+and+diabetic+macular+edema:+pathophysiology,+screening,+and+novel+therapies+&author=TA+Ciulla&author=AG+Amador&author=B+Zinman&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0066"> <div class="reference-title-banner"> <h4 class="title">Ciulla 2004</h4> </div> <div class="bibliography-section" id="CD007419-bib-0094"> <div class="citation-journal">Ciulla TA, Walker JD, Fong DS, Criswell MH. <span class="citation-title">Corticosteroids in posterior segment disease: an update on new delivery systems and new indications</span>. <span class="citation"> Current Opinions in Ophthalmology </span><span class="pubYear">2004</span>;<span class="volume">15</span>(3):211‐20. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Corticosteroids+in+posterior+segment+disease:+an+update+on+new+delivery+systems+and+new+indications+&author=TA+Ciulla&author=JD+Walker&author=DS+Fong&author=MH+Criswell&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0067"> <div class="reference-title-banner"> <h4 class="title">Cunningham 2005</h4> </div> <div class="bibliography-section" id="CD007419-bib-0095"> <div class="citation-journal">Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. <span class="citation-title">A phase II randomized double‐masked trial of pegaptanib, an anti‐vascular endothelial growth factor aptamer, for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2005</span>;<span class="volume">112</span>(10):1747‐57. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16154196" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+phase+II+randomized+double%E2%80%90masked+trial+of+pegaptanib,+an+anti%E2%80%90vascular+endothelial+growth+factor+aptamer,+for+diabetic+macular+edema+&author=ET+Cunningham&author=AP+Adamis&author=M+Altaweel&author=LP+Aiello&author=NM+Bressler&author=DJ+D'Amico&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0068"> <div class="reference-title-banner"> <h4 class="title">Deeks 2011</h4> </div> <div class="bibliography-section" id="CD007419-bib-0096"> <div class="citation-other">Deeks JJ, Higgins JP, Altman DG, editor(s). <span class="citation-title">Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0069"> <div class="reference-title-banner"> <h4 class="title">Dias 2010</h4> </div> <div class="bibliography-section" id="CD007419-bib-0097"> <div class="citation-journal">Dias S, Welton NJ, Caldwell DM, Ades AE. <span class="citation-title">Checking consistency in mixed treatment comparison meta‐analysis</span>. <span class="citation"> Statistics in Medicine </span><span class="pubYear">2010</span>;<span class="volume">29</span>:932‐944. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20213715" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Checking+consistency+in+mixed+treatment+comparison+meta%E2%80%90analysis&author=S+Dias&author=NJ+Welton&author=DM+Caldwell&author=AE+Ades&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0070"> <div class="reference-title-banner"> <h4 class="title">ETDRS 1985</h4> </div> <div class="bibliography-section" id="CD007419-bib-0098"> <div class="citation-journal">Early Treatment Diabetic Retinopathy Study Research Group. <span class="citation-title">Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">1985</span>;<span class="volume">103</span>(12):1796‐806. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2866759" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0071"> <div class="reference-title-banner"> <h4 class="title">EURETINA 2017</h4> </div> <div class="bibliography-section" id="CD007419-bib-0099"> <div class="citation-journal">Schmidt‐Erfurth U, Garcia‐Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. <span class="citation-title">Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)</span>. <span class="citation"> Ophthalmologica </span> 2017 Apr 20 [Epub ahead of print]. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0072"> <div class="reference-title-banner"> <h4 class="title">Ford 2012</h4> </div> <div class="bibliography-section" id="CD007419-bib-0100"> <div class="citation-journal">Ford JA, Elders A, Shyangdan D, Royle P, Waugh N. <span class="citation-title">The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review</span>. <span class="citation"> BMJ </span><span class="pubYear">2012</span>;<span class="volume">345</span>:e5182. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22890029" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+relative+clinical+effectiveness+of+ranibizumab+and+bevacizumab+in+diabetic+macular+oedema:+an+indirect+comparison+in+a+systematic+review+&author=JA+Ford&author=A+Elders&author=D+Shyangdan&author=P+Royle&author=N+Waugh&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0073"> <div class="reference-title-banner"> <h4 class="title">Frank 2004</h4> </div> <div class="bibliography-section" id="CD007419-bib-0101"> <div class="citation-journal">Frank RN. <span class="citation-title">Diabetic retinopathy</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2004</span>;<span class="volume">350</span>(1):48‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14702427" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetic+retinopathy&author=RN+Frank&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0074"> <div class="reference-title-banner"> <h4 class="title">Glanville 2006</h4> </div> <div class="bibliography-section" id="CD007419-bib-0102"> <div class="citation-journal">Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. <span class="citation-title">How to identify randomized controlled trials in MEDLINE: ten years on</span>. <span class="citation"> Journal of the Medical Library Association </span><span class="pubYear">2006</span>;<span class="volume">94</span>(2):130‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16636704" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=How+to+identify+randomized+controlled+trials+in+MEDLINE:+ten+years+on&author=JM+Glanville&author=C+Lefebvre&author=JN+Miles&author=J+Camosso%E2%80%90Stefinovic&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0075"> <div class="reference-title-banner"> <h4 class="title">GRADEpro 2014 [Computer program]</h4> </div> <div class="bibliography-section" id="CD007419-bib-0103"> <div class="citation-other">GRADE Working Group, McMaster University. <span class="citation-title">GRADEpro GDT</span>. Version accessed 6 April 2017. Hamilton (ON): GRADE Working Group, McMaster University, <span class="pubYear">2014</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0076"> <div class="reference-title-banner"> <h4 class="title">Grover 2008</h4> </div> <div class="bibliography-section" id="CD007419-bib-0104"> <div class="citation-journal">Grover D, Li TJ, Chong CC. <span class="citation-title">Intravitreal steroids for macular edema in diabetes</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2008</span>, Issue 1. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD005656.pub2" target="_blank"><span>10.1002/14651858.CD005656.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18254088" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+steroids+for+macular+edema+in+diabetes&author=D+Grover&author=TJ+Li&author=CC+Chong&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0077"> <div class="reference-title-banner"> <h4 class="title">Guyatt 2011</h4> </div> <div class="bibliography-section" id="CD007419-bib-0105"> <div class="citation-journal">Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso‐Coello P, Rind D, et al. <span class="citation-title">GRADE guidelines 6. Rating the quality of evidence‐imprecision</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2011</span>;<span class="volume">64</span>(12):1283‐93. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21839614" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=GRADE+guidelines+6.+Rating+the+quality+of+evidence%E2%80%90imprecision&author=GH+Guyatt&author=AD+Oxman&author=R+Kunz&author=J+Brozek&author=P+Alonso%E2%80%90Coello&author=D+Rind&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0078"> <div class="reference-title-banner"> <h4 class="title">Haller 2010</h4> </div> <div class="bibliography-section" id="CD007419-bib-0106"> <div class="citation-journal">Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. <span class="citation-title">Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">128</span>(3):289‐96. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20212197" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Randomized+controlled+trial+of+an+intravitreous+dexamethasone+drug+delivery+system+in+patients+with+diabetic+macular+edema+&author=JA+Haller&author=BD+Kuppermann&author=MS+Blumenkranz&author=GA+Williams&author=DV+Weinberg&author=C+Chou&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0079"> <div class="reference-title-banner"> <h4 class="title">Heier 2016</h4> </div> <div class="bibliography-section" id="CD007419-bib-0107"> <div class="citation-journal">Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, et al. <span class="citation-title">Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice</span>. <span class="citation"> JAMA Ophthalmology </span><span class="pubYear">2016</span>;<span class="volume">134</span>(1):95‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26512939" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+aflibercept,+bevacizumab,+and+ranibizumab+for+treatment+of+diabetic+macular+edema:+extrapolation+of+data+to+clinical+practice+&author=JS+Heier&author=NM+Bressler&author=RL+Avery&author=SJ+Bakri&author=DS+Boyer&author=DM+Brown&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0080"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011a</h4> </div> <div class="bibliography-section" id="CD007419-bib-0108"> <div class="citation-other">Higgins JP, Deeks JJ, Altman DG, editor(s). <span class="citation-title">Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0081"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011b</h4> </div> <div class="bibliography-section" id="CD007419-bib-0109"> <div class="citation-other">Higgins JP, Altman DG, Sterne JAC, editor(s). <span class="citation-title">Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0082"> <div class="reference-title-banner"> <h4 class="title">Higgins 2014</h4> </div> <div class="bibliography-section" id="CD007419-bib-0110"> <div class="citation-journal">Higgins JP, Giovane C, Chaimani A, Caldwell DM, Salanti G. <span class="citation-title">Evaluating the quality of evidence from a network meta‐analysis</span>. <span class="citation"> Value Health </span><span class="pubYear">2014</span>;<span class="volume">17</span>:A324. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27200533" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Evaluating+the+quality+of+evidence+from+a+network+meta%E2%80%90analysis&author=JP+Higgins&author=C+Giovane&author=A+Chaimani&author=DM+Caldwell&author=G+Salanti&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0083"> <div class="reference-title-banner"> <h4 class="title">Hussain 2015</h4> </div> <div class="bibliography-section" id="CD007419-bib-0111"> <div class="citation-journal">Hussain RM, Ciulla TA. <span class="citation-title">Treatment strategies for refractory diabetic macular edema: switching anti‐VEGF treatments, adopting corticosteroid‐based treatments, and combination therapy</span>. <span class="citation"> Expert Opinion on Biological Therapy </span><span class="pubYear">2016</span>;<span class="volume">16</span>(3):365‐74. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26674182" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+strategies+for+refractory+diabetic+macular+edema:+switching+anti%E2%80%90VEGF+treatments,+adopting+corticosteroid%E2%80%90based+treatments,+and+combination+therapy+&author=RM+Hussain&author=TA+Ciulla&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0084"> <div class="reference-title-banner"> <h4 class="title">Jampol 2014</h4> </div> <div class="bibliography-section" id="CD007419-bib-0112"> <div class="citation-journal">Jampol LM, Bressler NM, Glassman AR. <span class="citation-title">Revolution to a new standard treatment of diabetic macular edema</span>. <span class="citation"> JAMA </span><span class="pubYear">2014</span>;<span class="volume">311</span>(22):2269‐70. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24915254" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Revolution+to+a+new+standard+treatment+of+diabetic+macular+edema&author=LM+Jampol&author=NM+Bressler&author=AR+Glassman&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0085"> <div class="reference-title-banner"> <h4 class="title">Jiang 2015</h4> </div> <div class="bibliography-section" id="CD007419-bib-0113"> <div class="citation-journal">Jiang S, Barner JC, Park C, Ling YL. <span class="citation-title">Treatment patterns of anti‐vascular endothelial growth factor and laser therapy among patients with diabetic macular edema</span>. <span class="citation"> Journal of Managed Care and Specialty Pharmacy </span><span class="pubYear">2015</span>;<span class="volume">21</span>(9):735‐41. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26308221" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+patterns+of+anti%E2%80%90vascular+endothelial+growth+factor+and+laser+therapy+among+patients+with+diabetic+macular+edema+&author=S+Jiang&author=JC+Barner&author=C+Park&author=YL+Ling&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0086"> <div class="reference-title-banner"> <h4 class="title">Klein 1984</h4> </div> <div class="bibliography-section" id="CD007419-bib-0114"> <div class="citation-journal">Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. <span class="citation-title">The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1984</span>;<span class="volume">91</span>(12):1464‐74. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6521986" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Wisconsin+epidemiologic+study+of+diabetic+retinopathy.+IV.+Diabetic+macular+edema&author=R+Klein&author=BE+Klein&author=SE+Moss&author=MD+Davis&author=DL+DeMets&publication_year=1984&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0087"> <div class="reference-title-banner"> <h4 class="title">Korobelnik 2015</h4> </div> <div class="bibliography-section" id="CD007419-bib-0115"> <div class="citation-journal">Korobelnik JF, Kleijnen J, Lang SH, Birnie R, Leadley RM, Misso K, et al. <span class="citation-title">Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)</span>. <span class="citation"> BMC Ophthalmology </span><span class="pubYear">2015</span>;<span class="volume">15</span>:52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25975823" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Systematic+review+and+mixed+treatment+comparison+of+intravitreal+aflibercept+with+other+therapies+for+diabetic+macular+edema+(DME)+&author=JF+Korobelnik&author=J+Kleijnen&author=SH+Lang&author=R+Birnie&author=RM+Leadley&author=K+Misso&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0088"> <div class="reference-title-banner"> <h4 class="title">Kuppermann 2010</h4> </div> <div class="bibliography-section" id="CD007419-bib-0116"> <div class="citation-journal">Kuppermann BD, Chou C, Weinberg DV, Whitcup SM, Haller JA, Blumenkranz MS. <span class="citation-title">Intravitreous dexamethasone effects on different patterns of diabetic macular edema</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">128</span>(5):642‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20212194" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreous+dexamethasone+effects+on+different+patterns+of+diabetic+macular+edema&author=BD+Kuppermann&author=C+Chou&author=DV+Weinberg&author=SM+Whitcup&author=JA+Haller&author=MS+Blumenkranz&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0089"> <div class="reference-title-banner"> <h4 class="title">MEDCAC 2012</h4> </div> <div class="bibliography-section" id="CD007419-bib-0117"> <div class="citation-other"><span class="citation-title">Anti‐vascular endothelial growth factor treatment for diabetic macular edema</span>. www.cms.gov/medicare‐coverage‐database/details/technology‐assessments‐details.aspx?TAId=85&amp;bc=AAAQAAAAAAAA&amp; (accessed 24 Sept 2012). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0090"> <div class="reference-title-banner"> <h4 class="title">Moja 2014</h4> </div> <div class="bibliography-section" id="CD007419-bib-0118"> <div class="citation-journal">Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. <span class="citation-title">Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2014</span>, Issue 9. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD011230.pub2" target="_blank"><span>10.1002/14651858.CD011230.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Systemic+safety+of+bevacizumab+versus+ranibizumab+for+neovascular+age%E2%80%90related+macular+degeneration+&author=L+Moja&author=E+Lucenteforte&author=KH+Kwag&author=V+Bertele&author=A+Campomori&author=U+Chakravarthy&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0091"> <div class="reference-title-banner"> <h4 class="title">Olson 2013</h4> </div> <div class="bibliography-section" id="CD007419-bib-0119"> <div class="citation-journal">Olson J, Sharp P, Goatman K, Prescott G, Scotland G, Fleming A, et al. <span class="citation-title">Improving the economic value of photographic screening for optical coherence tomography‐detectable macular oedema: a prospective, multicentre, UK study</span>. <span class="citation"> Health Technology Assessment </span><span class="pubYear">2013</span>;<span class="volume">17</span>(51):1‐142. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24225334" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improving+the+economic+value+of+photographic+screening+for+optical+coherence+tomography%E2%80%90detectable+macular+oedema:+a+prospective,+multicentre,+UK+study+&author=J+Olson&author=P+Sharp&author=K+Goatman&author=G+Prescott&author=G+Scotland&author=A+Fleming&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0092"> <div class="reference-title-banner"> <h4 class="title">Ontario HTA 2009</h4> </div> <div class="bibliography-section" id="CD007419-bib-0120"> <div class="citation-journal">Medical Advisory Secretariat. <span class="citation-title">Optical coherence tomography for age‐related macular degeneration and diabetic macular edema: an evidence‐based analysis</span>. <span class="citation"> Ontario Health Technology Assessment Series </span><span class="pubYear">2009</span>;<span class="volume">9</span>(13):1‐22. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0093"> <div class="reference-title-banner"> <h4 class="title">OZDRY 2015</h4> </div> <div class="bibliography-section" id="CD007419-bib-0121"> <div class="citation-journal">Ramu J, Yang Y, Menon G, Bailey C, Narendran N, Bunce C, et al. <span class="citation-title">A randomized clinical trial comparing fixed vs pro‐re‐nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study)</span>. <span class="citation"> Eye </span><span class="pubYear">2015</span>;<span class="volume">29</span>(12):1603‐12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26493038" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+randomized+clinical+trial+comparing+fixed+vs+pro%E2%80%90re%E2%80%90nata+dosing+of+Ozurdex+in+refractory+diabetic+macular+oedema+(OZDRY+study)+&author=J+Ramu&author=Y+Yang&author=G+Menon&author=C+Bailey&author=N+Narendran&author=C+Bunce&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0094"> <div class="reference-title-banner"> <h4 class="title">Pagliarini 2014</h4> </div> <div class="bibliography-section" id="CD007419-bib-0122"> <div class="citation-journal">Pagliarini S, Beatty S, Lipkova B, Perez‐Salvador Garcia E, Reynders S, et al. <span class="citation-title">A 2‐year, phase IV, multicentre, observational study of ranibizumab 0.5 mg in patients with neovascular age‐related macular degeneration in routine clinical practice: The EPICOHORT study</span>. <span class="citation"> Journal of Ophthalmology </span><span class="pubYear">2014</span>;<span class="volume">2014</span>:Article ID 857148. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1155/2014/857148" target="_blank"><span>10.1155/2014/857148</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+2%E2%80%90year,+phase+IV,+multicentre,+observational+study+of+ranibizumab+0.5+mg+in+patients+with+neovascular+age%E2%80%90related+macular+degeneration+in+routine+clinical+practice:+The+EPICOHORT+study+&author=S+Pagliarini&author=S+Beatty&author=B+Lipkova&author=E+Perez%E2%80%90SalvadorGarcia&author=S+Reynders&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0095"> <div class="reference-title-banner"> <h4 class="title">Patrao 2016</h4> </div> <div class="bibliography-section" id="CD007419-bib-0123"> <div class="citation-journal">Patrao NV, Antao S, Egan C, Omar A, Hamilton R, Hykin PG, et al. <span class="citation-title">Real‐world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom national health service setting</span>. <span class="citation"> American Journal of Ophthalmology </span><span class="pubYear">2016</span>;<span class="volume">172</span>:51‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27637784" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Real%E2%80%90world+outcomes+of+ranibizumab+treatment+for+diabetic+macular+edema+in+a+United+Kingdom+national+health+service+setting+&author=NV+Patrao&author=S+Antao&author=C+Egan&author=A+Omar&author=R+Hamilton&author=PG+Hykin&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0096"> <div class="reference-title-banner"> <h4 class="title">PLACID 2013</h4> </div> <div class="bibliography-section" id="CD007419-bib-0124"> <div class="citation-journal">Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al. <span class="citation-title">Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">120</span>(9):1843‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23706947" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dexamethasone+intravitreal+implant+in+combination+with+laser+photocoagulation+for+the+treatment+of+diffuse+diabetic+macular+edema+&author=DG+Callanan&author=S+Gupta&author=DS+Boyer&author=TA+Ciulla&author=MA+Singer&author=BD+Kuppermann&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0097"> <div class="reference-title-banner"> <h4 class="title">Regnier 2014</h4> </div> <div class="bibliography-section" id="CD007419-bib-0125"> <div class="citation-journal">Regnier S, Malcolm W, Allen F, Wright J, Bezlyak V. <span class="citation-title">Efficacy of anti‐VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta‐analysis</span>. <span class="citation"> PloS ONE </span><span class="pubYear">2014</span>;<span class="volume">9</span>(7):e102309. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25029255" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+of+anti%E2%80%90VEGF+and+laser+photocoagulation+in+the+treatment+of+visual+impairment+due+to+diabetic+macular+edema:+a+systematic+review+and+network+meta%E2%80%90analysis+&author=S+Regnier&author=W+Malcolm&author=F+Allen&author=J+Wright&author=V+Bezlyak&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0098"> <div class="reference-title-banner"> <h4 class="title">Review Manager 5 2014 [Computer program]</h4> </div> <div class="bibliography-section" id="CD007419-bib-0126"> <div class="citation-other">Nordic Cochrane Centre, The Cochrane Collaboration. <span class="citation-title">Review Manager 5 (RevMan 5)</span>. Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, <span class="pubYear">2014</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0099"> <div class="reference-title-banner"> <h4 class="title">Salanti 2012</h4> </div> <div class="bibliography-section" id="CD007419-bib-0127"> <div class="citation-journal">Salanti G. <span class="citation-title">Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool</span>. <span class="citation"> Research Synthesis Methods </span><span class="pubYear">2012</span>;<span class="volume">3</span>:80‐97. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26062083" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Indirect+and+mixed%E2%80%90treatment+comparison,+network,+or+multiple%E2%80%90treatments+meta%E2%80%90analysis:+many+names,+many+benefits,+many+concerns+for+the+next+generation+evidence+synthesis+tool+&author=G+Salanti&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0100"> <div class="reference-title-banner"> <h4 class="title">Salanti 2014</h4> </div> <div class="bibliography-section" id="CD007419-bib-0128"> <div class="citation-journal">Salanti G, Giovane C, Chaimani A, Caldwell DM, Higgins JP. <span class="citation-title">Evaluating the quality of evidence from a network meta‐analysis</span>. <span class="citation"> PLoS One </span><span class="pubYear">2014</span>;<span class="volume">9</span>:e99682. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24992266" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Evaluating+the+quality+of+evidence+from+a+network+meta%E2%80%90analysis&author=G+Salanti&author=C+Giovane&author=A+Chaimani&author=DM+Caldwell&author=JP+Higgins&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0101"> <div class="reference-title-banner"> <h4 class="title">Schünemann 2011</h4> </div> <div class="bibliography-section" id="CD007419-bib-0129"> <div class="citation-other">Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. <span class="citation-title">Chapter 12: Interpreting results and drawing conclusions.In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0102"> <div class="reference-title-banner"> <h4 class="title">Stewart 2016</h4> </div> <div class="bibliography-section" id="CD007419-bib-0130"> <div class="citation-journal">Stewart MW, Narayanan R, Gupta V, Rosenfeld PJ, Martin DF, Chakravarthy U. <span class="citation-title">Counterfeit Avastin in India: Punish the criminals, not the patients</span>. <span class="citation"> American Journal of Ophthalmology </span><span class="pubYear">2016</span>;<span class="volume">170</span>:228‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27287822" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Counterfeit+Avastin+in+India:+Punish+the+criminals,+not+the+patients&author=MW+Stewart&author=R+Narayanan&author=V+Gupta&author=PJ+Rosenfeld&author=DF+Martin&author=U+Chakravarthy&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0103"> <div class="reference-title-banner"> <h4 class="title">Tranos 2004</h4> </div> <div class="bibliography-section" id="CD007419-bib-0131"> <div class="citation-journal">Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. <span class="citation-title">Macular edema</span>. <span class="citation"> Survey of Ophthalmology </span><span class="pubYear">2004</span>;<span class="volume">49</span>(5):470‐90. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15325193" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Macular+edema&author=PG+Tranos&author=SS+Wickremasinghe&author=NT+Stangos&author=F+Topouzis&author=I+Tsinopoulos&author=CE+Pavesio&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0104"> <div class="reference-title-banner"> <h4 class="title">White 2015</h4> </div> <div class="bibliography-section" id="CD007419-bib-0132"> <div class="citation-journal">White IR. <span class="citation-title">Network meta‐analysis</span>. <span class="citation"> Stata Journal </span><span class="pubYear">2015</span>;<span class="volume">15</span>:951‐85. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Network+meta%E2%80%90analysis&author=IR+White&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0105"> <div class="reference-title-banner"> <h4 class="title">Yau 2012</h4> </div> <div class="bibliography-section" id="CD007419-bib-0133"> <div class="citation-journal">Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. <span class="citation-title">Global prevalence and major risk factors of diabetic retinopathy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2012</span>;<span class="volume">35</span>(3):556‐64. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22301125" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Global+prevalence+and+major+risk+factors+of+diabetic+retinopathy&author=JW+Yau&author=SL+Rogers&author=R+Kawasaki&author=EL+Lamoureux&author=JW+Kowalski&author=T+Bek&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0106"> <div class="reference-title-banner"> <h4 class="title">Zhang 2016</h4> </div> <div class="bibliography-section" id="CD007419-bib-0134"> <div class="citation-journal">Zhang L, Wang W, Gao Y, Lan J, Xie L. <span class="citation-title">The efficacy and safety of current treatments in diabetic macular edema: a systematic review and network meta‐analysis</span>. <span class="citation"> PLoS One </span><span class="pubYear">2016</span>;<span class="volume">11</span>:e0159553. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27434498" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+efficacy+and+safety+of+current+treatments+in+diabetic+macular+edema:+a+systematic+review+and+network+meta%E2%80%90analysis+&author=L+Zhang&author=W+Wang&author=Y+Gao&author=J+Lan&author=L+Xie&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD007419-bbs2-0107"> <div class="reference-title-banner"> <h4 class="title">Ziemssen 2017</h4> </div> <div class="bibliography-section" id="CD007419-bib-0135"> <div class="citation-journal">Ziemssen F, Feltgen N, Holz FG, Guthoff R, Ringwald A, Bertelmann T, et al. <span class="citation-title">Demographics of patients receiving Intravitrealanti‐VEGF treatment in real‐world practice: healthcare research data versus randomized controlled trials</span>. <span class="citation"> BMC Ophthalmology </span><span class="pubYear">2017</span>;<span class="volume">17</span>:7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28103831" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Demographics+of+patients+receiving+Intravitrealanti%E2%80%90VEGF+treatment+in+real%E2%80%90world+practice:+healthcare+research+data+versus+randomized+controlled+trials+&author=F+Ziemssen&author=N+Feltgen&author=FG+Holz&author=R+Guthoff&author=A+Ringwald&author=T+Bertelmann&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD007419-bbs1-0006"> <h3 class="title">References to other published versions of this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD007419-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD007419-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_otherVersions" id="CD007419-bbs2-0108"> <div class="reference-title-banner"> <h4 class="title">Parravano 2008</h4> </div> <div class="bibliography-section" id="CD007419-bib-0136"> <div class="citation-journal">Parravano M, Menchini F. <span class="citation-title">Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2008</span>, Issue 4. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD007419" target="_blank"><span>10.1002/14651858.CD007419</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Antiangiogenic+therapy+with+anti%E2%80%90vascular+endothelial+growth+factor+modalities+for+diabetic+macular+oedema+&author=M+Parravano&author=F+Menchini&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_otherVersions" id="CD007419-bbs2-0109"> <div class="reference-title-banner"> <h4 class="title">Parravano 2009</h4> </div> <div class="bibliography-section" id="CD007419-bib-0137"> <div class="citation-journal">Parravano M, Menchini F, Virgili G. <span class="citation-title">Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2009</span>, Issue 4. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD007419.pub2" target="_blank"><span>10.1002/14651858.CD007419.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19821414" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Antiangiogenic+therapy+with+anti%E2%80%90vascular+endothelial+growth+factor+modalities+for+diabetic+macular+oedema+&author=M+Parravano&author=F+Menchini&author=G+Virgili&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_otherVersions" id="CD007419-bbs2-0110"> <div class="reference-title-banner"> <h4 class="title">Virgili 2012</h4> </div> <div class="bibliography-section" id="CD007419-bib-0138"> <div class="citation-journal">Virgili G, Parravano M, Menchini F, Brunetti M. <span class="citation-title">Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2012</span>, Issue 12. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD007419.pub3" target="_blank"><span>10.1002/14651858.CD007419.pub3</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23235642" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Antiangiogenic+therapy+with+anti%E2%80%90vascular+endothelial+growth+factor+modalities+for+diabetic+macular+oedema+&author=G+Virgili&author=M+Parravano&author=F+Menchini&author=M+Brunetti&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_otherVersions" id="CD007419-bbs2-0111"> <div class="reference-title-banner"> <h4 class="title">Virgili 2014</h4> </div> <div class="bibliography-section" id="CD007419-bib-0139"> <div class="citation-journal">Virgili G, Parravano M, Menchini F, Evans JR. <span class="citation-title">Anti‐vascular endothelial growth factor for diabetic macular oedema</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2014</span>, Issue 11. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD007419.pub4" target="_blank"><span>10.1002/14651858.CD007419.pub4</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90vascular+endothelial+growth+factor+for+diabetic+macular+oedema&author=G+Virgili&author=M+Parravano&author=F+Menchini&author=JR+Evans&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD007419-sec2-0033"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD007419-sec2-0034" class="jump-to">excluded studies</a></li> <li><a href="#CD007419-sec2-0035" class="jump-to">awaiting classification</a></li> <li><a href="#CD007419-sec2-0036" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ahmadieh 2008 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>People were randomly allocated to treatment but in bilateral cases eyes were randomly allocated to treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Iran</p> <p>Number of people randomised: 101 (115 eyes)</p> <p>Average age: 60 years (range 39 to 74)</p> <p>Sex: 51% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0016"> <li> <p>CSMO unresponsive to previous macular laser photocoagulation (with the last session being more than 3 months prior) </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0017"> <li> <p>VA ≥ 20/40</p> </li> <li> <p>history of cataract surgery within the past 6 months</p> </li> <li> <p>prior intraocular injection or vitrectomy</p> </li> <li> <p>glaucoma or ocular hypertension</p> </li> <li> <p>PDR with high‐risk characteristics</p> </li> <li> <p>vitreous haemorrhage</p> </li> <li> <p>significant media opacity</p> </li> <li> <p>presence of traction on the macula</p> </li> <li> <p>monocular</p> </li> <li> <p>pregnancy</p> </li> <li> <p>serum creatinine level ≥ 3 mg/100ml</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0018"> <li> <p>bevacizumab (1.25 mg) n = ? (41 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0019"> <li> <p>sham injection n = ? (37 eyes)</p> </li> </ul> </p> <p><i>"Three consecutive injections were performed at 6‐week intervals. Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the IVB group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann‐La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30‐gauge needle through the superotemporal quadrant."</i> Page 485 </p> <p><i>"In the control group, a needleless syringe was pressed against the conjunctiva and sclera in each session."</i> Page 485 </p> <p>There was another intervention arm that combined bevacizumab with triamcinolone acetonide, but this is not included in this review (n = 37 eyes) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0020"> <li> <p>change in CRT</p> </li> </ul> </p> <p><i>"Central macular thickness was defined by the average thickness of a central macularregion 1,000 ìm in diameter centered on the patient’s foveola."</i> Page 485 </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0021"> <li> <p>change in BCVA (logMAR)</p> </li> <li> <p>intraocular pressure</p> </li> <li> <p>cataract progression</p> </li> <li> <p>intraocular inflammation</p> </li> <li> <p>any serious adverse event</p> </li> </ul> </p> <p>Follow‐up: 18 and 24 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Date study conducted: November 2005 to September 2006</p> <p>Funding: not reported</p> <p>Conflict of interest: <i>"The authors have no proprietary interest in this study."</i> </p> <p>Trial registration: NCT00370422</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Randomization was performed using a random block permutation method according to a computer‐generated randomization list. The block lengths varied randomly. A random allocation sequence was performed by a biostatistician. Details of the series were unknown to the investigators."</i> Page 485 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Randomization was performed using a random block permutation method according to a computer‐generated randomization list. The block lengths varied randomly. A random allocation sequence was performed by a biostatistician. Details of the series were unknown to the investigators."</i> Page 485 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Subjects were masked to the treatment modality. Visual acuity assessment and OCT were performed by optometrists who were masked to the groups."</i> Page 485 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No incomplete outcome data were reported, but number of participants at 24 weeks' follow‐up was not speciﬁed </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study protocol is mentioned. However, dichotomous VA outcomes are not provided</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>28 eyes of 14 participants (14%) with bilateral CSMO were included in the analysis</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Azad 2012 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, unclear how eye selected</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: India</p> <p>Number of people randomised: 40 (40 eyes)</p> <p>Average age: 54 years</p> <p>Sex: 42% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0022"> <li> <p>diffuse DMO on FFA refractory to at least two prior sessions of macular laser photocoagulation</p> </li> <li> <p>CRT &gt; 250 µm on TD‐OCT</p> </li> <li> <p>no evidence of vitreo‐retinal traction</p> </li> <li> <p>good metabolic control (HbA1c &lt; 7.0%)</p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0023"> <li> <p>history of having received prior intraocular, peribulbar or systemic steroids or prior anti‐VEGF therapy </p> </li> <li> <p>uncontrolled diabetes mellitus</p> </li> <li> <p>diabetic nephropathy</p> </li> <li> <p>uncontrolled hypertension</p> </li> <li> <p>history of myocardial infarction, stroke or other thromboembolic</p> </li> <li> <p>episode</p> </li> <li> <p>monocular</p> </li> <li> <p>not available for a follow‐up duration of at least 6 months</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0024"> <li> <p>bevacizumab (1.25 mg) n = 20 (20 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0025"> <li> <p>macular grid augmentation n = 20 (20 eyes)</p> </li> </ul> </p> <p><i>"IVB [...] injected via pars plana route in the doses mentioned above by a single experienced investigator using full aseptic precautions. Postinjection, all patients were prescribed topical moxifloxacin 0.5% qid for 5 days. Macular grid laser augmentation was performed by a single experienced examiner according to the modified ETDRS protocol with a spot size of 100 μ, pulse duration of 100 ms, and a power of 50–100 mW titrated to produce mild intensity burns in areas showing diffuse leakage on the FFA in a ‘C’ shaped zone between 500 and 3000μ from the foveal center sparing the papilla‐macular bundle."</i> Page 167 </p> <p>Another intervention arm evaluated triamcinolone acetonide, but is not included in this review (n = 20 eyes) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Outcomes:</p> <p> <ul id="CD007419-lst1-0026"> <li> <p>BCVA measured used Snellen chart (mean at follow‐up, gain/loss of 3 lines)</p> </li> <li> <p>CRT assessed using OCT</p> </li> <li> <p>adverse effects (increased IOP, cataract progression, others)</p> </li> </ul> </p> <p>Primary outcome: not specified</p> <p>Follow‐up: 1, 3 and 6 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Date study conducted: not reported</p> <p>Funding: not reported</p> <p>Conflict of interest: not reported</p> <p>Trial registration: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No loss to follow‐up reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>VA data and other outcomes incompletely reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">BOLT 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person; if both eyes were eligible eye with worse VA was selected</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: UK</p> <p>Number of people randomised: 80 (80 eyes)</p> <p>Average age: 64 years (range 40 to 86)</p> <p>Sex: 31% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0027"> <li> <p>18 years or older</p> </li> <li> <p>diabetes mellitus</p> </li> <li> <p>BCVA in the study eye between 35 and 69 ETDRS letters at 4 m (Snellen equivalent 6/60 or 6/12) </p> </li> <li> <p>centre‐involving CSMO with CRT on OCT of ≥ 270 µm</p> </li> <li> <p>media clarity, pupillary dilation, and subject co‐operation sufficient for adequate fundus imaging </p> </li> <li> <p>at least 1 prior macular laser therapy</p> </li> <li> <p>intraocular pressure &lt; 30 mmHg</p> </li> <li> <p>ability to return for regular study visits</p> </li> <li> <p>fellow eye ≥ BCVA 3/60</p> </li> <li> <p>fellow eye received no anti‐VEGF treatment within the past 3 months and there was no expectation of such treatment during the study </p> </li> </ul> </p> <p>Exclusion criteria: (for study eye)</p> <p> <ul id="CD007419-lst1-0028"> <li> <p>macular ischaemia (FAZ ≥ 1000 µm GLD or severe perifoveal intercapillary loss on FFA)</p> </li> <li> <p>macular oedema due to a cause other than DMO</p> </li> <li> <p>pre‐existing ocular condition that was likely to preclude VA improvement despite resolution of macular oedema </p> </li> <li> <p>ocular condition that may affect macular oedema or alter VA during the course of the study, any treatment for DMO in the preceding 3 months </p> </li> <li> <p>PRP within 3 months of enrolment or anticipated 6 months thereafter</p> </li> <li> <p>PDR except for tufts of new vessels elsewhere &lt; 1 disc in area with no vitreous haemorrhage</p> </li> <li> <p>HbA1c &gt; 11.0%</p> </li> <li> <p>medical history of chronic renal failure requiring dialysis or kidney transplantation</p> </li> <li> <p>BP &gt; 170/100 mmHg</p> </li> <li> <p>any thromboembolic event within 6 months</p> </li> <li> <p>unstable angina, or evidence of active ischaemia on electrocardiogram at time of screening</p> </li> <li> <p>major surgery within 28 days of randomisation or planned during the subsequent 12 months </p> </li> <li> <p>participation in an investigational drug trial within 30 days of randomisation (or any time during the study) </p> </li> <li> <p>systemic anti‐VEGF or pro‐VEGF treatment within 3 months of enrolment</p> </li> <li> <p>pregnancy, breast feeding, or intention to become pregnant within the study period</p> </li> <li> <p>intraocular surgery within 3 months of randomisation</p> </li> <li> <p>aphakia</p> </li> <li> <p>uncontrolled glaucoma</p> </li> <li> <p>significant external ocular disease</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0029"> <li> <p>bevacizumab (1.25 mg) n = 42 (42 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0030"> <li> <p>macular laser therapy (MLT) n = 38 (38 eyes)</p> </li> </ul> </p> <p><i>"Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Roche Registration Limited, UK) was prepared by Moorfields Pharmaceuticals (London, UK) as a prefilled syringe containing 0.13 ml. In a designated intravitreal treatment room, under sterile conditions, using topical anesthesia and povidone‐iodine 5% into the conjunctival sac and onto the lid margins, and following application of a drape and insertion of a lid speculum, injections were undertaken with a 30‐gauge needle through the supra‐ or infratemporal quadrant, with a drop of ofloxacin placed in the fornix at the end of the procedure. Patency of the central retinal artery was determined by indirect ophthalmoscopy and VA of hand movements or better. The IOP was checked 30 minutes after the injection, and if the pressure was increased (30 mmHg) appropriate treatment was commenced. After the injection, topical ofloxacin was instilled 4 times per day for 4 days"</i>. Page 1080 </p> <p><i>"After baseline IVB, patients received 2 further IVB injections (6‐ and 12‐week time points). Subsequent</i> IVB<i>injections were guided by an OCT‐based retreatment protocol. In brief, if the thinnest recorded central retinal thickness was less than 270 m at 18 weeks, then treatment was continued only if macular thickness was not “stable.” If central retinal thickness was greater than 270 m at 18 weeks and subsequent visits, then</i> IV<i>B injections were administered until a “stable” macular thickness was attained. “Stable macular thickness” was defined as 3 consecutive visits with the central retinal thickness within 20 m of the patient’s thinnest recorded central retinal thickness. Patients could thereby receive a minimum of 3 injections and a maximum of 9 injections in the first 12 months."</i> Page 1080 </p> <p><i>"Modified ETDRS MLT comprised 50 m argon laser spot size, laser applied only greater than 500 m from the edge of the FAZ, with focal treatment aiming to cause mild blanching of the retinal pigment epithelium and not darkening/whitening of microaneurysms. Areas of diffuse leakage or nonperfusion were similarly treated in a grid pattern."</i> Page 1080 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0031"> <li> <p>mean change in BCVA (EDTRS letters measured at 4 m)</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0032"> <li> <p>mean CRT and mean change in CRT</p> </li> <li> <p>gain and loss of 15 and 10 letters of ETDRS</p> </li> <li> <p>loss of 30 ETDRS letters</p> </li> <li> <p>retinopathy severity (ETDRS grading)</p> </li> <li> <p>safety</p> </li> </ul> <ul class="plain" id="CD007419-lst1-0033"> <li> <ul id="CD007419-lst2-0001"> <li> <p>GLD of the FAZ</p> </li> <li> <p>area of the FAZ</p> </li> <li> <p>Retinal Nerve Fibre Layer thickness</p> </li> <li> <p>other ocular side effects</p> </li> <li> <p>systemic side effects, including thromboembolic events, BP, and ECG findings</p> </li> </ul> </li> </ul> </p> <p>Follow‐up: 12 and 24 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Date study conducted: May 2007 to August 2009</p> <p>Funding:<i>"Supported by grants from Moorfields Special Trustees and the National Institute for Health Research UK to the Biomedical Research Center for Ophthalmology based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology."</i> </p> <p>Conflict of interest: <i>"The author(s) have no proprietary or commercial interest in any materials discussed in this article"</i> </p> <p>Trial registration: eudract.ema.europa.eu Identifier: 2007‐000847‐89</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Patients were randomised into 2 groups by means of an in‐house computerized randomization program. The research investigator was not involved in the randomization process. Patients were stratified for BCVA, with the aim being that both groups would have comparable mean baseline BCVAs."</i> Page 1080 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The doctor had to phone the Clinical Trial Unit in order to obtain a randomisation from the statistician [personal communication from investigators] </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Although the patient and the study physician were not masked to the therapeutic modality, the study optometrist, OCT technician, photographer, graders performing assessment of the FAZ and ETDRS retinopathy grading, and study statistician were all masked to the patient randomization."</i> Page 1080 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Two patients in the laser group did not complete 12 months of follow‐up (1 patient moved away, and 1 patient could not be contacted). They were last reviewed at the 32‐week time point,with these data being carried forward and an intention‐to‐treat analysis undertaken. All 42 patients in the</i> IVB<i>group completed the study."</i> Page 1082 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>We could not find a protocol but primary outcomes were stated in the methods and were those routinely used in the field </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk for most items; we considered masking of outcome assessors, though not of participants and physicians, sufficient to ensure unbiased outcome measurement </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DA VINCI 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, unclear how eye selected</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA, Canada and Austria</p> <p>Number of people randomised: 221 (221 eyes)</p> <p>Average age: 64 years (range 40 to 86)</p> <p>Sex: 31% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0034"> <li> <p>18 years or older</p> </li> <li> <p>diabetes mellitus</p> </li> <li> <p>DMO involving the central macula defined as CRT ≥ 250 µm in the central subfield based on Stratus OCT </p> </li> <li> <p>BCVA letter score at 4 m of 73‐24 (Snellen equivalent: 20/40–20/320) measured by the ETDRS protocol </p> </li> <li> <p>women of childbearing potential were included only if they were willing to not become pregnant and to use a reliable form of birth control during the study period </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p>(for study eye)</p> <p> <ul id="CD007419-lst1-0035"> <li> <p>history of vitreoretinal surgery</p> </li> <li> <p>PRP or macular laser photocoagulation or use of intraocular or periocular corticosteroids or anti‐angiogenic drugs within 3 months of screening </p> </li> <li> <p>vision decrease due to causes other than DMO</p> </li> <li> <p>PDR (unless regressed and currently inactive)</p> </li> <li> <p>ocular inflammation</p> </li> <li> <p>cataract or other intraocular surgery within 3 months of screening</p> </li> <li> <p>laser capsulotomy within 2 months of screening</p> </li> <li> <p>aphakia</p> </li> <li> <p>spherical equivalent of &gt; −8 dioptres or any concurrent disease that would compromise VA or require medical or surgical intervention during the study period </p> </li> </ul> </p> <p>(in either eye)</p> <p> <ul id="CD007419-lst1-0036"> <li> <p>active iris neovascularisation</p> </li> <li> <p>vitreous haemorrhage</p> </li> <li> <p>traction retinal detachment</p> </li> <li> <p>preretinal fibrosis involving the macula</p> </li> <li> <p>visually significant vitreomacular traction or epiretinal membrane evident biomicroscopically or on OCT </p> </li> <li> <p>history of idiopathic or autoimmune uveitis</p> </li> <li> <p>structural damage to the center of the macula that is likely to preclude improvement in VA after the resolution of macular oedema </p> </li> <li> <p>uncontrolled glaucoma or previous filtration surgery</p> </li> <li> <p>infectious blepharitis, keratitis, scleritis, or conjunctivitis</p> </li> <li> <p>current treatment for serious systemic infection</p> </li> </ul> </p> <p>(systemic)</p> <p> <ul id="CD007419-lst1-0037"> <li> <p>uncontrolled diabetes mellitus</p> </li> <li> <p>uncontrolled hypertension</p> </li> <li> <p>history of cerebral vascular accident or myocardial infarction within 6 months</p> </li> <li> <p>renal failure requiring dialysis or renal transplant</p> </li> <li> <p>pregnancy or lactation</p> </li> <li> <p>history of allergy to fluorescein or povidone iodine</p> </li> <li> <p>only 1 functional eye</p> </li> <li> <p>ocular condition in the fellow eye with a poorer prognosis than the study eye</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0038"> <li> <p>VEGF Trap‐Eye n = 177 (177 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0039"> <li> <p>laser photocoagulation n = 44 (44 eyes)</p> </li> </ul> </p> <p><i>"Patients were randomly assigned in a 1:1:1:1:1 ratio to 1 of 5 treatment regimens in 1 eye only: 0.5 mg VEGF Trap‐Eye every 4 weeks (0.5q4); 2 mg VEGF Trap‐Eye every 4 weeks (2q4); 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then every 8 weeks, (2q8); 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then on an as‐needed (PRN) basis (2 PRN); or macular laser treatment by the modified ETDRS protocol"</i> Page 1820 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0040"> <li> <p>change in BCVA from baseline to week 24 (ETDRS chart at 4 m)</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0041"> <li> <p>retinal thickness assessed by OCT</p> </li> <li> <p>safety and tolerability</p> </li> <li> <p>change in BCVA from baseline at week 52</p> </li> <li> <p>proportion of eyes that gained at least 15 ETDRS letters in BCVA compared with baseline at weeks 24 and 52 </p> </li> <li> <p>the change in CRT (central subﬁeld on OCT) from baseline to weeks 24 and 52</p> </li> <li> <p>number of focal laser treatments given</p> </li> </ul> </p> <p>Follow‐up: 24 and 52 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Date study conducted: December 2008 to June 2009</p> <p>Funding: <i>"Sponsored by Regeneron Pharmaceuticals, Inc., Tarrytown, New York."</i> </p> <p>Conflict of interest: <i>"The author(s) have made the following disclosure (s): Diana V. Do: Genentech (financial support), Regeneron Pharmaceuticals (financial support). Ursula Schmidt‐Erfuth: Alcon Labs (consultant, lecturer), Bayer Healthcare (consultant, lecturer), Novartis (consultant, lecturer), Regeneron Pharmaceuticals (lecturer), Pfizer (lecturer). Victor H. Gonzalez: Pfizer (consultant, lecturer), Genentech (lecturer), Eyetech (consultant, lecturer), Regeneron (lecturer). Carmelina M. Gordon: Allergan (consultant), Regeneron Pharmaceuticals (lecturer), Novartis (consultant, lecturer). Michael Tolentino: Genentech (consultant, lecturer), Eyetech (consultant, lecturer), Regeneron Pharmaceuticals (consultant, lecturer). Alyson J Berliner: Regeneron Pharmaceuticals (employee, equity owner). Robert Vitti: Regeneron Pharmaceuticals (employee, equity owner). Rene Rückert: Bayer Schering Pharma (employee). Rupert Sandbrink: Bayer Schering Pharma (employee). David Stein: Regeneron Pharmaceuticals (employee,equity owner). Ke Yang: Regeneron Pharmaceuticals (employee, equity owner). Karola Beckmann: Bayer Schering Pharma (employee). Jeff S.Heier: Genentech (consultant, lecturer), Regeneron Pharmaceuticals (consultant,lecturer), Fovea (consultant)</i>. </p> <p>Trial registration:NCT00789477</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"The randomization was handled by an IVRS vendor. The study statistician at REGENERON provided the randomization plan and reviewed and approved the dummy rand table. Study Data Management at REGENERON tested the randomization function extensively along with the Clinical team.</i>" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Sites called into IVRS to randomize patients and received the randomization number and drug kit assignment at the completion of the call. The site also received a confirmation email. Neither of these contained the actual randomization assignment. The randomization assignments were kept by the IVRS vendor in a secure, access‐controlled database and were delivered to REGENERON by the IVRS vendor at the primary endpoint database lock."</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"To maintain participant masking, sham injections were performed on visits when an active dose was not given, and a sham laser was given to the VEGF Trap‐Eye groups at week 1. Study drug and sham injections and laser and sham laser treatments were performed by an unmasked physician who had no other role in the study except to assess adverse events (AEs) immediately posttreatment. Sham injections followed the active treatment protocol with the exception that no needle was attached to the syringe, and the syringe hub was gently applied to the sclera to mimic an injection. Sham laser consisted of placing a contact lens on the study eye and positioning the patient in front of the laser machine for the approximate duration of a laser treatment."</i> Page 1820‐1 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>A separate masked physician was assigned to assess adverse events (AEs) and retreatment and rescue criteria and to supervise the masked assessment of efficacy. Every effort was made to ensure that all other study site personnel remained masked to treatment assignment to facilitate an unbiased assessment of efficacy and safety.</i>" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Two randomised patients did not receive treatment and 19 patients discontinued the study after receiving at least 1 treatment for the following reasons: lost to follow‐up (6 patients), withdrew consent (6 patients), death (3 patients), treatment failures (2 patients), AE (1 patient), and protocol deviation (1 patient). Discontinuations were evenly distributed among the 5 treatment groups</i>." Page 1821 </p> <p>Comment: LOCF used</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome declared and consistent with our review</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DRCRnet 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group and within‐person RCT</p> <p>One or two study eyes per person. If both eyes eligible, right eye randomised first and then left eye assigned to "sham plus prompt laser group". If right eye already assigned to this group then left eye assigned randomly to 1 of the other 3 groups </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA</p> <p>Number of people randomised: 691 (854 eyes)</p> <p>Average age: 63 years</p> <p>Sex: 44% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0042"> <li> <p>18 years and older</p> </li> <li> <p>diabetes</p> </li> </ul> </p> <p>(in study eye)</p> <p> <ul id="CD007419-lst1-0043"> <li> <p>best‐corrected Electronic‐Early Treatment Diabetic Retinopathy Study (E‐ETDRS Visual Acuity Test) VA letter score 78‐24 (20/32–20/320) </p> </li> <li> <p>definite retinal thickening due to DMO on clinical examination involving the centre of the macula assessed to be the main cause of visual loss </p> </li> <li> <p>retinal thickness measured on TD‐OCT ≥ 250 micron in the central subfield</p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0044"> <li> <p>treatment for DMO within previous 4 months</p> </li> <li> <p>PRP within the previous 4 months or anticipated need for PRP within the next 6 months</p> </li> <li> <p>major ocular surgery within the previous 4 months</p> </li> <li> <p>history of open‐angle glaucoma or steroid‐induced IOP elevation that required IOP‐lowering treatment </p> </li> <li> <p>IOP ≥ 25 mmHg</p> </li> </ul> </p> <p>(participant)</p> <p> <ul id="CD007419-lst1-0045"> <li> <p>systolic BP was 180 mmHg or diastolic BP was 110 mmHg, or if a myocardial infarction, other cardiac event requiring hospitalisation, cerebrovascular accident, transient ischaemic attack, or treatment for acute congestive heart failure occurred within 4 months before randomisation </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0046"> <li> <p>ranibizumab (0.5 mg) and laser photocoagulation n = ? (375 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0047"> <li> <p>sham injection and laser photocoagulation n = ? (293 eyes)</p> </li> </ul> </p> <p>Ranibizumab group was also randomly allocated to prompt laser photocoagulation (187 eyes) which occurred within 3 to 10 days of the injection and deferred laser photocoagulation (188 eyes) which happened after 24 weeks. All eyes in comparator group were treated within 3 to 10 days of the sham injection </p> <p>Complex retreatment algorithm using web‐based, real‐time data‐entry system (page 1066)</p> <p>There was another intervention arm that combined triamcinolone with prompt laser photocoagulation, but this was not included in this review. n = ? (186 eyes) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome: BCVA and safety at 12 months</p> <p>Secondary outcomes: CRT</p> <p>Follow‐up: every 4 weeks for 12 months. After 12 months, the trial was unmasked and follow‐up continued to 3 years </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: March 2007 to December 2008</p> <p>Funding: <i>"Supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services EY14231, EY14229, and EY018817. The funding organization (National Institutes of Health) participated in oversight of the conduct of the study and review of the manuscript but not directly in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation of the manuscript. Genentech provided the ranibizumab for the study, and Allergan, Inc., provided the triamcinolone for the study. In addition, Genentech and Allergan, Inc., provided funds to the DRCR.net to defray the study’s clinical site costs. As described in the DRCR.net Industry Collaboration Guidelines (available at www.drcr.net), the DRCR.net had complete control over the design of the protocol, the ownership of the data, and all editorial content of presentations and publications related to the protocol."</i> </p> <p>Conflict of interest: "<i>A complete list of all DRCR.net investigator financial disclosures can be found at www.drcr.net"</i> </p> <p>Trial registration: NCT00445003</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The randomisation sequence was computer‐generated by the DRCR.net co‐ordinating centre</p> <p><i>"...study participants with 1 study eye were assigned randomly on the DRCR.net study website (using a permuted blocks design stratified by study eye visual acuity)"</i> Page 1065 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation assignments were obtained through the DRCR.net study website, therefore no study personnel had access to the list or to the next assignment before it was assigned </p> <p><i>"study participants with 1 study eye were assigned randomly on the DRCR.net study website (using a permuted blocks design stratified by study eye visual acuity)"</i> Page 1065 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Study participants in the 3 groups receiving laser were masked to treatment assignment through the primary outcome visit, whereas the ranibizumab deferred laser group was not masked."</i> Page 1065‐6 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Visual acuity examiners and OCT technicians were masked to treatment group assignment before and at the 1‐year primary outcome visit."</i> Page 1066 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants randomised in each group were: 293 laser, 187 ranibizumab + prompt laser, 188 ranibizumab + deferred laser and 186 IVTA + laser. At 1 year complete participants were 274, 171, 178, 176 respectively (91% to 95%) </p> <p>At 2 years complete participants were 211, 136, 139, 142 respectively (72% to 76%)</p> <p>Causes of missing data were balanced across groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>We could not find a protocol but primary outcomes were stated in the methods and were those routinely used in the field </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other source of bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DRCRnet 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group study</p> <p><i>"One eye of each participant was randomly assigned in a 1:1:1 ratio to be injected with aflibercept (at a dose of 2.0 mg), bevacizumab (1.25 mg), or ranibizumab (0.3 mg). Randomization was performed at the DRCR.net study website, in permuted blocks and with stratification according to study site and visual acuity in the study eye."</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA</p> <p>Number of people (eyes) randomised: 660</p> <p>Average age: 61 years</p> <p>Sex: not reported</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0048"> <li> <p>18 years and older</p> </li> <li> <p>diabetes</p> </li> </ul> </p> <p>(in study eye)</p> <p> <ul id="CD007419-lst1-0049"> <li> <p>best‐corrected Electronic‐Early Treatment Diabetic Retinopathy Study (E‐ETDRS Visual Acuity Test) VA letter score 78‐24 (20/32–20/320) </p> </li> <li> <p>definite retinal thickening due to DMO on clinical examination involving the centre of the macula assessed to be the main cause of visual loss </p> </li> <li> <p>retinal thickness measured on TD‐OCT ≥ 250 micron in the central subfield</p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0050"> <li> <p>treatment for DMO within previous 4 months</p> </li> <li> <p>PRP within the previous 4 months or anticipated need for PRP within the next 6 months</p> </li> <li> <p>major ocular surgery within the previous 4 months</p> </li> <li> <p>history of open‐angle glaucoma or steroid‐induced IOP elevation that required IOP‐lowering treatment </p> </li> <li> <p>IOP ≥ 25 mmHg</p> </li> </ul> </p> <p>(participant)</p> <p> <ul id="CD007419-lst1-0051"> <li> <p>systolic BP was 180 mmHg or diastolic BP was 110 mmHg, or if a myocardial infarction, other cardiac event requiring hospitalisation, cerebrovascular accident, transient ischaemic attack, or treatment for acute congestive heart failure occurred within 4 months before randomisation </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Interventions:</p> <p> <ul id="CD007419-lst1-0052"> <li> <p>aflibercept 2 mg: 224 eyes</p> </li> <li> <p>bevacizumab 1.25 mg: 218 eyes</p> </li> <li> <p>ranibizumab 0.3 mg: 218 eyes</p> </li> </ul> </p> <p>Randomisation was stratified by site and visual acuity: ≥ 66 letter score/ ≤ 65 letter score. </p> <p>retreatment algorithm:</p> <p><i>"In general, an eye will continue to receive an injection if the eye is improving or worsening on OCT or visual acuity. The first time an eye has not improved or worsened, the eye will receive an injection. If the eye has not improved or worsened for at least 2 consecutive 4‐week injections and OCT central subfield thickness is &lt;250μ and visual acuity is 20/20 or better, the injection will be deferred."</i> </p> <p><i>"In general, focal/grid laser will be initiated at or after the 24 week visit if 1) the OCT central subfield thickness is ≥250μ or there is edema that is threatening the fovea and 2) the eye has not improved on OCT or visual acuity from the last two consecutive injections."</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome: BCVA and safety at 12 months</p> <p>Secondary outcomes: CRT</p> <p>Follow‐up: after 12 months the trial was unmasked and follow‐up continued to 3 years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: March 2007 to December 2008</p> <p>Funding:<i>"Supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services EY14231, EY14229, and EY018817. The funding organization (National Institutes of Health) participated in oversight of the conduct of the study and review of the manuscript but not directly in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation of the manuscript. Genentech provided the ranibizumab for the study, and Allergan, Inc., provided the triamcinolone for the study. In addition, Genentech and Allergan, Inc., provided funds to the DRCR.net to defray the study’s clinical site costs. As described in the DRCR.net Industry Collaboration Guidelines (available at www.drcr.net), the DRCR.net had complete control over the design of the protocol, the ownership of the data, and all editorial content of presentations and publications related to the protocol."</i> </p> <p>Conflict of interest: "<i>A complete list of all DRCR.net investigator financial disclosures can be found at www.drcr.net"</i> </p> <p>Trial registration: NCT00445003 (Protocol T)</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The randomisation sequence was computer‐generated by the DRCR.net co‐ordinating centre</p> <p><i>"Randomization was performed at the DRCR.net study website, in permuted blocks and with stratification according to study site and visual acuity in the study eye."</i> Page 3 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Randomisation assignments were obtained through the DRCR.net study website, therefore no study personnel had access to the list or to the next assignment before it was assigned </p> <p>See above, Page 3</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Study participants, reading‐center graders, and the medical monitor who reviewed all adverse events were unaware of the treatment group assignments. Visual‐acuity and OCT technicians were unaware of the treatment‐group assignments at the 1‐year visit. Investigators and study coordinators were aware of the treatment group assignments."</i> Page 3 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Visual‐acuity and OCT technicians were unaware of the treatment‐group assignments at the 1‐year visit."</i> Page 3 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"<i>The 2‐year visit was completed by 90%, 85%, and 88% of the 660 randomised participants (91%, 90%, and 91% excluding deaths) in the aflibercept, bevacizumab, and ranibizumab groups, respectively (Fig S1, available at www.aaojournal.org). There were no substantial differences identified in the baseline characteristics of those who completed and those who did not complete the 2‐year visit (Table S1, available at www.aaojournal.org)</i>." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes match those in the Study Protocol available at http://publicfiles.jaeb.org/AntiVEGFCompPrtclv5_03_18_14.pdf</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other source of bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ekinci 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, unclear how eye selected</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Turkey</p> <p>Number of people randomised unclear: 100 (100 eyes) completed follow‐up</p> <p>Average age: 67 years (range 50 to 89)</p> <p>Sex: 68% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0053"> <li> <p>clinically significant DMO (CRT &gt; 300 mm), as found through FFA and OCT evaluations and dilate fundus examination, after 1‐year follow‐up period </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0054"> <li> <p>participants who received intravitreal treatment at another centre</p> </li> <li> <p>additional diseases that might have an effect on sight (age related macular degeneration, uveitis, occlusion on the vein root or branch, hereditary macular diseases) </p> </li> <li> <p>PRP, grid or focal laser photocoagulation application or intraocular surgery within 6 months </p> </li> <li> <p>participants with acute ocular infection, stroke, myocardial infarction, uncontrolled hypertension, pregnancy, renal failure and cataract formation during the follow‐up period were excluded from the study </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0055"> <li> <p>bevacizumab (1.25 mg) n = 50 (50 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0056"> <li> <p>ranibizumab (0.05 mg) n = 50 (50 eyes)</p> </li> </ul> </p> <p><i>"Topical anesthetic drops were instilled, and a drape application and blepharostat attachment were applied. Afterward, fornix lavage was applied using diluted povidone iodine. For Group 1, 1.25 mg (0.05 ml) of bevacizumab was injected into the eye that needed treatment, using a 30 gauge needle; for Group 2, 0.05 mg (0.05 cc) of ranibizumab was injected into the vitreous humor through the lower temporal quadrant, 3.5–4 mm behind the limbus. After the treatment, all patients were treated with topical antibiotics four‐times a day for 1 week."</i> Page 140 </p> <p>Bevacizumab and ranibizumab injections were applied, with an interval of 1 month for the first three doses. Retreatment criteria. “<i>After the third dose of bevacizumab/ranibizumab for patients in Groups 1 and 2, an additional three consecutive bevacizumab/ranibizumab injections were applied if the central macular thickness was greater than 275</i> µ<i>m or if there was an increase in BCVA of at least three letters compared with baseline. After the sixth intravitreal injection, if the central macular thickness was greater than 275 mm or if there was an increase in BCVA of at least two letters, additional intravitreal injections were performed until stable visual acuity was obtained."</i> Page 140 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Outcomes:</p> <p> <ul id="CD007419-lst1-0057"> <li> <p>BCVA using the Snellen chart</p> </li> <li> <p>CRT assessed with OCT</p> </li> <li> <p>IOP assessed with applanation tonometry</p> </li> </ul> </p> <p>Primary outcome not specified</p> <p>Follow‐up: monthly intervals after treatment to 12 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: 2011 to 2014</p> <p>Funding: not reported</p> <p>Conflict of interest: "<i>The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</i>" Page 142 </p> <p>Trial registration: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear if participants, care providers or outcome assessors were masked to treatment method </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear if participants, care providers or outcome assessors were masked to treatment method </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Exclusion after randomisation: 15 participants excluded</p> <p><i>“Patients with acute ocular infection (endophthalmitis after intravitreal injection, n</i> = <i>3), stroke, myocardial infarction (n = 2), uncontrolled hypertension (n = 4), pregnancy (n = 1), renal failure (n = 1) and cataract formation during follow‐up period (n = 4) were excluded from the study.”</i> Page 140 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>We could not find a protocol and our primary outcomes were not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Most items at high or unclear risk of bias</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ishibashi 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Allocation: randomised endpoint classification; safety/efficacy study intervention model; parallel assignment Masking: double‐masked </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>n = 243; country: Japan</p> <p>43 recruiting hospitals</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Drug: pegaptanib sodium (n = 123)<br> Other: sham injection (n = 120) </p> <p>Sex: female 113, male 130</p> <p>Age: (SD) pegaptanib 65.9 (9.0), sham 66.0 (9.2) years</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0058"> <li> <p>Participants with macular oedema including central fovea diagnosed by fluorescein angiography </p> </li> <li> <p>Thickening of the retina (≥ 250 μm)</p> </li> <li> <p>Corrected VA is 35‐68 letters by ETDRS charts</p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0059"> <li> <p>Participants who underwent focal/grid laser within 4 month before study started</p> </li> <li> <p>Atrophy, scar and fibrosis Including the centre of macula</p> </li> <li> <p>Underwent any eye surgery within 3 months before study started</p> </li> <li> <p>Participants with HbA1c 12.5% ≤ or with symptoms of uncontrolled diabetes</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p> <ul id="CD007419-lst1-0060"> <li> <p>Number of participants who experience a ≥ 10 letter improvement of VA in ETDRS chart from baseline to week 24 </p> </li> </ul> <ul id="CD007419-lst1-0061"> <li> <p>Change from baseline in VA: double‐masked phase (time frame: baseline, weeks 6, 12, 18, and 24); changes in VA were monitored through refraction and BCVA measurements using retro‐illuminated, modified Ferris‐Bailey ETDRS charts </p> </li> <li> <p>Number of participants underwent focal/grid laser, or vitrectomy: double‐masked phase (time frame: up to 24 weeks; included focal laser photocoagulation, grid laser photocoagulation, and vitrectomy </p> </li> <li> <p>Number of participants who experience a ≥ 10 letter improvement of VA in ETDRS chart from baseline at week 54: open phase (time frame: baseline and week 54); BCVA measurements performed using retro‐illuminated, modified Ferris‐Bailey ETDRS charts </p> </li> <li> <p>Change from baseline in VA: open phase (time frame: baseline, weeks 30, 36, 42, 48 and 54); changes in VA were monitored through refraction and BCVA measurements using retro‐illuminated, modified Ferris‐Bailey ETDRS charts </p> </li> <li> <p>Number of participants who underwent focal/grid laser, or vitrectomy: open phase (time frame: weeks 24 to 54; included focal laser photocoagulation, grid laser photocoagulation, and vitrectomy </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Completion Date: August 2012 (results also partly available on ClinicalTrials.gov, accessed on 5 December 2013) </p> <p>Sponsor: Pfizer, two authors (Isogawa N, Esaka E) employee of Pfizer</p> <p>Author contact not found</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“<i>Pegaptanib sodium or a syringe of sham was enclosed by aluminium bag, then the aluminium bag was put in a box. These boxes were supplied to each hospitals. These box could maintain masking. However, Pfizer Japan Inc, which requested this drug trial, made the mistake of allowing to open the box for some hospitals during transportation, so it was clear that it was possible not to ensure the masking sufficiently</i>.” </p> <p>In 71 cases, there was the evidence of opening the box of study drugs</p> <p>In 172 cases, there was no evidence of opening the box.</p> <p>In 50 cases, there was evidence of not opening the box, so it was clear that masking is sufficient </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Treating physician and his/her assistants were not masked and other staff (physician who did not directly give the drug, orthoptist, clinical research coordinator, nurses, laboratory technician, administrator for study drugs and other staffs) were masked. </p> <p>Participants were blinded</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Lost to follow‐up: 6 pegaptanib, 4 sham</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear or high risk for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Korobelnik 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>Eyes: 862 eyes from 862 participants. One eye per participant. <i>“For patients who met eligibility criteria in both eyes, the eye with the worst BCVA was selected as the study eye. If a patient had DME with similar BCVA in both eyes, the eye with the clearest media was selected as the study eye. If the ocular media of the both eyes were similar in clarity, the patient’s non‐dominant eye (if identifiable) was selected as the study eye. If neither eye is dominant, the right eye was designated as the study eye.” (</i><a href="appendices#CD007419-sec2-0017">Appendix 2</a><i>)</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: 54 centres in USA (VISTA study, 446 participants) and 73 centres in Europe, Japan, and Australia (VIVID study, 406 participants) </p> <p>Number of people randomised: 852 (852 eyes)</p> <p>Average age: 63 years</p> <p>Sex: 42% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0062"> <li> <p>adults ≥ 18 years with type 1 or 2 diabetes mellitus</p> </li> <li> <p>central DMO involvement (defined as retinal thickening involving the 1 mm central (OCT) subfield thickness) </p> </li> <li> <p>retinal thickness ≥ 300 µm (assessed by OCT)</p> </li> <li> <p>decrease in vision determined to be primarily the result of DME in the study eye</p> </li> <li> <p>BCVA ETDRS letter score of 73‐24 (20/40‐20/320) in the study eye</p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0063"> <li> <p>laser photocoagulation (panretinal or macular) in the study eye within 90 days of day 1 </p> </li> <li> <p>more than 2 previous macular laser treatments in the study eye</p> </li> <li> <p>previous use of intraocular or periocular corticosteroids in the study eye within 120 days of day 1 </p> </li> <li> <p>previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, bevacizumab, ranibizumab etc.) within 90 days of day 1 </p> </li> <li> <p>active PDR in the study eye, with the exception of inactive, regressed PDR</p> </li> <li> <p>uncontrolled diabetes mellitus, as defined by HbA1c &gt; 12%</p> </li> <li> <p>only 1 functional eye even if that eye is otherwise eligible for the study</p> </li> </ul> </p> <p>See paper for details</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0064"> <li> <p>aflibercept 2q4 n = 290 (290 eyes): aflibercept 2 mg every 4 weeks</p> </li> <li> <p>aflibercept 2q8 n = 286 (286 eyes): aflibercept 2 mg monthly for 5 months, then every 8 weeks </p> </li> </ul> </p> <p>Comparator</p> <p> <ul id="CD007419-lst1-0065"> <li> <p>laser photocoagulation and sham monthly injection = 286 (286 eyes)</p> </li> </ul> </p> <p><i>"Eyes were randomised in a 1:1:1 ratio to receive either 2 mg IAI every 4 weeks (2q4), 2 mg IAI every 8 weeks after 5 initial monthly doses (from baseline to week 16) with sham injections on non‐treatment visits (2q8), or macular laser photocoagulation at baseline and sham injections at every visit (laser control group)"</i> Page 2 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0066"> <li> <p>change in BCVA from baseline to week 52 (ETDRS chart at 4 m)</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0067"> <li> <p>proportion of eyes that gained at least 10 ETDRS letters in BCVA at week 52 compared with baseline </p> </li> <li> <p>proportion of eyes that gained at least 15 ETDRS letters in BCVA compared with baseline</p> </li> <li> <p>change in CRT (central subfield on OCT) from baseline to week 52</p> </li> <li> <p>proportion of eyes with a 2‐step improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) score </p> </li> <li> <p>change from baseline in the National Eye Institute Visual Function Questionnaire‐25 (NEI VFQ‐25) near activities subscale score </p> </li> <li> <p>change from baseline in the NEI VFQ‐25 distance activities subscale score</p> </li> </ul> </p> <p>Follow‐up: 52 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Date study conducted: May 2011 to June 2013</p> <p>Funding: <i>"</i>T<i>he VISTA and VIVID studies were funded by Regeneron Pharmaceuticals, Inc., Tarrytown, NY and Bayer HealthCare, Berlin, Germany. The sponsors participated in the design and conduct of the study, analysis of the data, and preparation of the manuscript</i>." </p> <p>Conflict of interest: <i>“Assistance with the study design and conduct and data analysis was provided by Karen Chu, MS, and Xiaoping Zhu, PhD, Regeneron Pharmaceuticals, Inc. (VISTA), and Jana Sachsinger, PhD, and Christiane Norenberg, MS, Bayer HealthCare (VIVID). Editorial and administrative assistance to the authors was provided by Hadi Moini, PhD, and S. Balachandra Dass, PhD, Regeneron Pharmaceuticals, Inc.”</i> Other conflicts of interest reported in the paper. </p> <p>Trial registration: VISTA NCT01363440, VIVID NCT01331681</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No details available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No details available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"A masked investigator assessed safety and efficacy and decided on the need for laser re‐treatment and additional treatment."</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Masked graders at independent central reading centers evaluated OCT images for central retinal thickness (center subfield))"</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>About 93% participants completed 52‐week follow‐up in each arm and causes of loss to follow‐up were balanced across arms. Slightly higher loss to follow‐up in laser group in VIVID – approx 15% compared to 8% and 11% in aflibercept groups </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Some differences between trial registration and final reports</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Though some items could not be fully assessed, we believe randomisation and allocation concealment should be adequate in this multicentre trial aiming at drug registration, as per regulatory requirement </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Lopez‐Galvez 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Multicentre, randomised, and open‐label controlled trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Spain</p> <p>Number of people randomised: 83 participants (40 ranibizumab, 43 grid laser)</p> <p>Average age: 63.5 (9.4) years.</p> <p>Sex: 59.8% M</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0068"> <li> <p>≥18 years old</p> </li> <li> <p>diabetes mellitus type 1/2</p> </li> <li> <p>altered VA due to DMO. The study eye must have had a BCVA = 78–25 letters, and CRT = 250 μm </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Participants were randomised to intravitreal injection of ranibizumab (0.5 mg) with 3 loading doses and then PRN treatment or to LP (ratio 1:1). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0069"> <li> <p>Differences in mean change in best corrected visual acuity (BCVA) of treatment with ranibizumab 0.5 mg versus laser photocoagulation (LP) over 12 months in participants with DMO. </p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0070"> <li> <p>% of participants with VA &gt; 73 letters with ranibizumab (0.5 mg) versus laser</p> </li> <li> <p>Time and mean change in CRT by OCT with ranibizumab (0.5 mg) versus laser</p> </li> <li> <p>Monitoring and registry of all adverse events, serious adverse events, VA, concomitant medications, ophthalmologic exams (including count of fingers and movement of the hands), IOP, vital constants and analytical parameters </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Sponsor: Novartis</p> <p>Trial Registration: NCT00901186</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information (abstract only; authors contacted but no response yet)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information (abstract only; authors contacted but no response yet)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information (abstract only; authors contacted but no response yet)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information (abstract only; authors contacted but no response yet)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9 and 11 participants lost to follow‐up for ranibizumab and laser respectively</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No information (abstract only; authors contacted but no response yet)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient information (abstract only; authors contacted but no response yet)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Most items at unclear risk</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">LUCIDATE 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, unclear how eye selected</p> <p>"<i>One eye per participant was included to avoid exposure of both eyes to the study drug. If both eyes were eligible, the eye with worse visual acuity became the study eye. Subjects were randomised with 2:1 probability to receive the intervention or standard care (ETDRS macular laser). The randomization list was created using permuted blocks of varying sizes, held by the trial statistician and concealed from the researcher who enrolled, assessed, and allocated treatment to participants.</i>" (Page 961) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: UK</p> <p>Number of people randomised: 37 (37 eyes)</p> <p>Average age: 66 years</p> <p>Sex: 36% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0071"> <li> <p>adult participants with type 1 or 2 diabetes</p> </li> <li> <p>BCVA of 55‐79 ETDRS letters (Snellen equivalent, 20/30‐20/80) resulting from <b>centre‐involving DMO </b>, with Spectralis OCT (Heidelberg Engineering GmbH, Heidelberg, Germany) central subfield thickness of 300 mm or more in the study eye </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0072"> <li> <p>uncontrolled glaucoma</p> </li> <li> <p>aphakia</p> </li> <li> <p>cataract precluding fundus photography</p> </li> <li> <p>external ocular infections</p> </li> <li> <p>previous anti‐VEGF or laser treatment in the preceding 3 months in both eyes</p> </li> <li> <p>angiographic evidence of macular ischaemia defined as FAZ GLD of &gt; 1000 mm or severe perifoveal capillary loss </p> </li> <li> <p>other causes for macular oedema, for example after cataract surgery</p> </li> <li> <p>other causes of visual loss in the study eye; other diseases that may affect the course of macular oedema in the study eye </p> </li> <li> <p>PDR, either active or treated within the previous 3 months</p> </li> <li> <p>systemic conditions that precluded trial enrolment included HbA1c &gt; 11.0%; past medical history of chronic renal failure requiring either dialysis or kidney transplantation; BP &gt; 170/100 mmHg; an arteriothrombotic event within 6 months before randomisation, including myocardial infarction, acute congestive heart failure or other cardiac event, and stroke or transient ischaemic attack </p> </li> <li> <p>planned surgery</p> </li> <li> <p>pregnancy or breastfeeding</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0073"> <li> <p>ranibizumab (0.5 mg) n = 25</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0074"> <li> <p>laser photocoagulation n = 12</p> </li> </ul> </p> <p>"<i>Subjects were randomised with 2:1 probability to receive the intervention or standard care (ETDRS macular laser).</i>" Page 961. "<i>Intravitreal injections of ranibizumab (Lucentis, 0.5 mg in 0.05 mL solution for injection; Novartis Pharmaceuticals UK Ltd., Frimley, United Kingdom) at baseline, 4 weeks, and 8 weeks then every 4 weeks as required according to predefined retreatment criteria to a maximum of 12 injections. Retreatment occurred if BCVA was reduced by 5 letters or more from maximum acuity or if OCT central subfield thickness was more than 300 mm. Subjects in the laser arm received ETDRS macular laser at baseline guided by fluorescein angiography, OCT, and clinical examination. Laser retreatment occurred at 12, 24, and 36 weeks if clinically significant macular edema was still present, in accordance with standard clinical practice at the time; this was guided by the most recent fluorescein angiogram, OCT, and clinical examination results</i>" Page 961 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Outcomes:</p> <p> <ul id="CD007419-lst1-0075"> <li> <p>change in ETDRS BCVA</p> </li> <li> <p>retinal sensitivity</p> </li> <li> <p>colour vision</p> </li> <li> <p>electrophysiologic parameters</p> </li> <li> <p>macular thickness and volume</p> </li> <li> <p>change in ETDRS severity grade of diabetic retinopathy from fundus photographs</p> </li> </ul> </p> <p>Follow‐up: 48 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Date study conducted: November 2010 to July 2011</p> <p>Sponsor: Moorfields Eye Hospital NHS Foundation Trust</p> <p>Conflict of interest: "<i>Dr Comyn receives travel support from Novartis. Dr Sivaprasad is a consult for and receives payment for lectures or speaker bureaus and travel support from Novartis, Allergan, and Bayer, and receives payment for development of educational materials from Allergan. Dr Holder is a consultant to Servier. Dr Patel receives grant support from Allergan, Heidelberg United Kingdom, and Topcon United Kingdom and is a consultant to Bayer, Novartis, and Thrombogenics. Dr Hykin is a consultant to and receives grant support from Novartis, Allergan, and Bayer. Drs Comyn, Sivaprasad, Peto, Patel, Egan, Bainbridge, and Hykin have received a proportion of their funding from the Department of Health’s National Institute for Health Research Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and University College London, Institute of Ophthalmology. Dr Bainbridge is supported by a National Institute for Health Research Professorship. Supported by an unrestricted research grant from Novartis and the National Institute for Health Research Biomedical Research Centre based at Moorfields Eye Hospital National Health Service Foundation Trust and University College London Institute of Ophthalmology."</i> Page 970 </p> <p>Trial registration: NCT01223612</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"The randomization list was created using permuted blocks of varying sizes, held by the trial statistician and concealed from the researcher who enrolled, assessed, and allocated treatment to participants."</i> Page 96 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No sham procedure</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"The microperimetry and electrophysiologic assessors were masked to the patient treatment arm. Evaluation of OCT scans, fundus photographs and fluorescein angiograms was performed by masked Reading Centre graders. The protocol states that the visual acuity assessors were also masked to the patient treatment arm but due to a protocol deviation they had access to the source notes and were potentially unmasked."</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22/25 (88%) of anti‐VEGF group compared to 11/12 (92%) laser group followed up</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other source of bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High or unclear risk of bias for nearly half the items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Macugen 2005 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, chosen by participant and physician. In 81% of cases the eye with the worse VA was chosen </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA<br> Number of people randomised: 172 (172 eyes) </p> <p>Average age: 62 years (range 27 to 89)</p> <p>Sex: 49% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0076"> <li> <p>18 years or older</p> </li> <li> <p>diabetes</p> </li> </ul> </p> <p>(study eyes)</p> <p> <ul id="CD007419-lst1-0077"> <li> <p>macular oedema involving the centre of the macula demonstrated on OCT with corresponding leakage from microaneurysms, retinal telangiectasis, or both on fluorescein angiography </p> </li> <li> <p>an area of retinal thickening of at least half a disc area involving the central macula as confirmed by graders at an independent fundus photograph and angiogram reading center (University of Wisconsin, Madison, Wisconsin) </p> </li> <li> <p>clear ocular media and adequate pupillary dilation to permit good stereoscopic fundus photographs </p> </li> </ul> </p> <p>(participants)</p> <p> <ul id="CD007419-lst1-0078"> <li> <p>BCVA letter scores between 68‐25 inclusive (approximate Snellen equivalent, 20/50–20/320) in the study eye and at least 35 (20/100 or better) in the fellow eye </p> </li> <li> <p>IOP ≤ 23 mmHg</p> </li> <li> <p>assessment by the treating ophthalmologist that focal photocoagulation could be deferred safely for 16 weeks </p> </li> <li> <p>an electrocardiogram that demonstrated no abnormalities judged to be clinically relevant and serological test results that suggested no clinically meaningful haematological, liver, or renal abnormalities </p> </li> <li> <p>women enrolling in the study were required to be postmenopausal for 12 months before the study, surgically sterile, or not pregnant and on 2 forms of effective contraception </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0079"> <li> <p>history of PRP or focal photocoagulation</p> </li> <li> <p>neodymium:yttrium–aluminum–garnet laser or peripheral retinal cryoablation within the previous 6 months </p> </li> <li> <p>any abnormality thought likely to confound VA assessments or fundus photography, including cataract; vitreoretinal traction within 1 disc diameter of the fovea confirmed either clinically or on OCT </p> </li> <li> <p>vitreous incarceration in a previous wound or incision</p> </li> <li> <p>any retinal vein occlusion involving the macula; and atrophy/scarring/fibrosis or hard exudates involving the centre of the macula that would preclude improvement in VA </p> </li> <li> <p>a history of any intraocular surgery within the previous 12 months, myopia of ≥ 8 dioptres, axial length of ≥ 25 mm, and the likelihood of requiring either scatter (panretinal) photocoagulation within the ensuing 9 months or cataract surgery within 12 months </p> </li> <li> <p>active ocular or periocular infection</p> </li> <li> <p>previous therapeutic radiation to the eye, head, or neck</p> </li> <li> <p>any treatment with an investigational agent for any condition in the 60 days before enrolment. Known serious allergies to fluorescein dye </p> </li> <li> <p>glycosylated haemoglobin (GHb) levels of ≥ 13%</p> </li> <li> <p>3 episodes of severe hypoglycaemia within 3 months of study entry</p> </li> <li> <p>2 episodes of ketoacidosis within 1 year of baseline</p> </li> <li> <p>any episode of ketoacidosis within 3 months of baseline</p> </li> <li> <p>evidence of severe cardiac disease</p> </li> <li> <p>clinically significant peripheral vascular disease (previous surgery, amputation, or symptoms of claudication) </p> </li> <li> <p>uncontrolled hypertension (treated systolic BP 155 or diastolic BP 95), or stroke within the preceding 12 months </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0080"> <li> <p>pegaptanib (0.3 mg, 1 mg, or 3 mg) n = 130 (130 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0081"> <li> <p>sham injection n = 42 (42 eyes)</p> </li> </ul> </p> <p><i>"Intravitreous pegaptanib or sham injections were administered at entry, week 6, and week 12, for a minimum of 3 injections. Thereafter, additional injections were administered every 6 weeks at the discretion of investigators if judged indicated, to a maximum of 6 injections up to week 30. [...] Pegaptanib was formulated for intravitreous injection at 0.3 mg/90 µl, 1 mg/90 µl, and 3 mg/90 µl concentrations in preservative‐free phosphate‐buffered saline (pH 5–7). Pegaptanib was packaged in sterile, single‐use, United States Pharmacopeia type 1 graduated glass 1‐ml syringes with preattached 27‐gauge needles"</i> Page 1748 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Outcomes:</p> <p> <ul id="CD007419-lst1-0082"> <li> <p>BCVA (measured using ETDRS chart)</p> </li> <li> <p>CRT on OCT</p> </li> <li> <p>change in retinal thickness derived by comparing measurements at baseline with those at week 36 or ﬁnal examination if before week 36 </p> </li> <li> <p>focal photocoagulation applied at week 12 or later</p> </li> <li> <p>size of the area of retinal thickness measured by photography</p> </li> <li> <p>macular capillary leakage and cystoid spaces</p> </li> <li> <p>adverse events</p> </li> <li> <p>laboratory test abnormalities</p> </li> </ul> </p> <p>Follow‐up: 36 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: not reported, study published 2005</p> <p>Funding:<i>"The study was sponsored by Eyetech Pharmaceuticals, Inc., New York, New York, and Pfizer Inc., New York, New York."</i> Page 1747 </p> <p>Conflict of interest: not reported</p> <p>Trial registration: NCT00040313</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Patients were allocated [...] by a dynamic minimization procedure using a stochastic treatment allocation algorithm based on the variance method. Randomization was stratified by study site, size of the thickened retina area [...] and baseline VA [...]"</i>. Page 1748 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"An independent fundus photograph and angiogram reading center confirmed eligibility and appropriate retinal thickness classification both for study entry and for randomization and stratification using baseline fluorescein angiography and OCT."</i> Page 1748 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Study subjects receiving sham or study medication were treated identically in all regards, including ocular antisepsis procedures and subconjunctival anesthetic, except that subjects receiving active treatment had pegaptanib injected into the vitreous, whereas those receiving sham had a needleless syringe pressed against the conjunctiva and sclera. The injection procedure prevented subjects from seeing the syringe and needle, to minimize the risk of unmasking. In all but 3 subjects, injection was administered by a staff member other than the study ophthalmologist responsible for all other aspects of the protocol, to maintain investigator masking."</i> Page 1748 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Study subjects receiving sham or study medication were treated identically in all regards, including ocular antisepsis procedures and subconjunctival anesthetic, except that subjects receiving active treatment had pegaptanib injected into the vitreous, whereas those receiving sham had a needleless syringe pressed against the conjunctiva and sclera. The injection procedure prevented subjects from seeing the syringe and needle, to minimize the risk of unmasking. In all but 3 subjects, injection was administered by a staff member other than the study ophthalmologist responsible for all other aspects of the protocol, to maintain investigator masking. Visual acuity was determined by a separate VA examiner masked to treatment."</i> Page 1748 </p> <p><i>"At baseline and at each study visit thereafter, refraction and VA were determined and OCT was performed by certified examiners masked both to randomization and to findings of the previous measurement."</i> Page 1749 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Nine participants were discontinued from the study before week 36. None in pegaptanib groups 0.3 mg and 1 mg, 3 in pegaptanib 3 mg group (3 mg subgroup: 2 participants by request at weeks 12 and 16 and 1 by other reason at week 1), 6 in sham group (5 participants by request at weeks 6, 11, 18, 30, and 33 and 1 due to death at week 8) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study protocol is available and all (primary and secondary) outcomes that are of interest in the study have been reported in the pre‐speciﬁed way </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other source of bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for all items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Macugen 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, unclear how eye selected</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Australia, Europe, India, North America, and South America</p> <p>Number of people randomised: 288 (288 eyes)</p> <p>Average age: 62 years (20 to 83)</p> <p>Sex: 43% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0083"> <li> <p>18 years or older</p> </li> <li> <p>diabetes</p> </li> <li> <p>DMO involving the centre of the macula not associated with ischaemia</p> </li> </ul> </p> <p>(study eye)</p> <p> <ul id="CD007419-lst1-0084"> <li> <p>foveal thickness of ≥ 250 µm (centre point thickness measured on OCT)</p> </li> <li> <p>BCVA with a letter score of 65‐35 (20/50–20/200 Snellen equivalents)</p> </li> <li> <p>IOP ≤ 21 mmHg</p> </li> <li> <p>clear ocular media and adequate pupillary dilation to allow good quality stereoscopic fundus photography </p> </li> <li> <p>focal or grid laser photocoagulation could be deferred for 18 weeks in the opinion of the treating ophthalmologist </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0085"> <li> <p>yttrium‐aluminum‐garnet laser, peripheral retinal cryoablation, laser retinopexy for retinal tears, or focal or grid photocoagulation within the prior 16 weeks or scatter PRP 6 months before baseline or likely to be needed within 9 months </p> </li> <li> <p>macular ischaemia if a nonperfusion area of &gt; 1 disc area involving the foveal avascular zone (2 quadrants centred around the FAZ) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0086"> <li> <p>pegaptanib sodium (0.3 mg) n = 145 (145 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0087"> <li> <p>sham injection n = 143 (143 eyes)</p> </li> </ul> </p> <p>Participants received pegaptanib 0.3 mg or sham injections every 6 weeks in year 1 (total 9 injections) and could receive focal/grid photocoagulation beginning at week 18. During year 2, participants received injections as often as every 6 weeks according to pre‐specified criteria </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0088"> <li> <p>10‐letter (2‐line) improvement from baseline at 12 months (ETDRS chart)</p> </li> </ul> </p> <p>Secondary outcomes: (at 12 and 24 months unless otherwise specified)</p> <p> <ul id="CD007419-lst1-0089"> <li> <p>10‐letter improvement from baseline at 24 months</p> </li> <li> <p>changes from baseline in mean VA</p> </li> <li> <p>15‐letter (3‐line) improvement in VA</p> </li> <li> <p>change in degree of retinopathy of 2 steps based on the 12‐step scale of retinopathy</p> </li> <li> <p>decrease in retinal thickness at the centre point by 25% and 50%</p> </li> <li> <p>focal or grid laser</p> </li> <li> <p>change in NEI VFQ‐25 and EQ‐5D</p> </li> </ul> </p> <p>Follow‐up: 12 and 24 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: September 2005 to July 2009</p> <p>Funding:<i>"Sponsored by Pfizer Inc, New York, New York. The sponsor participated in the design of the study, in the management, analysis, and interpretation of the data, and in the preparation and review of the manuscript."</i> Page 12 </p> <p>Conflict of interest: The authors were employees of Pfizer, the sponsor</p> <p>Trial registration: NCT00605280</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"[...] subjects were centrally allocated to receive either pegaptanib 0.3 mg or sham injections (1:1) using a dynamic minimization procedure stratified by the site, hemoglobin A1c (&lt;7.6% vs &gt;=7.6%), systolic blood pressure (&lt;140 vs &gt;=140 mmHg), diastolic blood pressure (80 vs 80 mmHg), and baseline BCVA (&lt;54 vs &gt;=54 letters); the dynamic minimization used a stochastic treatment allocation algorithm based on the variance method."</i> Page 3 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"...subjects were centrally allocated..."</i> Page 3 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"To maintain masking, the intravitreal procedure was identical between the sham and comparator arms, with the difference lying only in the application of an empty barrel of a needleless syringe in the sham procedure designed to mimic the intravitreal injection."</i> Page 3 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Throughout the study, BCVA was measured at 4 m by the study refractionist/ophthalmologist, who was masked to the subject’s treatment and to the subject’s previous visual acuity (VA) assessments"</i>. Page 3 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>At 1 year 116/144 (81%) pegaptanib‐treated participants and 114/142 (80%) controls completed the 54‐week visit. Adverse events led to discontinuation of 5 treated and 7 control participants </p> <p>At 2 years 66 participants in each group completed the 102 week visit</p> <p>ITT analysis with LOCF was used leading to the analysis of 133 treated and 127 control participants </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All primary outcomes reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other biases identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Nepomuceno 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT and within‐person study</p> <p>People randomised to treatment but two eyes sometimes included. If two eyes included then fellow eye randomised to other treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Brazil</p> <p>Number of people randomised: 48 (63 eyes)</p> <p>Average age 64 years</p> <p>Sex: 55% women (based on eyes included in analyses)</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0090"> <li> <p>centre‐involved DMO defined as a central subfield thickness &gt; 300 mm on Spectral Domain‐OCT, despite at least 1 session of macular laser photocoagulation performed at least 3 months previously </p> </li> <li> <p>BCVA ETDRS measurement between 0.3 logMAR (Snellen equivalent: 20/40) and 1.6 logMAR (Snellen equivalent: 20/800) </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0091"> <li> <p>vitreomacular traction on SD‐OCT</p> </li> <li> <p>PDR needing PRP or anticipated to need PRP in the next 12 months</p> </li> <li> <p>macular capillary dropout on fluorescein angiography</p> </li> <li> <p>history of glaucoma or ocular hypertension (defined as an intraocular pressure &gt; 22 mmHg) </p> </li> <li> <p>an ocular condition (other than diabetes) that, in the opinion of the investigator, might affect macular oedema or alter VA during the course of the study (e.g. retinal vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc) </p> </li> <li> <p>systemic corticosteroid therapy</p> </li> <li> <p>any condition that, in the opinion of the investigator, might preclude follow‐up throughout the study period </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0092"> <li> <p>bevacizumab (1.5 mg) n = 32 eyes</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0093"> <li> <p>ranibizumab (0.5 mg) n = 28 eyes</p> </li> </ul> </p> <p><i>“Retreatment with the originally assigned treatment was performed monthly if central subfield thickness was greater than 275 mm.”</i> </p> <p><i>“If, after 3 consecutive injections, there was not a reduction in central subfield thickness of at least 10% or an increase in BCVA of at least 5 letters compared with baseline, the patient could, at the discretion of the treating ophthalmologist, receive focal/grid laser photocoagulation or continue to receive the same intravitreal medication for an additional 3 consecutive visits.”</i> Page 503 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Outcomes reported in publication (primary outcome not specified):</p> <p> <ul id="CD007419-lst1-0094"> <li> <p>BCVA (standardised ETDRS refraction protocol)</p> </li> <li> <p>retinal thickness (using OCT)</p> </li> </ul> </p> <p>On ClinicalTrials.gov following outcomes listed:</p> <p> <ul id="CD007419-lst1-0095"> <li> <p>Primary outcome measures: CSFT change (time frame: monthly from baseline to week 48; not designated as a safety issue); CSFT measured with SD‐OCT </p> </li> <li> <p>Secondary outcome measures: BCVA change (time frame: monthly from baseline to week 48; not designated as a safety issue); BCVA using ETDRS charts </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: July 2010 to August 2011</p> <p>Funding:<i>"Fundacao de Amparo a` Pesquisa do Estado de Sao Paulo (FAPESP), grant number 2010/013368; and Fundacao Apoioao Ensino, Pesquisa e Assisteˆncia (FAEPA) do Hospital das Clınicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo."</i> </p> <p>Conflict of interest: Rodrigo Jorge received travel support from Novartis to attend the 2012 American Society of Retina Specialists (ASRS) meeting </p> <p>Trial registration: NCT01487629</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>“.... received the randomised treatment according to a computer‐generated sequence”</i> Page 503 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not mentioned</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>“Examiners (E.T., F.P.P.A., R.P.) were masked regarding which treatment drug was used for each patient. Throughout the study, a single masked, certified examiner performed BCVA measurements prior to any other study procedure. Patients, OCT technicians, and fundus photographers were also masked to treatment group”</i>. Page 504 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>“Examiners (E.T., F.P.P.A., R.P.) were masked regarding which treatment drug was used for each patient. Throughout the study, a single masked, certified examiner performed BCVA measurements prior to any other study procedure. Patients, OCT technicians, and fundus photographers were also masked to treatment group”</i>. Page 504 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>“The 3 patients excluded from the outcomes analyses consisted of 1 patient in the IV ranibizumab group who developed Staphylococcus aureus endophthalmitis after the first injection (this patient chose to exit the study and he did not complete any further study visits); 1 patient in the IV bevacizumab group who developed advanced posterior subcapsular cataract, which precluded adequate SDOCT images, after the ninth follow‐up visit; and 1 patient from the IV bevacizumab group who missed 3 consecutive follow‐up visits.”</i> Page 504 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Both outcomes listed on trial registration reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Fifteen out of 48 participants with both eyes in analyses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">READ2 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person; if both eyes were eligible, the eye with the greater centre subfield thickness was entered </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA</p> <p>Number of people randomised: 126 (126 eyes)</p> <p>Average age: 62 years</p> <p>Sex: 59% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0096"> <li> <p>18 years and older</p> </li> <li> <p>diabetes</p> </li> <li> <p>DMO</p> </li> <li> <p>reduction in VA between 20/40‐20/320</p> </li> <li> <p>centre subfield thickness measured by OCT ≥ 250 µm</p> </li> <li> <p>HbA1c ≥ 6% within 12 months before randomisation</p> </li> <li> <p>no potential contributing causes to reduced VA other than DMO</p> </li> <li> <p>reasonable expectation that scatter laser photocoagulation would not be required for the next 6 months </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0097"> <li> <p>received focal/grid laser treatment within 3 months</p> </li> <li> <p>intraocular injection of steroid within 3 months</p> </li> <li> <p>intraocular injection of a VEGF antagonist within 2 months</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0098"> <li> <p>ranibizumab 0.5 mg n = 42 (42 eyes)</p> </li> <li> <p>ranibizumab 0.5 mg plus laser photocoagulation n = 42 (42 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0099"> <li> <p>laser photocoagulation n = 42 (42 eyes)</p> </li> </ul> </p> <p>Participants were randomised 1:1:1 to receive 0.5 mg ranibizumab at baseline and months 1, 3, and 5 (group 1), focal or grid laser photocoagulation at baseline and month 3 if needed (group 2), or a combination of 0.5 mg ranibizumab and focal or grid laser at baseline and month 3 (group 3). Starting at month 6, if retreatment criteria were met, all participants could be treated with ranibizumab </p> <p>Duration: primary outcome at 6 months, extension to 24 and 36 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>As reported in publications:</p> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0100"> <li> <p>change in BCVA between baseline and follow‐up</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0101"> <li> <p>change in BCVA between baseline and month 24</p> </li> <li> <p>3 or more lines or 2 or more lines improvement at month 24</p> </li> <li> <p>change in foveal thickness between baseline and month 24</p> </li> <li> <p>elimination of 90% or 50% excess foveal thickness</p> </li> </ul> </p> <p>On ClinicalTrials.gov</p> <p><i>"Primary Outcome Measures: Improvement in vision of 15 or more letters, or achieve a final vision of 50 letters (20/25) or better if baseline VA was 40 letters (20/40) [Time Frame: 6 mos, 12 mos and 24 mos. Study Extended to 36 mos.] [Designated as safety issue: Yes]</i><br> <br> <i>Secondary Outcome Measures: Several outcomes related to OCT measurements and fluorescein angiography. [Time Frame: 6 mos, 12 mos and 24 mos, study extended to 36 mos.] [Designated as safety issue: Yes]"</i> </p> <p>Follow‐up: 6 months and 24 months.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: not reported</p> <p>Funding: <i>"Sponsored by the Juvenile Diabetes Research Foundation and Genentech, Inc."</i> </p> <p>Conflict of interest: <i>"QDN and PAC have served as members of Expert Panels for Genentech, Inc. without receiving an honorarium during the time of this study, but JHU has recently negotiated a contract through which JHU receives compensation. QDN is a consultant for Bausch and Lomb and has research support from Genentech, Inc., and Regeneron, Inc. PAC serves on the data and safety monitoring committee for a phase III trial sponsored by Regeneron, Inc., and has research support from Genentech, Alimera, and CoMentis for diabetic macular edema trials. Diana Do receives research support from Genentech. These activities are being managed by the Conflict of Interest Committee of the Johns Hopkins University School of Medicine. JSH is a consultant for Genentech, Alcon, Allergan, Bausch and Lomb, Eyemaginations, Fovea, Genzyme, Heidelburg, IScience, ISTA, Jerini, LPath, NeoVista, Nodal Vision, Novagali, Novartis, Optherion, Oxigene, Paloma, Pfizer, Regeneron, Resolvyx, Schering Plough, Scyfix, and VisionCare and has received honoraria from Genentech, Heidelberg, Jerini, NeoVista, Optimedica, and Regeneron. JL has received honoraria from Genentech. DB is a consultant and has received honoraria from Genentech, Novartis, Alcon, Allergan, and Pfizer. PA is a consultant for Genentech"</i> Page 2181 </p> <p>Trial registration: NCT00407381</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear method of sequence generation and information could not be obtained from the authors </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear method of allocation concealment and information could not be obtained from the authors </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear if masked and who was masked and information could not be obtained from the authors </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear if masked and who was masked and information could not be obtained from the authors </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants randomised to each group: 33 ranibizumab, 34 ranibizumab + laser, 34 laser </p> <p>Completed participants at 1 year: 29, 29, 30 (85% to 88%)</p> <p>Completed participants at 2 years: 24, 26, 24 (71% to 76%)</p> <p>Causes of missing data were balanced across groups</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The primary outcome differed in the protocol and the final report</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other source of bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk of bias for nearly half the items and unclear risk for the others</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">RELATION 2012 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, eye with worse VA selected</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Germany</p> <p>Number of people randomised: 128 (128 eyes)</p> <p>Average age: 64 years (range 31 to 79)</p> <p>Sex: 37% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0102"> <li> <p>18 years or older</p> </li> <li> <p>diabetes</p> </li> <li> <p>visual impairment (BCVA between 78‐39 letters, testing distance 4 m) due to focal or diffuse DMO in at least one eye eligible for laser treatment in the opinion of the investigator </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0103"> <li> <p>other eye diseases and conditions that might affect VA</p> </li> <li> <p>other eye and systemic treatments</p> </li> <li> <p>pregnancy or possibility of being pregnant</p> </li> <li> <p>Inability to comply with follow‐up</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0104"> <li> <p>ranibizumab (0.5 mg) plus laser n = 85 (85 eyes)</p> </li> </ul> <ul id="CD007419-lst1-0105"> <li> <p>laser plus sham injection n = 43 (43 eyes)</p> </li> </ul> </p> <p>Ranibizumab was applied at baseline, 30, 60, 90 days and reapplied at intervals no shorter than 28 days and laser was applied at baseline and re‐applied if needed at intervals no shorter than 3 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0106"> <li> <p>mean change in BCVA from baseline to month 12 (ETDRS chart, 4 m)</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0107"> <li> <p>adverse events</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: July 2010 to May 2011, terminated early</p> <p>Funding: Novartis</p> <p>Conflict of interest: Novartis</p> <p>Trial registration: NCT01131585</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reported as double‐masked, but no details given</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reported as double‐masked, but no details given</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Missing data: combined laser and ranibizumab: 7/85 (7%); laser 11/43 (26%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Only mean change of VA and harms reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study terminated early due to European Medicine Agency approval of ranibizumab for DMO but this is independent of effect estimates </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">RESOLVE 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, eye with worse VA selected</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: unclear exactly where conducted. Investigators from Australia, Denmark, Austria, France, Germany, Italy, Korea, Portugal, Spain, Switzerland, UK </p> <p>Number of people randomised: 151 (151 eyes)</p> <p>Average age: 64 years (range 32 to 85)</p> <p>Sex: 46% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0108"> <li> <p>18 years or older</p> </li> <li> <p>diabetes mellitus</p> </li> <li> <p>stable HbA1c levels (≤ 12%)</p> </li> <li> <p>DMO with centre involvement in at least one eye</p> </li> </ul> </p> <p>(study eye)</p> <p> <ul id="CD007419-lst1-0109"> <li> <p>CRT ≥ 300 μm (Stratus Zeiss Meditec)</p> </li> <li> <p>BCVA score between 73‐39 letters inclusively, using ETDRS charts at a testing distance of 4 m (approximate Snellen equivalent of 20/40‐20/160) </p> </li> <li> <p>decreased vision attributed to foveal thickening from DMO, that was not explained by any other causes in the opinion of the investigator </p> </li> <li> <p>laser photocoagulation, additional or first treatment, could be withheld for at least 3 months after randomisation </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0110"> <li> <p>PRP (focal peripheral laser photocoagulation) performed within 6 months prior to study entry. Grid/central laser photocoagulation was excluded except for participants with only mild laser burns at least 1000 µm from the centre of the fovea performed more than 6 months before the trial commenced </p> </li> <li> <p>PDR in the study eye, with the exception of tufts of neovascularization &lt; 1 disc area with no vitreous haemorrhage. As well as those with area of retinal ischaemia ≥ 500 µm and located ≤ 500 µm from the centre of the macula of the study eye as assessed by fluorescein angiography at visit 1 and confirmed by a central reading centre </p> </li> <li> <p>participants with unstable medical conditions such as poor glycaemic or BP control</p> </li> <li> <p>participants with hypertension for whom a change in antihypertensive treatment was initiated within 2 months preceding start of trial were not enrolled unless BP was maintained below 160/100 mmHg for at least 1 month prior to the first day of the trial by antihypertensive treatment </p> </li> <li> <p>history of treatment with systemic corticosteroids within 4 months prior to randomisation or topical, rectal or inhaled corticosteroids in current use more than 2 times per week </p> </li> <li> <p>previous participation in a study on antiangiogenic drugs</p> </li> <li> <p>ocular disorders and history of any condition that might confound the interpretation of study results or might render participant at high risk for treatment complications </p> </li> <li> <p>ocular inflammation in either eye or history of cataract surgery in the study eye within 6 months before study initiation </p> </li> <li> <p>pre‐menopausal women not using adequate contraception and pregnant or nursing women</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0111"> <li> <p>ranibizumab (0.3 mg or 0.5 mg) n = 102 (102 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0112"> <li> <p>sham injection n = 49 (49 eyes)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0113"> <li> <p>mean change in BCVA from baseline at 1 month and 12 months</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0114"> <li> <p>mean change in BCVA and CRT from baseline at 12 months</p> </li> <li> <p>categorised BCVA outcome</p> </li> <li> <p>safety</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: not reported</p> <p>Funding: Novartis</p> <p>Conflict of interest: authors served on advisory boards for Novartis and received honoraria and travel and accommodation payments; Novartis employees assisted with the analysis, interpretation and writing </p> <p>Trial registration:NCT00284050</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Eligible patients were randomised 1:1:1 to either ranibizumab (0.3 mg or 0.5 mg) or sham treatment according to a computer‐generated randomised allocation schedule"</i> Online appendix page 1 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>".<i>..allocation schedule (kept at a secure site and accessible only to the injecting physician"</i> Online appendix page 1 </p> <p><i>"Based on the patient strata the injecting physician would take the treatment allocation card and tear‐off the cover and follow instructions to choose vial from the box as indicated (3 boxes, randomisation block size 3). The randomisation data were kept strictly confidential until database<br> lock; not accessible to anyone involved in the study with the exception of injecting physician(s) and drug accountability monitor."</i> Online appendix page 1 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Sham injection for masking participants</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Masking was maintained through appointment of a minimum of 2 investigators at each study site; unmasked injecting physician and a masked evaluating physician (roles could not be switched)."</i> Online appendix page 1 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants who completed the trial at 1 year: 92/102 ranibizumab and 40/49 sham. Causes of missingness were balanced </p> <p>ITT analysis with LOCF was used</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>We could not find a protocol, but primary outcomes were stated in the methods and were those routinely used in the field </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other source of bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">RESPOND 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, unclear how eye selected</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Canada</p> <p>Number of people randomised: 239 (239 eyes)</p> <p>Average age: 62 years (range 26 to 87)</p> <p>Sex: 40% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0115"> <li> <p>18 years or older</p> </li> <li> <p>stable type 1 or type 2 diabetes with HbA1c ≤ 10%</p> </li> <li> <p>visual impairment due to focal or diffuse DMO in at least one eye eligible for laser treatment in the opinion of the investigator </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0116"> <li> <p>active conditions in study eye that could prevent improvement in VA</p> </li> <li> <p>active eye infection or inflammation</p> </li> <li> <p>history of stroke, renal failure or active hypertension</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0117"> <li> <p>ranibizumab (0.5 mg) n = 80 (80 eyes)</p> </li> <li> <p>ranibizumab (0.5 mg) plus laser n = 78 (78 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0118"> <li> <p>laser n = 81 (81 eyes)</p> </li> </ul> </p> <p>For combination and monotherapy, ranibizumab was administered as 3 monthly injections, then 10 months PRN injections given/withheld based on DME stability criteria. Laser was administered according to ETDRS guidelines at intervals of &gt; 3 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>On ClinicalTrials.gov</p> <p><i>Primary Outcome Measures: Measure: mean change from baseline in Best Correct Visual Acuity (BCVA) [Time Frame: 12 months] [Designated as safety issue: No]<br> Secondary Outcome Measures: Measure: number of patients with visual acuity above 73 letters [Time Frame: 3, 6, 9 and 12 months]<br> Measure: number of patients with improvement in BCVA [Time Frame: 3, 6, 9 and 12 months]<br> Measure: time course of BCVA changes [Time Frame: 3, 6, 9 and 12 months]</i> </p> <p><i>Measure: change in central retinal thickness and other anatomical changes [Time Frame: 3, 6, 9 and 12 months]<br> Measure: 15‐letter (3‐line) gain in BCVA [Time Frame: 3, 6, 9 and 12 months]</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: July 2010 to March 2013</p> <p>Funding: Novartis</p> <p>Conflict of interest: authors not reported since the study was obtained as a Novartis public report </p> <p>Trial registration: NCT01135914</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"<i>Randomization was stratified by centre and followed a permutated block size of 6.</i>" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unmasked study (described as open‐label)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unmasked study (described as open‐label)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>More missing data in the laser arm (27%), mainly due to lack of efficacy, compared to the 2 ranibizumab arms (5% to 6%) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>VA, OCT data and harms adequately reported (only loss of vision not reported)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">RESTORE 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, eye with worse VA selected unless other eye more suitable for treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: 10 European countries, Australia, Canada, Turkey</p> <p>Number of people randomised: 345 (345 eyes)</p> <p>Average age: 63 years</p> <p>Sex: 42% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0119"> <li> <p>18 years or older</p> </li> <li> <p>diabetes mellitus (according to the American Diabetes Association or World Health Organization guidelines) </p> </li> <li> <p>HbA1c ≤ 10%</p> </li> <li> <p>visual impairment due to DMO</p> </li> <li> <p>stable medication for the management of diabetes within 3 months before randomisation and expected to remain stable during the study </p> </li> <li> <p>visual impairment due to focal or diffuse DMO in at least 1 eye that was eligible for laser treatment in the opinion of the investigator </p> </li> <li> <p>BCVA letter score between 78‐39, both inclusive, based on ETDRS‐like VA testing charts administered at a starting distance of 4 m (approximate Snellen equivalent 20/32‐20/160) </p> </li> <li> <p>decreased vision due to DMO and not other causes, in the investigator’s opinion (at visit 1) </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0120"> <li> <p>concomitant conditions in the study eye that could prevent the improvement in VA on the study treatment in the investigator’s opinion </p> </li> <li> <p>active intraocular inflammation or infection in either eye</p> </li> <li> <p>uncontrolled glaucoma in either eye (e.g. IOP &gt; 24 mmHg on medication, or from the investigator’s judgement) </p> </li> <li> <p>laser PRP (within 6 months) or focal/grid laser photocoagulation (within 3 months) before study entry </p> </li> <li> <p>treatment with antiangiogenic drugs in the study eye within 3 months before randomisation</p> </li> <li> <p>history of stroke</p> </li> <li> <p>systolic BP &gt; 160 mmHg or diastolic BP &gt; 100 mmHg</p> </li> <li> <p>untreated hypertension</p> </li> <li> <p>change in antihypertensive treatment within 3 months preceding baseline</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0121"> <li> <p>ranibizumab (0.5 mg) plus sham laser n = 116 (116 eyes)</p> </li> <li> <p>ranibizumab (0.5 mg) plus laser n = 118 (118 eyes)</p> </li> </ul> </p> <p>Comparator</p> <p> <ul id="CD007419-lst1-0122"> <li> <p>laser treatment plus sham injections n = 111 (111 eyes)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0123"> <li> <p>mean average change in BCVA from baseline over 12 months</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0124"> <li> <p>VA improvement</p> </li> <li> <p>BCVA letter score 73 (20/40 Snellen equivalent) at month 12</p> </li> <li> <p>mean change in BCVA letter score</p> </li> <li> <p>mean change in central retinal (subfield) thickness</p> </li> <li> <p>patient‐reported outcomes</p> </li> <li> <p>safety</p> </li> </ul> </p> <p>Follow‐up: 12 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: not reported</p> <p>Funding: Novartis</p> <p>Conflict of interest: authors reported financial support of Novartis or were Novartis employees </p> <p>Trial registration: NCT00906464</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"A randomization list was produced by, or under the responsibility of, Novartis Drug Supply Management using a validated system that automated the random assignment of treatment arms to randomization numbers in the specified ratio.</i>" <a href="appendices#CD007419-sec2-0016">Appendix 1</a> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Central randomisation using an electronic Case Report Form after each participant was included by study investigators </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"The masked BCVA assessor evaluated the visual acuity of the patient and provided the results to the evaluating investigator who also was masked to the treatment assignment. The evaluating investigator was responsible for all other aspects of the study, excluding the injection procedures. Based on all the performed clinical assessments and the visual acuity (VA) results received from the BCVA assessor, the evaluating investigator had to decide on the treatment requirements for the patient each month and communicated this decision to the treating investigator. The treating investigator was unmasked to the treatment assignment and performed all injections or laser treatment as well as the corresponding sham treatments. He/she was required not be involved in any other aspect of the study and not to divulge the patient’s treatment assignment to anyone. Once the designated roles were determined, the roles could not be switched at any time during the conduct of the study. Every effort was made to limit the number of unmasked study personnel to ensure the integrity of this masked study. An independent review and standardized grading of fundus photography, fluorescein angiography, and optical coherence tomography (OCT) images for the patients screened and enrolled in the study was performed at a central reading center that did not have access to any other data of the patients."</i><a href="appendices#CD007419-sec2-0016">Appendix 1</a> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants randomised in each group were: 116 ranibizumab, 118 ranibizumab + laser, 111 laser </p> <p>At 1 year complete participants were 87.9%, 87.3% and 88.3% respectively</p> <p>There were 2 deaths in each of the 3 treatment arms</p> <p>Used ITT analysis with LOCF</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>We could not find a protocol, but primary outcomes were stated in the methods and were those routinely used in the field </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other source of bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">REVEAL 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, eye with worse VA selected unless other eye more suitable for treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Asian population from 52 centres across 6 countries, or regions: China, Hong Kong, Japan, South Korea, Singapore, and Taiwan. </p> <p>Number of people randomised: 396 (396 eyes)</p> <p>Average age: 61 years</p> <p>Sex: 44% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0125"> <li> <p>18 years or older</p> </li> <li> <p>diabetes mellitus (according to the American Diabetes Association or World Health Organization guidelines) </p> </li> <li> <p>HbA1c ≤ 10%</p> </li> <li> <p>visual impairment due to DMO</p> </li> <li> <p>stable medication for the management of diabetes within 3 months before randomisation and expected to remain stable during the study </p> </li> <li> <p>visual impairment due to focal or diffuse DMO in at least 1 eye that was eligible for laser treatment in the opinion of the investigator </p> </li> <li> <p>BCVA letter score between 78‐39, both inclusive, based on ETDRS‐like VA testing charts administered at a starting distance of 4 m (approximate Snellen equivalent 20/32‐20/160) </p> </li> <li> <p>decreased vision due to DMO and not other causes, in the investigator’s opinion (at visit 1) </p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0126"> <li> <p>concomitant conditions in the study eye that could prevent the improvement in VA on the study treatment in the investigator’s opinion </p> </li> <li> <p>active intraocular inflammation or infection in either eye</p> </li> <li> <p>uncontrolled glaucoma in either eye (e.g. IOP &gt; 24 mmHg on medication, or from the investigator’s judgement) </p> </li> <li> <p>laser PRP (within 6 months) or focal/grid laser photocoagulation (within 3 months) before study entry </p> </li> <li> <p>treatment with antiangiogenic drugs in the study eye within 3 months before randomisation</p> </li> <li> <p>history of stroke</p> </li> <li> <p>systolic BP &gt; 160 mmHg or diastolic BP &gt; 100 mmHg</p> </li> <li> <p>untreated hypertension</p> </li> <li> <p>change in antihypertensive treatment within 3 months preceding baseline</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>"<i>Patients were randomised in a 1:1:1 ratio to 1 of 3 treatment arms: intravitreal ranibizumab 0.5 mg injection + sham laser, intravitreal ranibizumab 0.5 mg injection + active laser, or active laser + sham injections for 12 months</i>" Page 1404 </p> <p>Number in each group: ranibizumab + sham laser (n = 133), ranibizumab + active laser (n =132), or sham injection + active laser (n = 131). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0127"> <li> <p>mean average change in BCVA from baseline over 12 months</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0128"> <li> <p>several BCVA expressions</p> </li> <li> <p>mean change in central retinal (subfield) thickness</p> </li> <li> <p>safety</p> </li> </ul> </p> <p>Follow‐up: 12 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: not reported</p> <p>Funding: Novartis</p> <p>Conflict of interest: authors reported financial support of Novartis or were Novartis employees </p> <p>Trial registration: NCT00989989</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"At Visit 2, all patients who fulfilled all the inclusion/exclusion criteria were given the lowest available number on the randomization list. This number assigned them to one of the treatment arms. The investigator entered the randomization number on the electronic case report form. A randomization list was produced by, or under the responsibility of Novartis Drug Supply Management using a validated system that automated the random assignment of treatment arms to randomization numbers in the specified ratio"</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"<i>To ensure successful masking in this double‐masked study, at the start of the study and at each study site, the following site personnel were required to demonstrate their role: BCVA assessor and evaluating investigator (masked to the treatment assignment) and treating investigator (unmasked to the treatment assignment</i>" Page 1404 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Higher proportion of loss to follow‐up in the laser group; this can decrease the benefit with anti‐VEGF (see below). </p> <p><i>"Overall, 345 (87.1%) patients completed the study. The proportion of patients who discontinued the study was 7.5% in the ranibizumab arm, 13.6% in the ranibizumab þ active laser treatment arm, and 17.6% in the laser treatment arm (Fig 2, available at www.aaojournal.org). Adverse events (range, 3.0%‐6.8%) were the most common reason for discontinuation across all treatment arms (Fig 2, available at www.aaojournal.org). Unsatisfactory therapeutic effect (n= 7 [5.3%]) was reported only in the laser arm</i>." Page 1405 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No protocol available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">RISE‐RIDE </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One eye per person, unclear how eye selected</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA and South America</p> <p>Number of people randomised: 759 (759 eyes)</p> <p>Average age: 62 years</p> <p>Sex: 43% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0129"> <li> <p>18 years or older</p> </li> <li> <p>diabetes mellitus</p> </li> <li> <p>decreased vision from DMO (study eye BCVA, 20/40–20/320 Snellen equivalent using ETDRS testing) </p> </li> <li> <p>macular oedema (TD‐OCT) central subfield thickness ≥ 275 µm</p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0130"> <li> <p>prior vitreoretinal surgery</p> </li> <li> <p>recent history (within 3 months of screening) of panretinal or macular laser in the study eye </p> </li> <li> <p>intraocular corticosteroids antiangiogenic drugs</p> </li> <li> <p>uncontrolled hypertension</p> </li> <li> <p>uncontrolled diabetes (HbA1c &gt; 12%)</p> </li> <li> <p>recent (within 3 months) cerebrovascular accident, or myocardial infarction</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0131"> <li> <p>ranibizumab (0.3 mg or 0.5 mg) n = 244 (244 eyes)</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0132"> <li> <p>sham injection n = 122 (122 eyes)</p> </li> </ul> </p> <p><i>"The median number of ranibizumab injections was 24. The mean number of macular laser treatments over 24 months was 1.8 and 1.6 in the sham groups and 0.3 to 0.8 in the ranibizumab groups. Substantially more sham‐treated patients received macular laser under the protocol‐speciﬁed criteria or underwent panretinal photocoagulation for proliferative diabetic retinopathy."</i> Page 5 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0133"> <li> <p>gain of 15 or more ETDRS letters in BCVA score from baseline at 24 months (corresponding to 3 lines on the eye chart) </p> </li> </ul> </p> <p>Secondary outcomes: (at 24 months)</p> <p> <ul id="CD007419-lst1-0134"> <li> <p>mean change from baseline BCVA score over time</p> </li> <li> <p>proportion of participants with BCVA Snellen equivalent of 20/40</p> </li> <li> <p>mean change from baseline BCVA score over time in participants with focal oedema as assessed on fluorescein angiography </p> </li> <li> <p>proportion of participants losing 15 letters in BCVA score from baseline</p> </li> <li> <p>mean change from baseline in OCT CFT over time</p> </li> <li> <p>proportion of participants with a 3‐step progression from baseline in ETDRS retinopathy severity on fundus photography </p> </li> <li> <p>proportion of participants with resolution of leakage on FA</p> </li> <li> <p>mean number of macular laser treatments</p> </li> </ul> </p> <p>Follow‐up: 24 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: June 2007 to January 2009</p> <p>Funding: "<i>This study was supported by Genentech Inc. Support for third‐party writing assistance by Ivo Stoilov, MD, CMPP, of Envision Scientific Solutions was provided by Genentech Inc.</i>" "<i>The sponsor participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation and review of the manuscript.</i>" Page 1121 </p> <p>Conflict of interest: "<i>Dr Ip is a consultant/advisor for Eye Technology Ltd, Genentech Inc, NicOx, Notal Vision, QLT Phototherapeutics Inc, Regeneron, and Sirion and has received grant support from Allergan Inc. Drs Hopkins and Ehrlich and Ms Wong are employees of Genentech Inc, a member of the Roche Group. Drs Hopkins and Ehrlich hold equity and/or options in Roche.</i>" Page 1121 </p> <p>Trial registration: RIDE NCT00473382 RISE NCT00473330</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"<i>Randomization was stratified by study eye BCVA (55 vs 55 ETDRS letters), baseline HbA1c (&lt;=8% vs &gt;8%), prior DME therapy in the study eye (yes vs no), and study site. Dynamic randomization was used to obtain approximately a 1:1:1 ratio among groups (Fig 1). Randomization was done via interactive phone system. The sponsor developed the specifications for the randomization, and a third party programmed and held the randomization algorithm.</i>" Page 3, Nguyen et al </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"<i>Randomization was stratified by study eye BCVA (55 vs 55 ETDRS letters), baseline HbA1c (&lt;=8% vs &gt;8%), prior DME therapy in the study eye (yes vs no), and study site. Dynamic randomization was used to obtain approximately a 1:1:1 ratio among groups (Fig 1). Randomization was done via interactive phone system. The sponsor developed the specifications for the randomization, and a third party programmed and held the randomization algorithm.</i>" Page 3, Nguyen et al </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>"<i>Ocular assessments, including the need for macular laser, were made by evaluating ophthalmologists masked to patients’ treatment assignments. Study treatments were administered by treating ophthalmologists unmasked to treatment assignments but masked to ranibizumab dose. To improve patient masking, all patients received subconjunctival anesthesia before sham or active injections (performed as previously described).22 Study site personnel (except treating physicians and assistants), central reading center personnel, and the sponsor and its agents (except drug accountability monitors) were masked to treatment assignment. Treating physicians were masked to the assigned dose of ranibizumab.</i>" Page 3, Nguyen et al </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The 2‐year study period was completed by 83.3% of participants in RISE and by 84.6% in RIDE; causes of missingness not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All VA cut‐offs and secondary outcomes available at 2 years, although not at 1 year, as pre‐planned </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Soheilian 2007 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> <p>One or two eyes per person, in bilateral cases unclear how the second eye allocated</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Iran</p> <p>Number of people randomised: 129 (150 eyes)</p> <p>Average age: 61 years</p> <p>Sex: 49% women</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0135"> <li> <p>clinically significant DMO based on ETDRS criteria&nbsp;</p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0136"> <li> <p>previous PRP or focal laser photocoagulation</p> </li> <li> <p>prior intraocular surgery or injection</p> </li> <li> <p>history of glaucoma or ocular hypertension</p> </li> <li> <p>VA of 20/40 or better, or worse than 20/300</p> </li> <li> <p>presence of iris neovascularisation</p> </li> <li> <p>high‐risk PDR</p> </li> <li> <p>significant media opacity</p> </li> <li> <p>monocularity</p> </li> <li> <p>pregnancy</p> </li> <li> <p>serum creatinine ≥ 3 mg/dL</p> </li> <li> <p>uncontrolled diabetes mellitus</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Intervention:</p> <p> <ul id="CD007419-lst1-0137"> <li> <p>bevacizumab (1.25 mg) n = 50 eyes</p> </li> </ul> </p> <p>Comparator:</p> <p> <ul id="CD007419-lst1-0138"> <li> <p>laser photocoagulation n = 50 eyes</p> </li> </ul> </p> <p>Re‐treatment was performed at 12‐week intervals whenever indicated</p> <p>There was another intervention arm which combined bevacizumab with triamcinolone, but this is not included in this review (n = 50 eyes) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0139"> <li> <p>change in BCVA (logMAR) at week 24 (data available at 36 weeks)</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0140"> <li> <p>VA change</p> </li> <li> <p>CRT change assessed by OCT</p> </li> <li> <p>injection‐related complications</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Dates participants enrolled: September 2005 to May 2007</p> <p>Funding: "<i>Supported by the Ophthalmic Research Center of Shahid Beheshti University (MC) Tehran, Iran.</i>" Page 1150 </p> <p>Conflict of interest: "<i>The author(s) have no proprietary or commercial interest in any materials discussed in this article</i>" Page 1150 </p> <p>Trial registration: NCT00370669</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Randomization was performed using random block permutation method according to a computer‐generated randomization list. The block length varied randomly (6, 12). Random allocation sequence was performed by a biostatistician. The detail of series was unknown by the study investigators."</i> Page 2 Soheilian 2009 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"Randomization was performed using random block permutation method according to a computer‐generated randomization list. The block length varied randomly (6, 12). Random allocation sequence was performed by a biostatistician. The detail of series was unknown by the study investigators."</i> Page 2 Soheilian 2009 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>"A sham laser procedure (20 seconds) was performed by aiming the laser beam on the macula for the eyes in the IVB and IVB/IVT groups. In the MPC group, a sham injection was done by a needleless syringe pressed against the conjunctiva. To keep the masking process, patients were prevented from seeing the syringes. All procedures were run by staff members other than the study investigators to preserve investigator masking. Best‐corrected VA measurement and OCT were performed by certified examiners masked both to the randomization and to the findings of previous measurements."</i> Page 2‐3 Soheilian 2009 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See above</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There were 6 missing eyes out of 50 at 36 weeks in the IVB group and 12 out of 50 in the photocoagulation group and causes were not clearly unrelated to VA outcome, except for 2 deaths. In a subsequent publication in 2012 the authors reported 39 (78%) and 38 (76%) eyes in the two arms; 8 participants (12 eyes) missing were dead for causes unrelated to treatment, but other causes of death were not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The primary outcomes are continuous measures and no arbitrary cut‐points were used</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There was an imbalance of baseline VA in the IVB and photocoagulation groups: 0.71 logMAR versus 0.55 logMAR. Although there was a potential unit of analysis issue (150 eyes of 129 patients, 16% of participants had both eyes included), comparisons were made in a marginal regression model (based on generalised estimating equation methods) adjusted for the baseline values and to eliminate any possible correlation effects between the 2 eyes of participants in bilateral enrolled cases. However, we could not take correlation into account when analysing dichotomous VA definitions </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High or unclear risk of bias for two items to a degree which we believe may influence effect estimates </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Turkoglu 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Prospective study, treatment in the better‐seeing eye</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Turkey</p> <p>Number of people randomised: 70 participants (35 ranibizumab, 35 grid laser)</p> <p>Average age: 64.6 ± 8.2 years ranibizumab; 63.8 ± 7.4 years laser</p> <p>Sex: 21% male ranibizumab, 18% male laser</p> <p>Inclusion criteria:</p> <p> <ul id="CD007419-lst1-0141"> <li> <p>evidence of CSME by means of FFA</p> </li> <li> <p>at least 6 months of follow‐up</p> </li> <li> <p>no other systemic or ocular disease that might affect vision</p> </li> </ul> </p> <p>Exclusion criteria:</p> <p> <ul id="CD007419-lst1-0142"> <li> <p>participants with a history of intravitreal injection and laser photocoagulation for proliferative diabetic retinopathy or CSME </p> </li> <li> <p>participants with vitreous haemorrhage present at the time of recruitment or vitreous haemorrhage which developed after enrolment </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Focal or grid laser photocoagulation treatment was performed in 35 participants and laser settings, including power, spot size, duration and number of burns, were recorded </p> <p>35 participants received initial injection of ranibizumab 0.5 mg/0.05 mL. All participants of both groups received treatment in their better‐seeing eye. After the induction phase, the intravitreal injections were administered if any of the following changes were observed: presence of visual acuity loss; persistent or recurrent subretinal or intraretinal fluid. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Group comparisons of absolute scores and mean changes from baseline scores at 6‐month visit were performed using analysis of the Turkish version of VFQ‐25; it has modifications to adjust for Turkish culture and lifestyle. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No data available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No loss to follow‐up reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No specific statement nor protocol available</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No other bias identified</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Most items not reported</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Wiley 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Randomised, double‐masked, 3‐period, 2‐treatment crossover design with 4 treatment sequence patterns </p> <p>Each of 3 12‐week periods consisted of 3 intravitreous injections of ranibizumab (0.3 mg) or bevacizumab (1.25 mg), given every 4 weeks, with evaluation of the treatment period 4 weeks after the third dose (i.e. weeks 12, 24, and 36) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA and UK</p> <p>Number of people randomised: 56 participants (62 eyes, 6 pz both eyes)</p> <p>Average age: 62 years</p> <p>Sex: 38.7% women</p> <p>Inclusion criteria:</p> <p>Eligible participants had type 1 or type 2 diabetes mellitus, were at least 18 years of age, and could enter one or both eligible eyes in the study. Principal eligibility criteria for a study eye included: (1) presence of DME involving the centre of the macula, (2) ETDRS BCVA letter score of 78 to 24 (Snellen equivalent, 20/32‐20/400), and (3) CSMT of 330 mm or more on Cirrus (Carl Zeiss Meditec, Inc, Dublin, CA) OCT. </p> <p>Exclusion criteria:</p> <p>Eye included presence of factors or other conditions judged to impact the course of oedema or to preclude possible improvement in vision with treatment; PRP, focal or grid laser photocoagulation, or depot corticosteroid injection within the previous 3 months; ocular injection with an anti‐VEGF agent within the previous 2 months; more than 4 injections with an anti‐VEGF agent within the previous year; or prior vitrectomy. Potential participants were excluded for history of renal failure (requiring haemodialysis or renal transplantation) and for a measured systolic BP of more than 180 mmHg or a diastolic BP of more than 110 mmHg. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Each of 3 12‐week periods consisted of 3 intravitreous injections of ranibizumab (0.3 mg) or bevacizumab (1.25 mg), given every 4 weeks, with evaluation of the treatment period 4 weeks after the third dose (i.e. weeks 12, 24, and 36). </p> <p>Each study eye received 9 monthly injections over the course of the trial, according to a pattern of treatments determined by 1 of 4 randomly assigned sequences: R‐R‐B (n = 17), R‐B‐B (n = 15), B‐B‐R (n = 16), or B‐R‐R (n = 14), where R indicates a series of 3 consecutive ranibizumab injections, and B represents a series of 3 consecutive bevacizumab injections. Study eyes meeting predefined criteria for significant worsening of DME at week 12 or later could receive focal or grid laser photocoagulation. Fellow eyes in participants only enrolling 1 eye could receive any necessary ocular treatment. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>The primary outcome: mean change in BCVA from baseline, estimated for a 3‐month dosing period in a linear mixed‐effects model. </p> <p>The main prespecified secondary outcome was the change in CRT, measured as OCT CSMT, estimated for a 3‐month dosing period using the linear mixed‐effects model. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>June 2012 and January 2014</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“<i>Participants were assigned to 1 of the 4 treatment sequences using a randomization list generated by the Data and Statistical Coordinating Center before study initiation, with balance after every 12 enrollments. The list was provided to unmasked pharmacists at each site, who confirmed a valid participant identification code before dispensing study treatment. Both clinical sites used the same randomised list, but selected treatment assignments from opposite ends. For participants entering both eyes in the trial, the right eye was assigned randomly as above to 1 of the 4 treatment sequences, and the left eye was assigned automatically</i> to the sequence<i>with the inverse schedule (for example, B‐R‐R in the right eye and R‐B‐B in the left eye).</i> Page 2 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>Participants were assigned to 1 of the 4 treatment sequences using a randomization list generated by the Data and Statistical Coordinating Center before study initiation, with balance after every 12 enrollments. The list was provided to unmasked pharmacists at each site, who confirmed a valid participant identification code before dispensing study treatment. Both clinical sites used the same randomised list, but selected treatment assignments from opposite ends. For participants entering both eyes in the trial, the right eye was assigned randomly as above to 1 of the 4 treatment sequences, and the left eye was assigned automatically</i> to the sequence<i>with the inverse schedule (for example, B‐R‐R in the right eye and R‐B‐B in the left eye).</i> Page 2 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>“Participants and investigators were masked to treatment. Site staff collecting study data, including research coordinators, technicians, and photographers, were also masked.”</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><i>“Site staff collecting study data, including research coordinators, technicians, and photographers, were also masked.”</i> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>“<i>One participant with a single eye assigned to the R‐B‐B group</i> </p> <p><i>withdrew after the week 4 visit after a hemorrhagic stroke. All</i> </p> <p><i>remaining participants completed the study, including the week 12, 24, and 36 visits, and were included in this analysis</i>” </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>VA (no SD), OCT (no SD) data and harms adequately reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Six out of 56 participants had both eyes included in analyses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall risk of bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk of bias for most items</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations</b><br> BCVA: best‐corrected visual acuity<br> BP: blood pressure<br> CRT: central retinal thickness<br> CSFT: central subfield thickness<br> CSMO: clinically significant macular oedema<br> CSMT: central subfield mean thickness<br> DMO: diabetic macular oedema (DME: US spelling edema)<br> ECG: electrocardiogram<br> EQ‐5D: EuroQol 5D<br> ETDRS: Early Treatment Diabetic Retinopathy Study<br> FAZ: foveal avascular zone<br> FFA: fundus fluorescein angiography<br> GLD: greatest linear dimension<br> HbA1c: glycated haemoglobin<br> IOP: intraocular pressure<br> ITT: intention‐to‐treat<br> iv: intravenous<br> IV: intravitreal injection<br> IVB: intravitreal bevacizumab<br> IVT: intravitreal triamcinolone<br> LOCF: last observation carried forward<br> logMAR: log of the Minimum Angle of Resolution<br> NEI VFQ‐25: National Eye Institute Visual Function Questionnaire‐25<br> OCT: optical coherence tomography<br> PDR: proliferative diabetic retinopathy<br> PFCL: perifoveal capillary loss<br> PRP: panretinal photocoagulation<br> RCT: randomised controlled trial<br> SD: standard deviation<br> SD‐OCT: spectral‐domain optical coherence tomography<br> TD‐OCT: time‐domain optical coherence tomography<br> VA: visual acuity<br> VEGF: vascular endothelial growth factor </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD007419-sec2-0034"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD007419-sec2-0033" class="jump-to">included studies</a></li> <li><a href="#CD007419-sec2-0035" class="jump-to">awaiting classification</a></li> <li><a href="#CD007419-sec2-0036" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0025">Ahmadieh 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not an RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0026">CRFB002DFR08 (LUDIC)</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single‐arm study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0027">CRFB002DGB14 (RELIGHT)</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single‐arm study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0028">CRFB002DNO02 (PTIMAL)</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single‐arm study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0029">DRCRnet 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Follow‐up at 12 weeks only</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0030">DRCRnet 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Follow‐up at 14 weeks only. RCT comparing ranibizumab (2 injections), triamcinolone (1 injection) to sham in participants with DMO undergoing grid and panretinal laser photocoagulation </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0031">DRCRnet 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Follow‐up of <a href="references#CD007419-bbs2-0005">DRCRnet 2010</a> comparing prompt to deferred laser in participants treated for ranibizumab for DMO: does not report on comparison of ranibizumab with laser </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0032">Faghihi 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Follow‐up at 16 weeks only</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0033">NCT02985619 (BEVATAAC)</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Triamcinolone as comparator, unpublished study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0034">Paccola 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single injection of intravitreal triamcinolone acetonide (4 mg/0.1 mL) compared to single injection of intravitreal bevacizumab (1.5 mg/0.06 mL). Duration: 24 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0035">Solaiman 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Single intravitreal injection of bevacizumab (inadequate dose); follow‐up 6 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD007419-bbs2-0036">Zehetner 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Physiological study of anti‐VEGF levels only</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations</b><br> DMO: diabetic macular oedema<br> RCT: randomised controlled trial<br> VEGF: vascular endothelial growth factor </p> </div> </div> </p> </section> <section class="characteristicsOfAwaitingStudies" lang=""> <div class="section-header" id="CD007419-sec2-0035"> <h3 class="title">Characteristics of studies awaiting assessment [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD007419-sec2-0033" class="jump-to">included studies</a></li> <li><a href="#CD007419-sec2-0034" class="jump-to">excluded studies</a></li> <li><a href="#CD007419-sec2-0036" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Chen 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation: randomised<br> Endpoint classification: efficacy study<br> Intervention model: parallel assignment<br> Masking: unclear<br> Primary purpose: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>42 (72 eyes); country: China</p> <p>Male 55%, average age 60 years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental: ranibizumab 0.5 mg; one week after ranibizumab, the participants received grid photocoagulation intervention: macular area C‐shaped manner, spot size 100 μm to 200 μm, 1 spot width apart, level I to II power and exposure time 0.1 second<br> Active comparator: laser only </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome (time frame: 3 and 6 months):</p> <p> <ul id="CD007419-lst1-0143"> <li> <p>Improvement of VA (2 or more lines on a letter chart, but not ETDRS)</p> </li> <li> <p>Ranibizumab plus laser: 28/36 (78%)</p> </li> <li> <p>Laser only: 18/36 (50%)</p> </li> </ul> </p> <p>Secondary outcome:</p> <p> <ul id="CD007419-lst1-0144"> <li> <p>Reduction in retinal thickening based on OCT</p> </li> <li> <p>Baseline: ranibizumab plus laser: 487 (SD: 85) micron; laser 480 (SD: 83) micron</p> </li> <li> <p>6 months: ranibizumab plus laser: 246 (SD: 26) micron; laser: 370 (SD: 36) micron</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Articles in Chinese</p> <p>Authors contacted to obtain additional data</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Fouda 2017 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation: randomised study but no other information reported<br> Endpoint classification: efficacy study<br> Intervention model: parallel assignment<br> Masking: unclear<br> Primary purpose: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70 eyes randomised (42 participants); country: Egypt</p> <p>Male % not reported, average age 55 years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental: ranibizumab 0.5 mg; aflibercept 2 mg</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome (time frame: 12 months): VA and CRT (cut‐off and instrument not specified)</p> <p>Decimal VA used: no significant difference between ranibizumab and aflibercept<br> Reduction in retinal thickening based on OCT: no significant difference between ranibizumab and aflibercept </p> <p>Number of re‐injections after the loading dose: 2.62 (SD 0.68) aflibercept, 3.03 (SD 0.95) ranibizumab (P = 0.02) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Authors contacted to obtain additional data</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Huang 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation: quasi‐randomised, participants with even visit numbers were allocated to intervention group, whereas participants with odd visit numbers were allocated to control group<br> Endpoint classification: efficacy study<br> Intervention model: parallel assignment<br> Masking: unclear<br> Primary purpose: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78; country: China</p> <p>Male 55%, average age 51 to 54 years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental: ranibizumab 0.5 mg</p> <p>Active comparator: argon laser 532μm, green, 50 μm to 100 μm spots, intensity 100 mW to 200 mW and exposure time 0.1 second </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome (time frame: 3 and 6 months):</p> <p> <ul id="CD007419-lst1-0145"> <li> <p>Improvement of VA (cut‐off and instrument not specified)</p> </li> <li> <p>Ranibizumab plus laser: 24/41 (59%)</p> </li> <li> <p>Laser only: 11/27 (30%)</p> </li> </ul> </p> <p>Secondary outcome:</p> <p> <ul id="CD007419-lst1-0146"> <li> <p>Reduction in retinal thickening based on OCT</p> </li> <li> <p>Baseline: ranibizumab: 401 (SD: 39) micron; laser: 387 (SD: 31) micron</p> </li> <li> <p>6 months: ranibizumab: 289 (SD: 34) micron; laser: 320 (SD: 37) micron</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Article in Chinese</p> <p>Authors contacted to obtain additional data</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Jovanovic 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation: randomised<br> Endpoint classification: efficacy study<br> Intervention model: parallel assignment<br> Masking: unclear<br> Primary purpose: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72 (120 eyes); country: Poland</p> <p>Average age: 60 years</p> <p>Inclusion criteria: severe DMO that affects the fovea, reduction in VA and/or metamorphopsia, diffuse oedema with or without cystic oedema (confirmed by fluorescein angiography and by OCT), CRT ≥ 300 μm, the absence of hard lipid exudates in the form of plaque in the subfoveal region, no prior laser treatment, no prior VEGF inhibitor treatment, and no previous intravitreal or subtenonian corticosteroid administration. The exclusion criteria were: high risk and advanced proliferative DR (PDR), the presence of other eye diseases that could affect VA, prior eye surgeries </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental: bevacizumab 1.25 mg, one or more injections, with or without laser photocoagulation after 4 to 6 weeks depending on clinical response<br> Active comparator: laser only </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome: not specified<br> Outcommes reported: VA (logMAR), CRT based on OCT </p> <p>Quantitative results are available, but not at specified follow‐up times and by number of injection and combination rather than by assigned subgroup </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Sponsor: none reported</p> <p>Authors contacted to obtain additional information</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT00387582 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation: randomised<br> Endpoint classification: efficacy study<br> Intervention model: parallel assignment<br> Masking: open‐label<br> Primary purpose: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>49, country: USA</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental: I</p> <p> <ul id="CD007419-lst1-0147"> <li> <p>Lucentis injections for the first 3 months of the study and then according to the protocol for the duration of the trial </p> </li> </ul> </p> <p>Active comparator: II</p> <p> <ul id="CD007419-lst1-0148"> <li> <p>Argon laser treatment at enrolment and then according to the protocol for the duration of the study </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome (time frame: 6 and 12 months):</p> <p> <ul id="CD007419-lst1-0149"> <li> <p>Prevention of vision loss at 1 year as evidenced by ETDRS VA</p> </li> </ul> </p> <p>Secondary outcome:</p> <p> <ul id="CD007419-lst1-0150"> <li> <p>Reduction in retinal thickening based on OCT</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Completion Date: February 2009 (No Results)</p> <p>Author contact not found</p> <p>Sponsor: Rocky Mountain Retina Consultants</p> <p>Collaborator: Genentech, Inc.</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT00997191 (IBeTA) </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation: randomised<br> Endpoint classification: safety/efficacy study<br> Intervention model: parallel assignment<br> Masking: open‐label<br> Primary purpose: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12; country: Brazil</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Procedure: laser photocoagulation<br> Drug: intravitreal triamcinolone<br> Drug: intravitreal bevacizumab </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome (time frame: 1 year):</p> <p> <ul id="CD007419-lst1-0151"> <li> <p>BCVA</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0152"> <li> <p>macular mapping test</p> </li> <li> <p>multifocal electroretinogram</p> </li> <li> <p>CRT</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Completion date: November 2011 (no results)</p> <p>Author could not be contacted</p> <p>Sponsor: University of Sao Paulo</p> <p>Collaborator: Fundacao de Amparo a Pesquisa do Estado de Sao Paolo</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01445899 (MATISSE) </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation: randomised<br> Endpoint classification: safety/efficacy study<br> Intervention model: parallel assignment<br> Masking: double‐masked (participant, caregiver, investigator) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>264; countries: USA, Israel</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Drug: PF‐04523655 (Stratum I)<br> Drug: PF‐04523655 and ranibizumab<br> Drug: ranibizumab<br> Drug: PF‐04523655 (Stratum II) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcomes:<br> Safety and dose‐limiting toxicities (Stratum I): to determine the safety and dose‐limiting toxicities of a single intravitreal (IVT) injection of PF‐04523655 in people with low vision<br> Pharmacokinetics (Stratum I): to determine the pharmacokinetics (PK) of a single IVT injection of PF‐04523655 in people with low vision<br> Safety and tolerability (Stratum II): to evaluate the safety and tolerability of PF‐04523655 alone and in combination with ranibizumab in participants with DMO<br> Efficacy (Stratum II): to evaluate the ability of PF‐04523655 alone and in combination with ranibizumab to improve VA compared to ranibizumab alone in people with DMO </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Completion date: November 2013 (no results)</p> <p>Author contact not found</p> <p>Sponsor: Quark Pharmaceuticals</p> <p>Consider putting in excluded studies</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01565148 (IDEAL) </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation: randomised<br> Endpoint classification: safety/efficacy study<br> Intervention model: factorial assignment<br> Masking: open‐label </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>208; country: USA</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental Group 1: drug: iCo‐007 350 µg as an intravitreal injection at baseline followed by another iCo‐007 dose (350 μg) at month 4<br> Experimental Group 2: drug: iCo‐007 700 µg as an intravitreal injection at baseline followed by another iCo‐007 dose (700 μg) at month 4<br> Experimental Group 3: drug: iCo‐007 350 µg as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At month 4, intravitreal injection of iCo‐007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation </p> <p>Experimental Group 4: drug: ranibizumab 0.5 mg intravitreal injection at baseline followed by iCo‐007 350 μg intravitreal injection 2 weeks later; re‐treatment with ranibizumab 0.5 mg mandatory at month 4 followed by iCo‐007 350 μg 2 weeks later </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0153"> <li> <p>Change in VA from baseline to month 8</p> </li> </ul> </p> <p>Secondary outcomes:</p> <p> <ul id="CD007419-lst1-0154"> <li> <p>Number of participants in a given study arm experiencing the same drug‐related serious adverse event as a measure of safety and tolerability </p> </li> <li> <p>Safety of repeated iCo‐007 intravitreal injections in treatment of people with DMO as monotherapy and in combination with ranibizumab or laser photocoagulation. Serious consideration will be given if 2 or more participants in a particular treatment arm experience the same drug‐related serious adverse event </p> </li> <li> <p>Change in VA from baseline to month 12</p> </li> <li> <p>Change in retinal thickness measured by OCT from baseline to month 8</p> </li> <li> <p>Change in retinal thickness measured by OCT from baseline to month 12</p> </li> <li> <p>Duration of iCo‐007 treatment effect during the 12‐month follow‐up period as measured by VA and OCT thickness </p> </li> <li> <p>Peak plasma concentration (Cmax) of iCo‐007 after multiple injections</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study has passed its completion date and status has not been verified in more than 2 years on ClinicalTrials.gov </p> <p>Author contacted</p> <p>Sponsor: Quan Dong Nguyen<br> Collaborators: Juvenile Diabetes Research Foundation, iCo Therapeutics Inc </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations</b><br> BCVA: best‐corrected visual acuity<br> CFST: central subfield macular thickness<br> CRT: central retinal thickness<br> DMO: diabetic macular oedema<br> EQ‐5D: EuroQol 5D<br> ETDRS: Early Treatment Diabetic Retinopathy Study<br> OCT: optical coherence tomography<br> PRN: pro re nata<br> SD: standard deviation<br> TE: treat and extend<br> VA: visual acuity<br> VEGF: vascular endothelial growth factor<br> VFQ‐25: Visual Function Questionnaire 25‐item </p> </div> </div> </p> </section> <section class="characteristicsOfOngoingStudies" lang=""> <div class="section-header" id="CD007419-sec2-0036"> <h3 class="title">Characteristics of ongoing studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD007419-sec2-0033" class="jump-to">included studies</a></li> <li><a href="#CD007419-sec2-0034" class="jump-to">excluded studies</a></li> <li><a href="#CD007419-sec2-0035" class="jump-to">awaiting classification</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">ChiCTR‐TRC‐12002417 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A randomised controlled trial to compare the efficacy and safety of 1) macular laser vs 2) repeated intravitreal bevacizumab vs 3) combined repeated intravitreal bevacizumab with macular laser for diabetic macular edema </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>People with type 2 diabetes and DMO</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Group 1 (Control): macular laser photocoagulation performed every 4 months unless the deferral criteria are met. Group 2: intravitreal bevacizumab injections (1.25 mg each) given at 0, 1, 2 months and repeated en bloc every 4 months unless the deferral criteria are met. </p> <p>Group 3: Intravitreal bevacizumab injections (1.25 mg each) given at 0, 1, 2 months, followed by macular laser photocoagulation at month 3; and repeated en bloc every 4 months unless the deferral criteria are met </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>BCVA at 2 years</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unknown; trial registered 13 August 2013</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Joyce Kung (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="cfa5a0b6acaaa4baa1a88facbaa7a4e1aaabbae1a7a4">[email&#160;protected]</a>); Carmen Chan (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="f992949a9acbc9c9c8b991968d94989095d79a9694">[email&#160;protected]</a>)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Status checked on Chictr.Org.Cn on 1 December 2016. Author contacted</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01635790 (BRDME) </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comparing the effectiveness and costs of bevacizumab to ranibizumab in participants with diabetic macular edema (BRDME) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>246 people with DMO</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ranibizumab compared to bevacizumab</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>From clinical trials record:</p> <p>Primary outcome:</p> <p> <ul id="CD007419-lst1-0155"> <li> <p>change in BCVA in the study eye from baseline to month 6 (designated as safety issue: no) </p> </li> </ul> </p> <p>Secondary outcome measures:</p> <p> <ul id="CD007419-lst1-0156"> <li> <p>proportion of participants with a gain or loss of 15 letters or more at 6 months compared to baseline BCVA (designated as safety issue: no) </p> </li> <li> <p>change in leakage on fluorescein angiography, baseline compared to 6 month exit visit (designated as safety issue: no) </p> </li> <li> <p>change in foveal thickness (central retinal area) by OCT, 6 month exit visit compared to baseline (designated as safety issue: no) </p> </li> <li> <p>total number of adverse events that occurred during the 6 month study, with secondary a classification of the types of adverse events (designated as safety issue: yes) </p> </li> <li> <p>costs per quality adjusted life‐year of the 2 treatments (time frame: 6 months; designated as safety issue: no), results will be based on the use of standardised health questionnaires (EQ‐5D or Health Utility Index Mark 3) </p> </li> <li> <p>proportion of participants with a BCVA of 20/40 or more at 6 months compared to baseline BCVA (designated as safety issue: no) </p> </li> </ul> </p> <p>http://clinicaltrials.gov/show/NCT01635790</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study start date: June 2012</p> <p>Estimated primary completion date: June 2016 (Final data collection date for primary outcome measure). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reinier O Schlingemann (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="f280dc81919a9e9b9c95979f939c9cb2939f91dc878493dc9c9e">[email&#160;protected]</a>); Monique Wezel (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="9ef3b0e9ffe4fbf2defff3fdb0ebe8ffb0f0f2">[email&#160;protected]</a>)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Recruiting (status checked on ClinicalTrials.gov on 1 December 2016)</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02194634 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>type 1 or type 2 diabetes mellitus with DMO</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental: Conbercept treatment group<br> Conbercept injection and sham laser treatment at day 0 for 1st time, the investigators will decide whether the participants need to get repeated treatment according to monthly assessment. </p> <p>Active Comparator: Laser treatment group<br> Laser treatment and sham injection at day 0 for 1st time, the investigators will decide whether the repeated laser treatment is needed according to monthly results during the visit after 3 months. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome measures:</p> <p> <ul id="CD007419-lst1-0157"> <li> <p>Mean change from baseline in BCVA at month 12 (time frame: baseline and month 12) (designated as safety issue: no) </p> </li> <li> <p>To compare mean change from baseline BCVA between treatment group and controlled group at month 12 </p> </li> </ul> </p> <p>Secondary outcome measures:</p> <p> <ul id="CD007419-lst1-0158"> <li> <p>Mean change from baseline in CRT between two groups (time frame: baseline and month 12 (designated as safety issue: no) </p> </li> <li> <p>To compare mean change from baseline CRT between two groups at month 12</p> </li> <li> <p>Safety (e.g. incidence of adverse events) of Conbercept ophthalmic injection (time frame: 12 months) (designated as safety issue: yes) </p> </li> <li> <p>To assess safety parameters during the study, such as incidence of adverse events, incidence of adverse drug reactions etc </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>July 2014<br> Estimated Study Completion Date: September 2017<br> Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Chengdu Kanghong Biotech Co.,Ltd.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This study is recruiting participants. (Status checked on ClinicalTrials.Gov on 5 December 2016) </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02259088 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A 12‐month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese DME Patients </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants with DMO with BCVA score between 78 and 39</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ranibizumab PRN versus laser</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome measures:</p> <p> <ul id="CD007419-lst1-0159"> <li> <p>Mean average BCVA change (time frame: 12 months)</p> </li> <li> <p>Mean average BCVA change from Month 1 through Month 12 compared to baseline.</p> </li> </ul> </p> <p>Secondary Outcome Measures:</p> <p> <ul id="CD007419-lst1-0160"> <li> <p>Mean BCVA change by visit (time frame: 12 months)</p> </li> <li> <p>Mean BCVA change from baseline at each visit</p> </li> <li> <p>Mean change in CSFT (time frame: 12 months)</p> </li> <li> <p>Mean change in CSFT from baseline at each visit</p> </li> <li> <p>BCVA improvement of ≥ 10 and ≥ 15 letters (time frame: 12 months)</p> </li> <li> <p>Proportion of participants achieving BCVA improvement of ≥ 10 and ≥ 15 letters from baseline to Month 12 </p> </li> <li> <p>BCVA loss of &lt; 10 and &lt; 15 letters (time frame: 12 months)</p> </li> <li> <p>Proportion of participants with BCVA loss of &lt; 10 and &lt; 15 letters from baseline to Month 12 </p> </li> <li> <p>VA ≥ 73 letters (time frame: 12 months)</p> </li> <li> <p>Proportion of participants with VA ≥ 73 letters (approximate 20/40 Snellen chart equivalent) at Month 12 </p> </li> <li> <p>Mean average BCVA change after month 3 (time frame: 12 months)</p> </li> <li> <p>Mean average BCVA change from Month 4 to Month 12 compared to Month 3</p> </li> <li> <p>Mean change in patient‐reported visual functioning scale (time frame: 6 and 12 months)Mean change in the patient‐reported visual functioning through VFQ‐25 composite and subscale scores at Month 6 and Month 12 compared to baseline. </p> </li> <li> <p>Adverse events (time frame: 12 months)</p> </li> <li> <p>To evaluate the safety of 0.5 mg ranibizumab intravitreal injections relative to laser photocoagulation, as assessed by the type, frequency and severity of ocular and non‐ocular adverse events over 12 months. </p> </li> <li> <p>Evaluation of treatment patterns (time frame: 12 months)</p> </li> <li> <p>To evaluate the number of re‐treatments and retreatment patterns (assessed by time of stabilization/time to re‐initiation of treatment) in participants treated with 0.5 mg ranibizumab </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>November 2014</p> <p>Estimated study completion date: January 2017<br> Estimated primary completion date: January 2017 (final data collection date for primary outcome measure) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Novartis (Novartis Pharmaceuticals)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This study is ongoing, but not recruiting participants. (Status checked on ClinicalTrials.gov on 5 December 2016) </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02348918 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A Phase 2 Randomized, Controlled, Double‐Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG‐1001) as Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>DMO participants</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental: Luminate 1.0 mg group</p> <p> <ul id="CD007419-lst1-0161"> <li> <p>Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with PRN Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if PRN Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks </p> </li> </ul> </p> <p>Experimental: Luminate 2.0 mg group</p> <p> <ul id="CD007419-lst1-0162"> <li> <p>Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with PRN Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if PRN Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks </p> </li> </ul> </p> <p>Experimental: Luminate 3.0 mg group</p> <p> <ul id="CD007419-lst1-0163"> <li> <p>Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with PRN Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if PRN Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks </p> </li> </ul> </p> <p>Active Comparator: Avastin® group</p> <p> <ul id="CD007419-lst1-0164"> <li> <p>Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with PRN Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if PRN Avastin is not required; sham laser treatment will be administered at baseline and at 16 weeks </p> </li> </ul> </p> <p>Active Comparator: focal laser photocoagulation group</p> <p> <ul id="CD007419-lst1-0165"> <li> <p>Focal laser photocoagulation performed at baseline (Day 0) with possible PRN laser retreatment at week 16. Sham intravitreal injections will be performed at baseline (Day 0), 4 weeks, 8 weeks, 12 weeks, 16 weeks and 20 weeks </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome measures:</p> <p> <ul id="CD007419-lst1-0166"> <li> <p>Change in OCT CSFT at Week 24 (time frame: 24 weeks)</p> </li> <li> <p>The primary efficacy outcome is OCT CSFT at Week 24 as compared to baseline</p> </li> </ul> </p> <p>Secondary outcome measures:</p> <p> <ul id="CD007419-lst1-0167"> <li> <p>Change in BCVA at Week 24 (time frame: 24 weeks)</p> </li> <li> <p>Secondary efficacy outcome is BCVA changes at Week 24 as compared to baseline</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>October 2014<br> Estimated study completion date: March 2016<br> Estimated primary completion date: December 2015 (final data collection date for primary outcome measure) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allegro Ophthalmics, LLC</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This study is recruiting participants; (status checked on ClinicalTrials.gov on 5 Dec. 2016) </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02645734 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The Effect of Bevacizumab and Ziv‐aflibercept in Diabetic Macular Edema</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>DMO participants</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Active comparator: injection intravitreous bevacizumab</p> <p>Active comparator: injection ziv‐aflibercept at dose of 1.25 mg</p> <p>Active comparator: injection ziv‐aflibercept at dose of 2.5 mg</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome measures:</p> <p> <ul id="CD007419-lst1-0168"> <li> <p>VA (time frame: until 6 months)</p> </li> </ul> </p> <p>Secondary outcome measures:</p> <p> <ul id="CD007419-lst1-0169"> <li> <p>CSFT (time frame: until 6 months)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study first received: 2 January 2016<br> Last updated: 4 January 2016 </p> <p>Estimated primary completion date: February 2016 (final data collection date for primary outcome measure) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Zahra Rabbani Khah, Shahid Beheshti Medical University</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This study is recruiting participants; (status checked on ClinicalTrials.gov on 5 December 2016) </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02699450 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A Phase 2 Study of RO6867461 in Participants With Center‐Involving Diabetic Macular Edema (CI‐DME) (BOULEVARD) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>DMO</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental: RO6867461 1.5 mg</p> <p> <ul id="CD007419-lst1-0170"> <li> <p>Participants will receive 1.5 milligrams (mg) RO6867461 intravitreal (IVT) every 4 weeks up to Week 20, followed by 1 sham administration at Week 24. </p> </li> </ul> </p> <p>Experimental: RO6867461 6 mg</p> <p> <ul id="CD007419-lst1-0171"> <li> <p>Participants will receive 6 mg RO6867461 IVT every 4 weeks up to Week 20, followed by 1 sham administration at Week 24. </p> </li> </ul> </p> <p>Active Comparator: Ranibizumab 0.3 mg</p> <p> <ul id="CD007419-lst1-0172"> <li> <p>Participants will receive 0.3 mg ranibizumab IVT every 4 weeks up to Week 24</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome measures:</p> <p> <ul id="CD007419-lst1-0173"> <li> <p>Mean change from baseline in BCVA at week 24 using ETDRS modified charts (time frame: baseline, Week 24) </p> </li> <li> <p>Apparent plasma clearance of RO6867461 (time frame: pre‐dose on Days 1, 28, 84, 140, and 168; post‐dose on Days 7, 182, and 196 or early termination) </p> </li> <li> <p>Apparent plasma volume of RO6867461 (time frame: pre‐dose on Days 1, 28, 84, 140, and 168; post‐dose on Days 7, 182, and 196 or early termination) </p> </li> </ul> </p> <p>Secondary Outcome Measures:<br> Percentage of participants gaining ≥ 15 letters from baseline BCVA at Week 24 (time frame: baseline, and Week 24) </p> <p>Percentage of participants with BCVA ≥ 69 letters (20/40 or better) at Week 24 (time frame: Week 24)<br> Percentage of participants with BCVA ≥ 84 letters (20/20 or better) at Week 24 (time frame: Week 24)<br> Mean change from baseline in BCVA at Week 28 (time frame: baseline, and Week 28)<br> Mean change from baseline in foveal centre point thickness at Week 24 and 28, as measures by spectral domain OCT (SD‐OCT) (time frame: baseline, Weeks 24 and 28)<br> Mean change from baseline in mean CSFT at Week 24 and 28, as measures by SD‐OCT (time frame: baseline, Weeks 24 and 28)<br> Percentage of participants with resolution of subretinal and intraretinal fluid at Week 24 and 28, as measures by SD‐OCT (time frame: Weeks 24 and 28)<br> Percentage of participants with resolution of leakage at the macula at Week 24, as measures by FFA (time frame: Week 24)<br> Change from baseline in the size of the foveal avascular zone at Week 24, as measures by FFA (time frame: baseline and Week 24)<br> Change from baseline in plasma levels of vascular endothelial growth factor (VEGF) (time frame: baseline, Weeks 1, 4, 12, 24, 26, and 28 or early termination)<br> Change from baseline in plasma levels of angiopoietin‐2 (Ang‐2) (time frame: baseline, Weeks 1, 4, 12, 24, 26, and 28 or early termination) (designated as safety issue: no)<br> Maximum observed plasma concentration (Cmax) of RO6867461 (time frame: pre‐dose on Days 1, 28, 84, 140, and 168; post‐dose on Days 7, 182, and 196 or early termination)<br> Area under the plasma concentration‐time curve from time zero to extrapolated infinite time [AUC (0‐inf)] of RO6867461 (time frame: pre‐dose on Days 1, 28, 84, 140, and 168; post‐dose on Days 7, 182, and 196 or early termination)<br> Area under the plasma concentration‐time curve from time zero to end of dosing interval [AUC (0‐tau)] of RO6867461 (time frame: pre‐dose on Days 1, 28, 84, 140, and 168; post‐dose on Days 7, 182, and 196 or early termination)<br> Time to reach maximum observed plasma concentration (Tmax) of RO6867461 (time frame: pre‐dose on Days 1, 28, 84, 140, and 168; post‐dose on Days 7, 182, and 196 or early termination)<br> Plasma decay half‐life (t1/2) of RO6867461 (time frame: pre‐dose on Days 1, 28, 84, 140, and 168; post‐dose on Days 7, 182, and 196 or early termination)<br> Number of participants with adverse events (time frame: baseline up to Week 28 or early termination)<br> Number of participants with anti‐RO6867461 antibodies (time frame: baseline, Weeks 1, 4, 12, 20, 24, 26, and 28 or early termination) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>March 2016<br> Estimated Study Completion Date: October 2017<br> Estimated Primary Completion Date: October 2017 (final data collection date for primary outcome measure) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Hoffmann‐La Roche</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This study is recruiting participants; (status checked on ClinicalTrials.gov on 5 December 2016) </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02712008 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Anti‐vasculaR Endothelial Growth Factor plUs Anti‐angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Parallel group RCT</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>participants with DMO</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Experimental: Group 1<br> Participants in Group 1 will receive REGN910‐3 dosing regimen 1 </p> <p>Experimental: Group 2<br> Participants in Group 2 will receive REGN910‐3 dosing regimen 2 </p> <p>Active Comparator: Group 3<br> Participants in Group 3 will receive IAI </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary outcome measures:</p> <p> <ul id="CD007419-lst1-0174"> <li> <p>Change from baseline in BCVA measured by the ETDRS letter score at week 12 (time frame: baseline to week 12) </p> </li> </ul> </p> <p>Secondary outcome measures:</p> <p> <ul id="CD007419-lst1-0175"> <li> <p>Change from baseline in CSFT at week 12 (time frame: baseline to week 12)</p> </li> <li> <p>Change from baseline in CSFT at week 36 (time frame: baseline to week 36)</p> </li> <li> <p>Proportion of participants with a ≥2‐step improvement in Diabetic Retinopathy Severity Scale from baseline at week 12 (time frame: baseline to week 12) </p> </li> <li> <p>Proportion of participants with a ≥2‐step improvement in Diabetic Retinopathy Severity Scale from baseline at week 36 (time frame: baseline to week 36) </p> </li> <li> <p>Change from baseline in BCVA measured by the ETDRS letter score at week 36 (time frame: baseline to week 36) </p> </li> <li> <p>Proportion of participants with no retinal and/or subretinal fluid at week 12 (time frame: baseline to week 12) </p> </li> <li> <p>Proportion of participants with no retinal and/or subretinal fluid at week 36 (time frame: baseline to week 36) </p> </li> <li> <p>Time to no retinal and/or subretinal fluid at week 12 (time frame: baseline to week 12) </p> </li> <li> <p>Time to no retinal and/or subretinal fluid at week 36 (time frame: baseline to week 36) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>March 2016<br> Estimated study completion date: October 2017<br> Estimated primary completion date: April 2017 (final data collection date for primary outcome measure) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Regeneron Pharmaceuticals</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>This study is on ongoing, but not recruiting participants; (status checked on ClinicalTrials.gov on 5 December 2016) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Abbreviations</b><br> BCVA: best‐corrected visual acuity<br> CSFT: central subfield thickness<br> CRT: central retinal thickness<br> CSMO: clinically significant macular oedema<br> DMO: diabetic macular oedema (DME: US spelling edema)<br> ETDRS: Early Treatment Diabetic Retinopathy Study<br> FFA: fundus fluorescein angiography<br> IOP: intraocular pressure<br> NA: not available<br> OCT: optical coherence tomography<br> PDR: proliferative diabetic retinopathy<br> PRN: pro re nata (as required in the circumstances)<br> PRP: panretinal photocoagulation<br> RCT: randomised controlled trial<br> VA: visual acuity </p> </div> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD007419-sec1-0011"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD007419-tbl-0004"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Ranibizumab versus laser photocoagulation at 6 to 12 months</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Quality of life: NEI‐VFQ composite score at 6 to 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>412</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.14 [2.96, 7.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD007419-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-CMP-001-01.png?filename=nCD007419-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Ranibizumab%20versus%20laser%20photocoagulation%20at%206%20to%2012%20months%2C%20Outcome%201%20Quality%20of%20life%3A%20NEI%E2%80%90VFQ%20composite%20score%20at%206%20to%2012%20months.&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"><img data-id="CD007419-fig-00101" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-CMP-001-01.png" alt="Comparison 1 Ranibizumab versus laser photocoagulation at 6 to 12 months, Outcome 1 Quality of life: NEI‐VFQ composite score at 6 to 12 months."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Ranibizumab versus laser photocoagulation at 6 to 12 months, Outcome 1 Quality of life: NEI‐VFQ composite score at 6 to 12 months. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD007419-fig-0001"> <img data-id="CD007419-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG01.png" alt="Study flow diagram."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG01.png?filename=nCD007419-AFig-FIG01.ppt&amp;title=1&amp;caption=Study%20flow%20diagram.&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0002"><img data-id="CD007419-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG02.png" alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG02.png?filename=nCD007419-AFig-FIG02.ppt&amp;title=2&amp;caption=Methodological%20quality%20summary%3A%20review%20authors%27%20judgements%20about%20each%20methodological%20quality%20item%20for%20each%20included%20study.&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG02.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0003"><img data-id="CD007419-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG03.png" alt="Network structure for efficacy outcomes at 1 year"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Network structure for efficacy outcomes at 1 year</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG03.png?filename=nCD007419-AFig-FIG03.ppt&amp;title=3&amp;caption=Network%20structure%20for%20efficacy%20outcomes%20at%201%20year&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG03.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0004"><img data-id="CD007419-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG05.png" alt="All direct and mixed comparisons: gain of 3 or more lines of visual acuity at 1 year"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>All direct and mixed comparisons: gain of 3 or more lines of visual acuity at 1 year</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0004" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG05.png?filename=nCD007419-AFig-FIG05.ppt&amp;title=4&amp;caption=All%20direct%20and%20mixed%20comparisons%3A%20gain%20of%203%20or%20more%20lines%20of%20visual%20acuity%20at%201%20year&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG05.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0005"><img data-id="CD007419-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG06.png" alt="All direct and mixed comparisons: mean change in visual acuity at 1 year"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>All direct and mixed comparisons: mean change in visual acuity at 1 year</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0005" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG06.png?filename=nCD007419-AFig-FIG06.ppt&amp;title=5&amp;caption=All%20direct%20and%20mixed%20comparisons%3A%20mean%20change%20in%20visual%20acuity%20at%201%20year&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG06.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0006"><img data-id="CD007419-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG07.png" alt="All direct and mixed comparisons: mean change in central retinal thickness at 1 year (micron)"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>All direct and mixed comparisons: mean change in central retinal thickness at 1 year (micron) </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0006" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG07.png?filename=nCD007419-AFig-FIG07.ppt&amp;title=6&amp;caption=All%20direct%20and%20mixed%20comparisons%3A%20mean%20change%20in%20central%20retinal%20thickness%20at%201%20year%20%28micron%29&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG07.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0007"><img data-id="CD007419-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG04.png" alt="Contribution plot of mean overall study risk of bias to pairwise network estimates. Legends show the risk of bias of each direct comparison."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Contribution plot of mean overall study risk of bias to pairwise network estimates. Legends show the risk of bias of each direct comparison. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0007" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG04.png?filename=nCD007419-AFig-FIG04.ppt&amp;title=7&amp;caption=Contribution%20plot%20of%20mean%20overall%20study%20risk%20of%20bias%20to%20pairwise%20network%20estimates.%20Legends%20show%20the%20risk%20of%20bias%20of%20each%20direct%20comparison.&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG04.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0008"><img data-id="CD007419-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG08.png" alt="Network structure for safety outcomes at 1 year"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Network structure for safety outcomes at 1 year</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0008" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG08.png?filename=nCD007419-AFig-FIG08.ppt&amp;title=8&amp;caption=Network%20structure%20for%20safety%20outcomes%20at%201%20year&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG08.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0009"><img data-id="CD007419-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG09.png" alt="All direct and mixed comparisons: serious systemic adverse events at the longest available follow‐up (1 or 2 years)"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>All direct and mixed comparisons: serious systemic adverse events at the longest available follow‐up (1 or 2 years) </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0009" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG09.png?filename=nCD007419-AFig-FIG09.ppt&amp;title=9&amp;caption=All%20direct%20and%20mixed%20comparisons%3A%20serious%20systemic%20adverse%20events%20at%20the%20longest%20available%20follow%E2%80%90up%20%281%20or%202%20years%29&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG09.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0010"><img data-id="CD007419-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG10.png" alt="All direct and mixed comparisons: arterial thromboembolic events at the longest available follow‐up (1 or 2 years)"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>All direct and mixed comparisons: arterial thromboembolic events at the longest available follow‐up (1 or 2 years) </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0010" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG10.png?filename=nCD007419-AFig-FIG10.ppt&amp;title=10&amp;caption=All%20direct%20and%20mixed%20comparisons%3A%20arterial%20thromboembolic%20events%20at%20the%20longest%20available%20follow%E2%80%90up%20%281%20or%202%20years%29&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG10.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0011"><img data-id="CD007419-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG11.png" alt="All direct and mixed comparisons: all‐cause death at the longest available follow‐up (1 or 2 years)"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>All direct and mixed comparisons: all‐cause death at the longest available follow‐up (1 or 2 years) </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0011" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG11.png?filename=nCD007419-AFig-FIG11.ppt&amp;title=11&amp;caption=All%20direct%20and%20mixed%20comparisons%3A%20all%E2%80%90cause%20death%20at%20the%20longest%20available%20follow%E2%80%90up%20%281%20or%202%20years%29&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG11.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0012"><img data-id="CD007419-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG12.png" alt="Comparison‐adjusted funnel plot for all outcome measures"> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Comparison‐adjusted funnel plot for all outcome measures</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-fig-0012" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-AFig-FIG12.png?filename=nCD007419-AFig-FIG12.ppt&amp;title=12&amp;caption=Comparison%E2%80%90adjusted%20funnel%20plot%20for%20all%20outcome%20measures&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-AFig-FIG12.png">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-00101"><img data-id="CD007419-fig-00101" src="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-CMP-001-01.png" alt="Comparison 1 Ranibizumab versus laser photocoagulation at 6 to 12 months, Outcome 1 Quality of life: NEI‐VFQ composite score at 6 to 12 months."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ranibizumab versus laser photocoagulation at 6 to 12 months, Outcome 1 Quality of life: NEI‐VFQ composite score at 6 to 12 months. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/references#CD007419-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/ppt/CDSR/CD007419/image_n/nCD007419-CMP-001-01.png?filename=nCD007419-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Ranibizumab%20versus%20laser%20photocoagulation%20at%206%20to%2012%20months%2C%20Outcome%201%20Quality%20of%20life%3A%20NEI%E2%80%90VFQ%20composite%20score%20at%206%20to%2012%20months.&amp;citation=Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti%E2%80%90vascular endothelial growth factor for diabetic macular oedema: a network meta%E2%80%90analysis. Cochrane Database of Systematic Reviews 2018, 10. Art. No.: CD007419. DOI: http://dx.doi.org/10.1002/14651858.CD007419.pub6"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD007419.pub6/media/CDSR/CD007419/image_n/nCD007419-CMP-001-01.png">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD007419-tbl-0001" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Antiangiogenic therapy versus control</span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Antiangiogenic therapy versus control</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with diabetic macular oedema<br> <b>Settings:</b> ophthalmology clinics<br> <b>Interventions:</b> laser photocoagulation, aflibercept, bevacizumab, ranibizumab </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk*</b> </p> </td> <td align="" valign="" colspan="3" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk and relative risk** (95% CI) , mixed evidence</b> </p> </td> <td align="" valign="" colspan="1" rowspan="2" class="table-header"> <p><b>Certainty of evidence and reason for downgrading </b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Laser photocoagulation</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Aflibercept</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Bevacizumab</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Ranibizumab</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Gain 3+ lines of visual acuity at 1 year</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>100 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>366 per 1000</b><br> (279 to 479) </p> <p><b>RR: 3.66 (2.79 to 4.79)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>247 per 1000</b> </p> <p>(181 to 337)</p> <p><b>RR: 2.47 (1.81 to 3.37)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>276 per 1000</b> </p> <p>(212 to 359)</p> <p><b>RR: 2.76 (2.12 to 3.59)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊕<br> high </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Visual acuity change at 1 year</b> </p> <p><b>Measured on the logMAR scale, range −0.3 to 1.3. Higher values represent worse visual acuity.</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>On average visual acuity improved by <b>−0.01 logMAR</b> units in the laser group between the start of treatment and 1 year (effectively no change) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Average change in visual acuity was <b>−0.20 (−0.22 to −0.17) logMAR units better</b> with aflibercept compared with laser photocoagulation </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Average change in visual acuity was <b>−0.12 (−0.15 to −0.09) logMAR units better</b> with bevacizumab compared with laser photocoagulation </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Average change in visual acuity was <b>−0.12 (−0.14 to −0.10) logMAR units better</b> with ranibizumab compared with laser photocoagulation </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊕<br> high for aflibercept and ranibizumab ⊕⊕⊕<br> moderate for bevacizumab (−1 for inconsistency of indirect versus direct evidence) </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Central retinal thickness μm (CRT) change at 1 year</b> </p> <p><b>The aim of treatment is to reduce central retinal thickness so thinner is better.</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>On average CRT changed by <b>−64 μm</b> in the laser group between the start of treatment and 1 year (became thinner) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Average change in CRT was <b>−114 (−147 to −81) μm more (thinner) with aflibercept</b> compared with<br> laser photocoagulation </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Average change in CRT was <b>−46 (−78 to −14) μm more (thinner)</b>with bevacizumab<br> compared with laser photocoagulation </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Average change in CRT was <b>−75 (−100 to −50) μm more (thinner)</b> with ranibizumab compared with laser photocoagulation </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊕</p> <p>high</p> </td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Quality of life: NEI‐VFQ composite score at 6 to 12 months</b> </p> <p><b>An improvement by 5 units is clinically significant.</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>On average the composite score improved by +2 units in the laser group between the start of treatment and 6 to 12 months </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Average change in composite score was 5.14 (2.96 to 7.32) with ranibizumab compared with laser photocoagulation </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕<br> moderate (−1 for risk of bias) </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>All serious systemic adverse events at 1 to 2 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>200 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>196 per 1000</b><br> (166 to 232) </p> <p><b>RR: 0.98 (0.83 to 1.16)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>186 per 1000</b> </p> <p>(146 to 238)</p> <p><b>RR: 0.93 (0.73 to 1.19)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>194 per 1000</b> </p> <p>(160 to 234)</p> <p><b>RR: 0.97 (0.80 to 1.17)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊕<br> high </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Arterial thromboembolic events at 1 to 2 years</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>45 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>38 per 1000</b><br> (16 to 94) </p> <p><b>RR: 0.88 (0.37 to 2.13)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>41 per 1000</b> </p> <p>(15 to 117)</p> <p><b>RR: 0.94 (0.33 to 2.66)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>48 per 1000</b> </p> <p>(23 to 101)</p> <p><b>RR: 1.09 (0.52 to 2.29)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕<br> low </p> <p>(−2 for imprecise estimates)</p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Death at 1 to 2 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>20 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>20 per 1000</b><br> (7 to 61) </p> <p><b>RR: 1.01 (0.34 to 3.03) a</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>32 per 1000</b> </p> <p>(9 to 114)</p> <p><b>RR: 1.61 (0.45 to 5.69)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>18 per 1000</b> </p> <p>(8 to 40)</p> <p><b>RR: 0.90 (0.40 to 2.01)</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕<br> low for bevacizumab and aflibercept </p> <p>(−2 for imprecise estimates)</p> <p>⊕<br> very low for aflibercept (additional −1 direct evidence inconsistent, higher risk) </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>The <b>assumed risk</b> in the laser group was estimated as the row sum of the events divided by the row sum of the participants (eyes) for dichotomous variables, and as the (unweighted) median change of visual acuity or central retina thickness. </p> <p>The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** The risk ratio was estimated from mixed (direct and indirect) comparisons.<br> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br> <b>High‐certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate‐certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low‐certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low‐certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Antiangiogenic therapy versus control</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0002" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">Ranibizumab versus aflibercept for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Ranibizumab versus aflibercept for diabetic macular oedema</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with diabetic macular oedema<br> <b>Settings:</b> ophthalmology clinics<br> <b>Interventions:</b> aflibercept, ranibizumab </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI), mixed evidence**</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Certainty of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Reason for downgrading certainty of evidence</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Aflibercept</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Ranibizumab</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Gain 3+ lines of visual acuity at 1 year</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>370 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>278 per 1000</b><br> (222 to 348) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR: 0.75</b><br> (0.60 to 0.94) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕<br> moderate </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>−1 for imprecision as confidence intervals include both clinically important and clinically unimportant effects </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Visual acuity change at 1 year</b> </p> <p><b>Measured on the logMAR scale, range −1.3 to 1.3. Higher values represent worse visual acuity.</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>On average visual acuity improved by<b>−0.23 logMAR</b> units in the aflibercept group between the start of treatment and 1 year </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Average change in visual acuity was <b>0.08 (0.05 to 0.11) logMAR units worse</b> with ranibizumab </p> <p>compared with aflibercept</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕<br> moderate </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>−1 for imprecision as confidence intervals include both clinically important and clinically unimportant effects </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Central retinal thickness μm (CRT) change at 1 year</b> </p> <p><b>The aim of treatment is to reduce central macular thickness so thinner is better.</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>On average CRT changed by <b>−181 μm</b> in the aflibercept group between the start of treatment and 1 year (became thinner) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Average change in CRT was <b>39 (2 to 76) μm more (thicker) with ranibizumab</b> </p> <p>compared with aflibercept</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕<br> low </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>−1 for high heterogeneity in two direct comparisons and large predictive intervals</p> <p>−1 for imprecision</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Quality of life at 1 year</b> </p> </td> <td align="center" valign="" colspan="5" rowspan="1" class="table-tint table-highlight"> <p>No data available.</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>All serious systemic adverse events at 1 to 2 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>345 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>338 per 1000</b> </p> <p>(283 to 411)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.98</b> </p> <p>(0.82 to 1.19)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊕<br> high </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Arterial thromboembolic events at 1 to 2 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>60 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>74 per 1000</b> </p> <p>(29 to 191)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.24</b> </p> <p>(0.48 to 3.19)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕<br> very low </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inconsistency between direct and indirect evidence (−1), and imprecise estimates (−2)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Death at 1 to 2 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>30 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>35 per 1000</b> </p> <p>(11 to 108)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.16</b> </p> <p>(0.38 to 3.58)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕<br> very low </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Inconsistency between direct and indirect evidence (−1), and imprecise estimates (−2)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>The <b>assumed risk</b> in the aflibercept group was estimated as the row sum of the events divided by the row sum of the participants (eyes) for dichotomous variables, and as the (unweighted) median change of visual acuity or central retina thickness. </p> <p>The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** The risk ratio was estimated from mixed (direct and indirect) comparisons.<br> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br> <b>High‐certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate‐certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low‐certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low‐certainty:</b> we are very uncertain about the estimate. </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">Ranibizumab versus aflibercept for diabetic macular oedema</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0002" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0003" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>&nbsp;<span class="table-title">Ranibizumab versus bevacizumab for diabetic macular oedema</span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Ranibizumab versus bevacizumab for diabetic macular oedema</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with diabetic macular oedema<br> <b>Settings:</b> ophthalmology clinics<br> <b>Interventions:</b> bevacizumab, ranibizumab </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI), mixed evidence**</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Certainty of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Reason for downgrading certainty of evidence</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Bevacizumab</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Ranibizumab</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Gain 3+ lines of visual acuity at 1 year</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>300 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>333 per 1000</b><br> (261 to 429) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.11</b><br> (0.87 to 1.43) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕<br> moderate </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Imprecise estimate (−1)</p> </td> </tr> <tr class="table-header separated"> <td align="left" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Visual acuity change at 1 year</b> </p> <p><b>Measured on the logMAR scale, range −1.3 to 1.3. Higher values represent worse visual acuity.</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>On average visual acuity improved by <b>−0.19 logMAR units</b> in the bevacizumab group between the start of treatment and 1 year </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Average change in visual acuity was<b>0.00 (−0.02 to 0.03) logMAR</b><br> units (same) with ranibizumab compared with bevacizumab </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕<br> moderate </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk of bias (−1)</p> </td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Central retinal thickness (CRT) change at 1 year</b> </p> <p><b>The aim of treatment is to reduce central macular thickness so thinner is better.</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>On average CRT changed by <b>−98 μm</b> in the bevacizumab group between the start of treatment and 1 year (became thinner) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Average change in CRT was <b>−29 (−58 to −1) μm more (thinner) with ranibizumab</b> compared with<br> bevacizumab </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕<br> low </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk of bias (−1) Imprecise estimate (−1)</p> </td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Quality of life at 1 year</b> </p> </td> <td align="center" valign="" colspan="5" rowspan="1" class="table-tint table-highlight"> <p>No data available</p> </td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>All serious systemic adverse events at 1 to 2 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>240 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>250 per 1000</b> </p> <p>(202 to 307)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.04</b> </p> <p>(0.84 to 1.28)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕<br> moderate </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk of bias (−1)</p> </td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Arterial thromboembolic events at 1 to 2 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>60 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>70 per 1000</b> </p> <p>(26 to 189)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.17</b> </p> <p>(0.43 to 3.13)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕<br> very low </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk of bias (−1) Imprecise estimate (−2)</p> </td> </tr> <tr class="table-header separated"> <td align="" valign="" colspan="1" rowspan="1" class="table-header"> <p><b>Death at 1 to 2 years</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>40 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>29 per 1000</b> </p> <p>(9 to 95)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.73</b> </p> <p>(0.22 to 2.37)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕<br> very low </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk of bias (−2) Imprecise estimate (−2)</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>The <b>assumed risk</b> in the bevacizumab group was estimated as the row sum of the events divided by the row sum of the participants (eyes) for dichotomous variables, and as the (unweighted) median change of visual acuity or central retina thickness. </p> <p>The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** The risk ratio was estimated from mixed (direct and indirect) comparisons.<br> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br> <b>High‐certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate‐certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low‐certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low‐certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>&nbsp;<span class="table-title">Ranibizumab versus bevacizumab for diabetic macular oedema</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0003" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Reporting of all outcomes across studies</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study</b> </p> </td> <td align="center" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Gain 3+</b> </p> <p><b>VA lines</b> </p> </td> <td align="center" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Mean VA</b> </p> <p><b>change</b> </p> </td> <td align="center" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Mean CMT</b> </p> <p><b>change</b> </p> </td> <td align="center" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>QOL</b> </p> </td> <td align="center" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>SSAE</b> </p> </td> <td align="center" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>ATC</b> </p> </td> <td align="center" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Death</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Follow‐up year</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0001">Ahmadieh 2008</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0002">Azad 2012</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>40</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0003">BOLT 2010</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>65</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0004">DA VINCI 2011</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>87</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0005">DRCRnet 2010</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>668</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>486</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>668</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>486</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>617</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>483</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>240</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>505</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>505</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0006">DRCRnet 2015</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>620</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>577</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>620</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>577</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>620</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>577</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>660</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>660</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>660</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0007">Ekinci 2014</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0008">Ishibashi 2014</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>233</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>233</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>233</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>233</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>233</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>233</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0009">Korobelnik 2014</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>573</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>573</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>573</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>865</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>865</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>865</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0011">LUCIDATE 2014</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0012">Macugen 2005</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0013">Macugen 2011</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>260</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>207</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>260</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>236</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>286</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>286</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>286</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0014">Nepomuceno 2013</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>60</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>60</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>60</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>60</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0015">READ2 2009</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>115</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>115</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>117</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>117</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0016">RELATION 2012</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>128</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>128</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>128</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>128</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0017">RESOLVE 2010</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>151</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>151</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>151</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>151</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>151</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>151</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0018">RESPOND 2013</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>203</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>203</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>202</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>237</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>237</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0019">RESTORE 2011</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>343</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>343</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>343</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>299</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>345</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>345</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>345</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0020">REVEAL 2015</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>390</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>390</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>268</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0021">RISE‐RIDE</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>509</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>504</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>500</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>500</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0022">Soheilian 2007</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>87</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>85</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>85</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>96</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0023">Turkoglu 2015</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0024">Wiley 2016</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>124</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>124</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Total studies</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>17</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>5</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>21</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>3</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>16</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>3</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>4</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>12</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>6</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>10</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>5</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>12</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>5</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Total participants</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>4031</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1844</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>4489</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1128</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>3491</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1125</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>838</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>504</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1598</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2631</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1322</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2396</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1639</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2816</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="15"> <div class="table-footnote"> <p>Numbers in the table are the total number of eyes for each study,as available by follow‐up year (1 or 2) and outcome measure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Reporting of all outcomes across studies</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0005" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span>&nbsp;<span class="table-title">Network structure: efficacy at 12 months</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Laser</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Aflibercept</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bevacizumab</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Pegaptanib</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Ranibizumab</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Ranibizumab<br> deferredlaser</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Ranibizumab<br> prompt laser</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sham</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Overall</b> </p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Gain 3+ lines</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1074</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>539</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>344</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>410</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>713</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>545</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>218</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4031</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Mean VA change</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>21</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1131</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>539</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>476</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>410</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>861</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>629</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>255</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4489</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Mean CRT change</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>986</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>538</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>476</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>779</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>175</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>451</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3491</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>QOL</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>838</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>838</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>For each efficacy outcome, numbers in the table are the total number of studies (upper line for each outcome) and the total number of eyes (lower line for each outcome), as available by treatment and measured at one year. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span>&nbsp;<span class="table-title">Network structure: efficacy at 12 months</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0006" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span>&nbsp;<span class="table-title">Gain of 3 or more lines of visual acuity at 12 months: direct (upper‐right triangle) and mixed (lower‐left triangle) estimates</span></div> <tbody> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LASER</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>3.82 (2.61 to 5.58)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2.74 (1.34 to 5.61)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2.82 (1.82 to 4.38)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1.88 (1.31 to 2.70)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2.30 (1.74 to 3.03)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>3.66 (2.79 to 4.79)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>AFLI</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.68 (0.52 to 0.90)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.77 (0.59 to 0.99)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2.47 (1.81 to 3.37)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.68 (0.53 to 0.86)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>BEVA</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.14 (0.88 to 1.48)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.70 (0.58 to 4.94)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.46 (0.16 to 1.34)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.69 (0.24 to 1.89)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PEGA</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.51 (0.30 to 0.89)</b> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2.76 (2.12 to 3.59)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.75 (0.60 to 0.94)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.11 (0.87 to 1.43)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.62 (0.58 to 4.57)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.90 (0.67 to 1.21)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.31 (0.13 to 0.76)</b> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2.02 (1.46 to 2.81)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.55 (0.37 to 0.82)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 (0.54 to 1.24)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.19 (0.40 to 3.58)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.73 (0.51 to 1.06)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI‐DL</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.10 (0.80 to 1.51)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>2.33 (1.81 to 3.00)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.64 (0.47 to 0.86)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.94 (0.68 to 1.31)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.37 (0.47 to 3.99)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.85 (0.65 to 1.09)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.15 (0.85 to 1.56)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI‐PL</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.87 (0.35 to 2.17)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.24 (0.10 to 0.59)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.35 (0.14 to 0.87)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.51 (0.30 to 0.89)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.32 (0.13 to 0.76)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.43 (0.17 to 1.11)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.37 (0.15 to 0.93)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>SHAM</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>P value for overall inconsistency = 0.883 in the network meta‐analysis.</p> <p>Values in the table are risk ratios and 95% confidence intervals. Values in <b>bold</b> are ones where the 95% confidence intervals does not include 1 (null effect). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span>&nbsp;<span class="table-title">Gain of 3 or more lines of visual acuity at 12 months: direct (upper‐right triangle) and mixed (lower‐left triangle) estimates</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0007" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span>&nbsp;<span class="table-title">Mean visual acuity change at 12 months: direct (upper‐right triangle) and mixed (lower‐left triangle) estimates</span></div> <tbody> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LASER</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.20 (−0.24 to −0.17)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.20 (−0.28 to −0.12)<sup>a</sup> </b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.11 (−0.13 to −0.08)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.12 (−0.16 to −0.075)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.10 (−0.13 to −0.08)</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.20 (−0.22 to −0.17)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>AFLI</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.07 (0.03 to 0.11)</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.04 (0.00 to 0.08)</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.12 (−0.15 to −0.09)<sup>a</sup> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.08 (0.05 to 0.11)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>BEVA</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>−0.02 (−0.05 to 0.01)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.01 (−0.09 to 0.07)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.19 (0.11 to 0.27)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.11 (0.04 to 0.19)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PEGA</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.08 (0.03 to 0.13)</b> </p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.12 (−0.14 to −0.10)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.08 (0.05 to 0.11)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.00 (−0.02 to 0.03)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.11 (−0.19 to −0.04)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.01 (−0.02 to 0.03)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.23 (0.15 to 0.32)</b> </p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.11 (−0.13 to −0.09)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.08 (0.04 to 0.13)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.01 (−0.04 to 0.06)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.11 (−0.19 to −0.02)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.00 (−0.04 to 0.05)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI‐DL</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.00 (−0.05 to 0.05)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.11 (−0.14 to −0.08)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.09 (0.06 to 0.12)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.01 (−0.02 to 0.05)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−0.10 (−0.18 to −0.02)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.01 (−0.01 to 0.03)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.01 (−0.04 to 0.05)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI‐PL</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.08 (0.01 to 0.15)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.28 (0.21 to 0.35)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.20 (0.13 to 0.27)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.09 (0.06 to 0.12)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.20 (0.13 to 0.27)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.20 (0.11 to 0.28)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>0.19 (0.12 to 0.26)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>SHAM</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> P value for differences between direct and indirect estimates = 0.031 in the network meta‐analysis. </p> <p>P value for overall inconsistency = 0.665.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span>&nbsp;<span class="table-title">Mean visual acuity change at 12 months: direct (upper‐right triangle) and mixed (lower‐left triangle) estimates</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0008" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span>&nbsp;<span class="table-title">Mean central retinal thickness change at 12 months: direct (upper‐right triangle) and mixed (lower‐left triangle) estimates</span></div> <tbody> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>LASER</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−119 (−143 to −95)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−44 (−82 to −5)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−71 (−120 to −22)<sup>^</sup> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−35 (−62 to −8)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−64 (−103 to −25)<sup>b*</sup> </b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−114 (−147 to −81)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>AFLI</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>68 (43 to 94)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22 (−4 to 48)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−46 (−78 to −14)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>68 (29 to 108)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>BEVA</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−38 (−56 to −20)</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>132 (72 to 187)</b> </p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−75 (−100 to −50)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>39 (2 to 76)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−29 (−58 to −1)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>−19 (−39 to 2)<sup>a</sup> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>1470 (95 to 196)</b> </p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−57 (−111 to −2)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>57 (−6 to 120)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>−11 (−73 to 51)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18 (<b>−</b>40 to 76) </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI‐DL</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6 (−22 to 34)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>−72.90 (−103 to −42)<sup>b</sup> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>41 (−2 to 84)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>−27 (−68 to 13)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 (<b>−</b>31 to 35)<sup>a</sup> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>−16 (−71 to 38)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI‐PL</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>77 (18 to 137)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>191 (127 to 256)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>123 (67 to 179)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>153 (97 to 208)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>134 (55 to 213)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>150 (87 to 214)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>SHAM</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> P value for differences between direct and indirect estimates = 0.003. </p> <p><sup>b</sup> P value for differences between direct and indirect estimates = 0.044. </p> <p><sup>*</sup> P value for heterogeneity = 0.002; I² = 80% in the direct meta‐analysis. </p> <p><sup>^</sup> P value for heterogeneity = 0.000; I² = 91% in the direct meta‐analysis. </p> <p>P value for overall inconsistency = 0.209 in the network meta‐analysis.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span>&nbsp;<span class="table-title">Mean central retinal thickness change at 12 months: direct (upper‐right triangle) and mixed (lower‐left triangle) estimates</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0009" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span>&nbsp;<span class="table-title">Network structure: safety at the longest available follow‐up</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Laser</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Aflibercept</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bevacizumab</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Pegaptanib</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Ranibizumab</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Sham</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Overall</b> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>SSAE</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1013</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>556</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>410</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>186</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1303</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>528</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4229</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ATC*</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>824</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>846</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>330</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1113</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>184</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3718</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Death</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>903</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>846</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>333</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>188</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1521</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>434</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4455</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>For each safety outcome, numbers in the table are the total number of studies (upper line for each outcome) and the total number of eyes (lower line for each outcome), as available by treatment and measured at the longest available follow‐up. </p> <p>(*) combined incidence of (1) cardiovascular, hemorrhagic, and unknown death; (2) nonfatal MI; and (3) nonfatal stroke. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span>&nbsp;<span class="table-title">Network structure: safety at the longest available follow‐up</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0010" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span>&nbsp;<span class="table-title">All serious systemic adverse events (longest available follow‐up)</span></div> <tbody> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>CONTROL</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.95 (0.75 to 1.20)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.29 (0.43 to 3.84)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.02 (0.67 to 1.53)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.98 (0.76 to 1.25)</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.98 (0.83 to 1.16)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>AFLI</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.95 (0.75 to 1.20)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.04 (0.83 to 1.32)</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.93 (0.73 to 1.19)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.95 (0.76 to 1.18)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>BEVA</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.96 (0.77 to 1.20)</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.02 (0.64 to 1.64)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.04 (0.63 to 1.72)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.09 (0.64 to 1.86)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PEGA</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.97 (0.80 to 1.17)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.98 (0.82 to 1.19)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.04 (0.84 to 1.28)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.95 (0.57 to 1.58)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>P value for overall inconsistency = 0.859.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span>&nbsp;<span class="table-title">All serious systemic adverse events (longest available follow‐up)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0011" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0012"> <div class="table-heading"><span class="table-label">Table 8.</span>&nbsp;<span class="table-title">Antiplatelet Trialists Collaboration arterial thromboembolic events at the longest available follow‐up</span></div> <tbody> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>CONTROL</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.50 (0.81 to 2.79)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.92 (0.17 to 5.12)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.78 (0.31 to 1.97)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.64 (0.38 to 1.07)</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.88 (0.37 to 2.13)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>AFLI</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.46 (0.71 to 2.98)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.26 (1.15 to 4.23)<sup>a</sup> </p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.94 (0.33 to 2.66)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.06 (0.36 to 3.11)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>BEVA</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.51 (0.85 to 2.69)</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.79 (0.20 to 3.02)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.89 (0.18 to 4.43)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.83 (0.15 to 4.61)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PEGA</b> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.09 (0.52 to 2.29)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.24 (0.48 to 3.19)<sup>a</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.17 (0.43 to 3.13)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.17 (0.43 to 3.16)</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> P value for differences between direct and indirect estimates = 0.002. </p> <p>P value for overall inconsistency = 0.274 in the network meta‐analysis.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span>&nbsp;<span class="table-title">Antiplatelet Trialists Collaboration arterial thromboembolic events at the longest available follow‐up</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0012" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0013"> <div class="table-heading"><span class="table-label">Table 9.</span>&nbsp;<span class="table-title">All‐cause mortality at the longest available follow‐up</span></div> <tbody> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>CONTROL</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.69 (0.30 to 9.42)<sup>a</sup> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.95 (0.06 to 14.85)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.82 (0.25 to 2.65)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.64 (0.32 to 1.25)<sup>d</sup> </p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.01 (0.34 to 3.03)<sup>a</sup> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>AFLI</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.67 (0.97 to 7.37)<sup>b</sup> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.26 (0.80 to 6.40)<sup>c</sup> </p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.61 (0.45 to 5.69)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.59 (0.43 to 5.94)<sup>b</sup> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>BEVA</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.85 (0.40 to 1.83)</p> </td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 (0.16 to 4.03)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.81 (0.12 to 5.62)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.51(0.07 to 3.90)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>PEGA</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.90 (0.40 to 2.01)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.16 (0.38 to 3.58)<sup>c</sup> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.73 (0.22 to 2.37)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.44 (0.24 to 8.48)</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RANI</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> P value for differences between direct and indirect estimates = 0.011. </p> <p><sup>b</sup> P value for differences between direct and indirect estimates = 0.030. </p> <p><sup>c</sup> P value for differences between direct and indirect estimates = 0.015. </p> <p><sup>d</sup> P value for differences between direct and indirect estimates = 0.022. </p> <p>P value for overall inconsistency = 0.087 in the network meta‐analysis.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span>&nbsp;<span class="table-title">All‐cause mortality at the longest available follow‐up</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0013" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0014"> <div class="table-heading"><span class="table-label">Table 10.</span>&nbsp;<span class="table-title">Similarity among studies. baseline values and number of injections</span></div> <tbody> <tr> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Participants</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Interventions</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Mean n.</b> </p> <p><b>injections</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Visual</b> </p> <p><b>acuity (logMAR)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Retinal</b> </p> <p><b>thickness (µm)</b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Study</b> </p> <p><b>sponsor</b> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0001">Ahmadieh 2008</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bevacizumab</p> <p>Sham</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None reported</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0003">BOLT 2010</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bevacizumab</p> <p>Laser</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9*</p> <p>3*</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.59</p> <p>0.61</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>507</p> <p>482</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Public</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0004">DA VINCI 2011</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Aflibercept</p> <p>Laser</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.6 to 5.5</p> <p>1.7</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.55</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>441</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0005">DRCRnet 2010</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>668</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Laser</p> <p>Ranibizumab‐DL</p> <p>Ranibizumab‐PL</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3*</p> <p>9*</p> <p>8*</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.38</p> <p>0.39</p> <p>0.38</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Public</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0006">DRCRnet 2015</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>620</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Aflibercept</p> <p>Bevacizumab</p> <p>Ranibizumab</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.2</p> <p>9.4</p> <p>9.7</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.40</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>412</p> <p>414</p> <p>407</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Public</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0007">Ekinci 2014</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bevacizumab</p> <p>Ranibizumab</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1</p> <p>6.5</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.22</p> <p>0.24</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>484</p> <p>490</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Public</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0008">Ishibashi 2014</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>233</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pegaptanib</p> <p>Sham</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.56</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0009">Korobelnik 2014</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>268</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Aflibercept</p> <p>Laser</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.5</p> <p>2.4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.50</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0010">Lopez‐Galvez 2014</a> </p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>83</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ranibizumab</p> <p>Laser</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.3</p> <p>2.1</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0011">LUCIDATE 2014</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Laser</p> <p>Ranibizumab</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.6</p> <p>9</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.42</p> <p>0.30</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>489</p> <p>455</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No details</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0012">Macugen 2005</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pegaptanib</p> <p>Sham</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> <p>4.5</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.56</p> <p>0.58</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>476</p> <p>423</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0013">Macugen 2011</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>260</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pegaptanib</p> <p>Sham</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.3</p> <p>8.4</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.56</p> <p>0.58</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>442</p> <p>465</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0016">RELATION 2012</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>128</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Laser</p> <p>Ranibizumab‐PL</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0014">Nepomuceno 2013</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>60</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bevacizumab</p> <p>Ranibizumab</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.8</p> <p>7.7</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.60</p> <p>0.63</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>451</p> <p>421</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Public</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0015">READ2 2009</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>115</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Laser</p> <p>Ranibizumab</p> <p>Ranibizumab‐PL</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.4</p> <p>5.3</p> <p>2.9</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.60</p> <p>0.54</p> <p>0.60</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>228</p> <p>190</p> <p>263</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0017">RESOLVE 2010</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>151</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ranibizumab</p> <p>Sham</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>10.2</p> <p>8.9</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.50</p> <p>0.48</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>455</p> <p>449</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0018">RESPOND 2013</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>203</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Laser</p> <p>Ranibizumab</p> <p>Ranibizumab‐PL</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9.2</p> <p>8.8</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.46</p> <p>0.44</p> <p>0.40</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>458</p> <p>448</p> <p>422</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0019">RESTORE 2011</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>343</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Laser</p> <p>Ranibizumab</p> <p>Ranibizumab‐PL</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.3</p> <p>7</p> <p>6.8</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.46</p> <p>0.40</p> <p>0.42</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>412</p> <p>427</p> <p>416</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0020">REVEAL 2015</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>390</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Laser</p> <p>Ranibizumab</p> <p>Ranibizumab‐PL</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.9</p> <p>7.8</p> <p>7</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.54</p> <p>0.52</p> <p>0.52</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>395</p> <p>419</p> <p>430</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Industry</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0022">Soheilian 2007</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>85</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bevacizumab</p> <p>Laser</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.71</p> <p>0.55</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>352</p> <p>319</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Public</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0023">Turkoglu 2015</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>70</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Laser</p> <p>Ranibizumab</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.84</p> <p>0.80</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>460</p> <p>488</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>None reported</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="./references#CD007419-bbs2-0024">Wiley 2016</a> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>124</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Bevacizumab</p> <p>Ranibizumab</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> <p>3</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.42</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>477</p> </td> <td align="center" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Public</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>DL: plus deferred laser<br> PL: plus prompt laser </p> <p>(*): median, not mean, available and reported</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span>&nbsp;<span class="table-title">Similarity among studies. baseline values and number of injections</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/full#CD007419-tbl-0014" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0004" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Ranibizumab versus laser photocoagulation at 6 to 12 months</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Quality of life: NEI‐VFQ composite score at 6 to 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>412</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.14 [2.96, 7.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Ranibizumab versus laser photocoagulation at 6 to 12 months</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub6/references#CD007419-tbl-0004" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007419-note-1203">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007419-note-1206">Español</a> </li> <li class="section-language"> <a class="" href="ms#CD007419-note-1205">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD007419-note-1204">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="/cochrane-theme/vendor/ie9.js?t=1581422282000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581422282000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007419\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007419\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007419\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007419\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581422282000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007419.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007419.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD007419.pub6/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD007419.pub6/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007419.pub6%2Freferences" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583245879646" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x2f;references" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583245879650" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD007419&#x2e;pub6&#x2f;references" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD007419.pub6";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 